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Abstract 
People with asthma suffer from worse respiratory infections. The underlying causes have 
been suggested to arise from type 2-biased inflammation, deficiencies in antiviral immune 
response, epithelial damage, or a combination of all three. The antiviral immune response 
is activated by pathogen recognition receptors that include the viral ssRNA detecting toll-
like receptor (TLR)7 and its paralogue TLR8. TLR7 induces the production of the antiviral 
cytokine type I interferon (IFN) that has been reported to be deficient in people with asthma. 
Additional reports that asthma is associated with reduced TLR7 function and genetic 
variation in TLR7/8 gene region warrants investigation of the roles of TLR7/8 in antiviral 
immune response in healthy people and those with asthma. Three primary aims of this study 
are: 
1. To determine what clinical and immunological parameters are associated with self-
reported respiratory infection frequency, the presence of asthma, asthma severity and 
control, with a specific focus on the role of TLR7/8 gene expression and function, and the 
extent to which this differs between women and men. 
2. To examine what host and transcriptional variations predict variation in antiviral type I IFN 
responses in vitro and determine how transcriptome patterns vary between individuals with 
high and low antiviral type I IFN responses. 
3. To examine the functional impact that genetic variations in the TLR7/8 region has on 
TLR7/8 gene expression, downstream cytokine production, antiviral immunity, and immune 
cell counts in peripheral blood. 
To address the study aims, I recruited 150 asthma cases and 151 controls, documented 
self-reported respiratory infection frequency by questionnaire, and measured baseline 
TLR7/8 gene expression in whole blood, and cytokine responses using rhinovirus (RV)16-
stimulated or TLR7/8-ligand stimulated peripheral blood mononuclear cells (PBMC). 
Plasmacytoid dendritic cells (pDC) are of interest to the current study because they are the 
primary producers of type I IFN and express TLR7. In Chapter 2, we show that measuring 
CLEC4C gene expression provides a useful alternative method for quantifying pDC numbers 
that may be particularly relevant to large cohort studies where flow cytometry is impractical 
or inaccessible. 
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Chapter 3 addresses the first aim of the study and we report that CLEC4C gene expression 
(beta = 0.90, p = 0.01) together with TLR7 gene expression (beta = -1.13, p = 0.02) are 
associated with self-reported respiratory infection frequency in men. In women, age (beta = 
-0.02, p < 0.001) and body mass index (BMI; beta = 0.03, p < 0.001) are associated with 
respiratory infection frequency. Asthma cases reported significantly more respiratory 
infections per year than controls (median 3 vs 2, p < 0.001) and reduced TLR7 gene 
expression (odds ratio (OR) = 0.12, p = 0.02) and increased BMI (OR = 1.1, p < 0.001). 
Asthma symptom control was associated with reduced TLR8 gene expression (beta = -1.4, 
p = 0.036) and increased BMI (beta = 0.04, p = 0.004), whereas, increased age (OR = 1.0, 
p = 0.005) and BMI (OR = 1.1, p = 0.004) were associated with asthma severity. 
To address the second aim, we sequenced transcriptomes of baseline and RV16-stimulated 
PBMC samples from subsets of participants with the highest and lowest 15% of IFNα 
response determined in Chapter 3. In Chapter 4, we report that at baseline in comparison 
to the low IFNα producers, high IFNα producers have a higher gene expression of innate 
immune variables including the pDC gene CLEC4C and complement genes; and lower gene 
expression genes, which may be markers of oxidative stress. During antiviral immune 
response, in comparison to the low IFNα producers, the high IFNα producers express IFNα 
genes and IFNα response genes at a higher level, as expected, and lower levels of genes 
linked to antibacterial activity. 
For Chapter 5, we genotyped the TLR7/8 gene region in participants with European ancestry 
to address aim three. This revealed associations between an asthma risk SNP rs850637 in 
the TLR7/8 gene region and basophil count in our study population. Additional analyses 
using publicly available external databases revealed associations between rs850637 and 
TLR7 and TLR8-AS1 gene expression. TLR8-AS1 is a type of antisense gene, which are 
thought to have a function in regulating the gene expression of their complementary gene 
product. However, we did not find any genetic variants linked to respiratory infection 
frequency or capacity for IFNα production in vitro. 
These findings indicate that multiple risk factors are associated with antiviral immune 
responses and susceptibility to respiratory infections. These risk factors differ between 
women and men, with age and BMI prominent in women, whereas innate immune variations 
were more prominent in men. Decreased TLR7/8 expression in asthma patients may also 
contribute towards the respiratory infection susceptibility. The asthma-related SNP 
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rs850637 was associated with lower TLR7 gene expression and increased basophil count 
that is associated with asthma inflammation. Considering these findings, TLR7/8 appear to 
be crucial for the antiviral immune response and asthma inflammation. 
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1.1. Introduction 
Viral respiratory infections are an unavoidable part of everyday life. Though often considered 
harmless, they disrupt productivity, and in some individuals, these infections may develop 
into life-threatening illnesses or cause exacerbations of underlying conditions. Asthma 
patients in particular experience viral respiratory infection-associated complications. This 
thesis intends to investigate variability in antiviral immune responses in healthy people and 
those with asthma, with a focus on the role of toll-like receptor (TLR)7 and -8. 
The purpose of the current Chapter is to review the current scientific literature concerning 
these topics. In section 1.2, I first describe the antiviral immune response against rhinovirus, 
the most common respiratory virus. Next in section 1.3, I review asthma-associated 
inflammation and the evidence that asthma patients experience worse respiratory infections 
than their healthy counterparts. Finally in section 1.4, I discuss the current understanding of 
the immunological and genetic variations influencing antiviral immunity in asthma. It is 
beyond the scope of this thesis to examine antiviral immunity comprehensively; therefore, 
the thesis focuses on rhinoviral infections that are the leading cause of respiratory infection-
related complications in asthma, and the TLR7/8 mediated immune response. However, for 
enhanced understanding of those topics, a broader discussion is provided. To expand the 
knowledge on the topic, we recruited 301 persons for this research study. The research is 
divided into four parts. The second Chapter describes a methodology to quantify 
plasmacytoid dendritic cells that are relevant for our understanding of the topic. The 
methodology was used in the subsequent Chapters. Chapter 3 examines clinical and 
immunological determinants of respiratory infection frequency and asthma in a large cohort. 
Some unexpected results from Chapter 3 prompted a comparison of the transcriptomes in 
individuals whose antiviral immune response was characterised by either high or low 
interferon alpha production, as detailed in Chapter 4. The fifth Chapter investigates the 
consequences of genetic variations in TLR7/8. Finally, the results are discussed in Chapter 
6 with an emphasis on the central themes of this thesis, and future directions arising from 
this project. 
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1.2. The antiviral immune response against viral pathogens 
The immune response against viral pathogens consists of secreted antimicrobial molecules, 
efficient detection of pathogen and the subsequent activation of both innate and adaptive 
arms of immunity. Protection from pathogens is critical for survival; however, excessive 
immune responses can lead to inflammatory conditions. While all cells respond to viral 
infection, in the respiratory system bronchial epithelial and immune cells are responsible for 
their appropriate detection and elimination. 
1.2.1. Rhinoviruses cause respiratory infections 
Many types of viruses cause respiratory infections; most commonly rhinovirus (RV), 
adenovirus, influenza, parainfluenza, metapneumovirus, bocavirus, respiratory syncytial 
virus and coronaviruses. Notably, over 90% of the causal viruses are RNA viruses, and of 
those, RV is detected most commonly (Arden et al. 2006). The RV is known to be the major 
cause of asthma exacerbations (Denlinger et al. 2011; Miller et al. 2012). 
Human rhinoviruses (HRV) are single-stranded RNA (ssRNA) viruses (family 
Picornaviridae) consisting of three different species with HRV-A and HRV-B being the most 
common and better-known species (Fuchs & Blaas 2012). HRV-C has been identified most 
recently and has been associated with increased asthma exacerbations in children in 
comparison to HRV-A and HRV-B (Bizzintino et al. 2011). HRV-A and HRV-B bind to the 
cell surface receptors intercellular adhesion molecule 1 (ICAM-1), low density lipoprotein 
receptor or very low density lipoprotein receptors (Greve et al. 1989; Okun et al. 2001) and 
HRV-C to a cadherin related family member 3 (CDHR3) (Bochkov et al. 2015). Once within 
the endosome, the virus releases its genome to the cytosol for replication by rupturing the 
endosome, as shown in Figure 1:1. 
Whereas most viruses grow best at the normal body temperature of 37°C, most RV species 
grow preferentially at 33–35°C, the temperature of the nasal mucosa (Foxman et al. 2015). 
At 33°C, airway epithelial cells show impaired antiviral responses, with less expression of 
type I and type III IFNs relative to 37°C (Foxman et al. 2015). This may explain why RV are 
so adept at causing upper respiratory tract infections. Due to the abundance of ICAM-1 
receptor in polarised epithelial cells, the HRV-A and HRV-B are generally found in the 
respiratory airways (Jakiela, Bogdan et al. 2008), but HRV-A and HRV-C have been shown 
to primarily infect ciliated epithelial cells (Griggs et al. 2017; Jakiela, B. et al. 2014). This 
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could explain why RV is unable to infect ciliated nasal epithelial cells that also have low 
ICAM-1. However, RV can access the basal cells for infection by disrupting the epithelial 
barrier. RV also upregulates ICAM-1 via a nuclear factor κB (NF-κB)-dependent mechanism, 
thereby enhancing its capacity to cause infection (Fuchs & Blaas 2012). 
Interestingly, atopic patients showed higher levels of ICAM-1 expression in their nasal 
brushings without infection (Bianco et al. 2000), although in another study bronchial 
epithelial cells in asthmatic people were found to express less ICAM-1 questioning the role 
of the receptor in increasing viral titres but perhaps signifying that intracellular mechanisms 
are more important (Wark et al. 2005). People with asthma have increased numbers of 
goblet cells, and this may be an additional mechanism promoting RV infection since RV is 
efficient at replicating in mucus-producing goblet cells (Lachowicz-Scroggins et al. 2010). 
RV infection does not cause any necrosis to the epithelium. Instead, the symptoms are 
mainly caused by the host response (Kennedy et al. 2012). The host response to RV will be 
described in the following section. 
1.2.2. Virus detection 
Antiviral immunity depends firstly on sensing of the virus infection by pathogen recognition 
receptors (PRRs) that activate inflammatory and antiviral cytokine secretion, which in turn 
activate antigen presenting cells (APC) to respond and present antigens to the adaptive 
immune cells. Epithelial cells and innate immune cells such as neutrophils, macrophages 
and dendritic cells comprise the first line defence against the virus and activate adaptive 
immunity that subsequently forms targeted immunity and immune memory against the 
pathogen. 
Toll-like receptors (TLRs) are pathogen recognition receptors that have each specialised to 
recognise a particular pathogen-associated molecular pattern (PAMP) from viruses or 
bacteria. With such a crucial role, toll-like receptors are highly conserved through evolution 
(Roach et al. 2013). There are 10 TLRs in humans known today [reviewed for example, by 
Vidya et al. (2018)]. TLRs recognise a wide variety of PAMPs as their ligands to cover 
different invading pathogens. TLR1, -2, -4, -5, and -6 receptors are located on the cell 
surface. TLR1 and -2 recognise bacterial lipoproteins, lipoteichoic acids as well as yeast 
PAMPs, TLR4 recognises bacterial lipopolysaccharide, TLR6 recognises mycoplasma 
PAMP, and TLR5 recognises bacterial flagellin. The nucleic acid-detecting TLRs (TLR3, -7, 
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-8, -9, and -10) are located in endosomes and recognise viral and bacterial nucleic acids. 
Breakdown of viral material in endosomes exposes the nucleic acid material to which TLRs 
bind. TLR3 and TLR10 recognise viral double-stranded RNA (dsRNA), TLR9 recognises 
bacterial DNA, and TLR7 and -8 recognise ssRNA. The function of TLR10 has been 
elucidated only recently, and it seems to regulate TLR3 function (Lee, SM et al. 2018). 
The recognition of ssRNA respiratory viruses, including RV, relies on TLR7 and TLR8. 
Single-stranded RNA viruses also form dsRNA during their replication process as an 
intermediate product (Weber et al. 2006), enabling the RV to be recognised by dsRNA 
receptors TLR3, melanoma differentiation-associated gene 5 (MDA-5) and retinoic acid–
inducible protein I (RIG-1) (Parsons, Hsu & Wark 2014). TLR2 is also able to recognise RV 
capsid proteins (Triantafilou et al. 2011). However, research has suggested that 
picornaviruses can block RIG-1 action, demonstrating the only known way RV can interfere 
with interferon (IFN) production (Barral et al. 2009). Despite the reported blocking action, 
others have shown a function for RIG-1 in RV recognition (Slater et al. 2010). MDA-5 null 
mice showed reduced IFN response to RV but also reduced airway responsiveness (Wang, 
Q et al. 2011). This evidence suggests that even though both MDA-5 and TLR7/8, rather 
than RIG-1, are essential in recognising the nucleic acids from RV and inducing type I and 
III IFNs, the downstream proinflammatory responses they induce are distinct with MDA-5 
driven proinflammatory response probably contributing to airway hyperresponsiveness. 
1.2.3. Toll-like receptors 7 and 8 
The TLR7 and TLR8 genes are located on the X chromosome at Xp22 adjacent to each 
other; both TLR7 and TLR8 have three exons, while TLR8 has two splice variants (Du, X et 
al. 2000). TLR7 and TLR8 share similarity in their gene sequence and protein structure and 
are considered close paralogues, derived from the same ancestral gene. TLR7 is expressed 
constitutively and at a high level in pDC but can also be induced by viral infection in other 
cell types such as B cells, monocytes, macrophages, natural killer (NK) cells, eosinophils, 
bronchial epithelial and smooth muscle cells (Drake et al. 2012; Hornung et al. 2002; 
Shikhagaie et al. 2014; Uehara et al. 2007). In contrast, TLR8 is expressed mainly in 
monocytes, macrophages and conventional dendritic cells (cDCs)(Hornung et al. 2002; 
Makni-Maalej et al. 2015). 
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TLR7/8 are traditionally recognised as viral ssRNA receptors (Heil et al. 2004); however, 
continued research reveals that RNA degradation products guanosine and uridine activate 
the receptors in combination with ssRNA (Shibata et al. 2016; Tanji et al. 2015). In addition 
to viral ssRNA degradation products, DNA derived guanosine activates TLR7, and the 
receptors also respond to nucleosides from bacteria and protozoa origin (Coch et al. 2019; 
Gantier et al. 2010; Mancuso et al. 2009). TLR7/8 are proteolytically cleaved to their active 
forms with the support of a chaperone protein, Unc-93 homolog B1 (UNC93B1), localised in 
endosomes, where pathogen degradation occurs (Ishii et al. 2014; Lee, BL et al. 2013). 
Recent advances in understanding the mechanisms regulating TLR7-induced cytokine 
secretion reveal that TLR7 cytokine secretion exists in two modes, depending on the location 
with cells. Following TLR7 localisation in endosomes, TLR7 activation induces 
proinflammatory cytokines such as tumour necrosis factor (TNF) and interleukin (IL)12. In 
contrast, upon the recruitment of Arl8b and SKIP, TLR7 traffics to the pDC cell periphery to 
enable type I IFN production (Miyake et al. 2018; Saitoh, S-I et al. 2017). 
TLR7 is better studied than TLR8 since for long TLR8 research was hindered by the lack of 
TLR-specific agonists and antagonists and the assumption that TLR8 is dysfunctional in 
mice. Currently, a range of agonists are available, and while mice TLR8 function is 
understood better, it is clear that is functionally distinct from its human homologue as the 
human TLR8 in mice causes considerable pathology (Snyder et al. 2014). Mouse models 
reveal that TLR8 depletion in mice results in TLR7 overexpression and oversensitivity to 
TLR7 agonists, suggesting that TLR8 expression is required to suppress TLR7 expression 
(Desnues et al. 2014; Pelka et al. 2016; Tran, Manzin-Lorenzi & Santiago-Raber 2015). 
However, TLR7 and TLR8 are co-expressed in several immune cells in mouse, whereas in 
humans they are only co-expressed in monocytes and neutrophils, suggesting that the 
human TLR8 role as a TLR7 regulator may be less significant. Nevertheless, considerable 
crosstalk exists between individual human TLRs and synergistic effects between TLRs 
augment the innate immune response (Ghosh et al. 2007). The activation of a combination 
of TLRs may provide a more tailored response to specific pathogens. For example, the 
synergistic activation of TLR4 and TLR8 induced augmented IL12 production (Ghosh et al. 
2007), and TLR8 has been shown to upregulate TLR2 expression during bacterial infection 
and downregulate TLR7 and -9 expressions (Cervantes et al. 2011; Cervantes et al. 2012; 
Wang, J et al. 2006). These studies reinforce the understanding that TLRs have distinct yet 
complementary roles in pathogen recognition and response. 
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Even though TLR7 and TLR8 are structurally similar and both recognise similar ligands, it is 
clear that both serve distinct purposes in antiviral immunity. Not only are they expressed in 
different cell populations apart from a few cell types but both TLR8 induced cytokines TNF 
and IL12 participate in activating the adaptive immunity, whereas TLR7 induced IFN 
production is crucial for innate immune activation. The ability of TLR8 to downregulate TLR7 
function, suggests that there is a delicate balance between the effects of the two receptors. 
The purpose of TLR8 suppressing TLR7 may be to suppress TLR7 induced cytokines in 
favour of the TLR8 induced cytokines. 
 TLR7/8 downstream signalling pathways 
To exert their downstream effects, TLRs employ a network of signalling molecules. The 
TLR7/8 downstream signalling pathways are shown in Figure 1:1. Most TLRs transduce cell 
signalling via myeloid differentiation primary response protein 88 (MyD88), which is highly 
conserved and crucial in antiviral immunity. Activation of TLR7 in pDC leads to MyD88 
attaching to the receptor and in turn recruiting a signalling complex consisting of IL-1R-
associated kinase (IRAK) 1, IRAK4 and interferon regulatory factor (IRF)7. TNF receptor-
associated factor (TRAF) 3 and TRAF6 are subsequently recruited to the complex. The 
inhibitor of NF-κB kinase (IKK)-α phosphorylates IRF7. Also, NF-κB-inducing kinase (NIK), 
IRAK1 and osteopontin are thought to have a role in its activation. IRF7 is a major hub in 
RV-induced in vivo models, and it is vital in mediating TLR7 response in plasmacytoid 
dendritic cells (pDCs) (Bosco et al. 2012). IRF7 is transported to the nucleus where it 
activates the genes for type I IFN production. IRF7 has been found to have central 
importance in TLR7 signalling as its depletion results in type I IFN deficiency (Honda et al. 
2005). MyD88 is essential for initiating the signalling cascade also in other cell types such 
as cDCs, B cells and macrophages, where TLR8 is mainly expressed. In the TLR8 signalling 
pathway, IRAK4 is recruited that then phosphorylates IRAK1 and IRAK2 that activate 
TRAF6. A complex consisting of TGF-β activated kinase 1 (TAK1), TAK1-binding proteins 
(TAB)1 and TAB2 is formed that firstly, initiates mitogen-activated kinases (MAPK) pathway 
resulting in cAMP-responsive element binding protein (CREB) via p38 and Jun kinases 
(JNKs), secondly, activates IKKβ and NF-kB essential modulator (NEMO) that release NF-
κB, and finally, activates mitogen-activated protein kinase kinase kinase 8 (MAP3K8) 
pathway resulting in AP1. CREB, NF-κB and AP1 translocate in the nucleus and activate 
proinflammatory cytokines including IL12 and TNF. IRF5 and IRF1 are activated directly by 
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MyD88 that also regulate gene expression in the nucleus (Blasius & Beutler 2010; Gay et 
al. 2014). 
 
Figure 1:1 TLR7 and -8 signalling pathways.  
Rhinovirus (RV) attaches to the intercellular adhesion molecule 1 (ICAM-1) cell surface 
receptor and enters the plasmacytoid dendritic cell (pDC) (left) by endocytosis. Within the 
endosome, its ssRNA genome is degraded into oligo-RNA and nucleoside that are TLR7 
ligands. Activation of TLR7 recruits a signalling complex that is described in the text in detail. 
The complex activates IRF7, which acts as a transcription factor for type I interferon 
production. On the right side, TLR8 in conventional dendritic cell (cDC) detects ssRNA and 
recruits a signalling complex to release the transcription factors NF-κB and AP1. MyD88 
also directly activates transcription factors IRF1 and IRF5 that together with NF-KB and AP1 
induce proinflammatory cytokine production. (Original artwork) 
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  Type I interferon induced by TLR7 
Once PRRs detect microbes, the signalling pathways culminate in the production of antiviral 
cytokines. TLR7 activation can induce either proinflammatory cytokines or type I IFN, one 
of the most critical types of cytokines in inducing an antiviral state in the organism. IFNα is 
expressed only upon viral stimulation and otherwise suppressed by the action of IRFs (Levy, 
Marié & Durbin 2011), whereas IFNβ expression is always maintained at low levels even in 
the absence of viral infection. The transcriptional regulation of IFNβ is complex as its 
expression needs to be maintained with a delicate feedback loop. 
IFNAR, the common receptor for the type I IFNs, IFNα and IFNβ, consists of IFNAR1 and 
IFNAR2 and is expressed on all nucleated cells. The type III IFN IFN-λ is produced by many 
cells, but a component of its receptor IFNλR, IL28Rα, is only expressed in hepatocytes and 
epithelial cells (Mitchell et al. 2011), conveying a role of epithelial cell protection. IFNAR 
activation leads to ISGF3 complex activation, which consists of signal transducer and 
activator of transcription protein (STAT)1, STAT2 and IRF9. The downstream signalling 
pathways for all IFNs are very similar, but the effect is different for each. The complex 
initiates IFN-stimulated gene (ISG) activation. Modern computational approaches have 
enabled the recognition of thousands of differentially regulated genes upon IFN stimulation 
(Green, R, Ireton & Gale 2018). Core ISGs lead to the induction of an antiviral state in cells, 
dendritic cell maturation, adaptive immune response activation, and secretion of 
chemokines to recruit lymphocytes and monocytes to the site (Raftery & Stevenson 2017; 
Schneider, Chevillotte & Rice 2014). 
During viral infection, type I IFN production in pDCs is significantly enhanced with pDC 
clustering, where cell-cell contact triggers a paracrine loop amplifying type I IFN production 
(Kim et al. 2014; Wimmers et al. 2018). A detailed study by Saitoh, S-I et al. (2017), reveals 
that TLR7 activation induces proinflammatory cytokines in the absence of pDC clustering 
and further evidence of feedback loop between the proinflammatory cytokines (TNF and 
IL12) and type I IFN suggests that the TLR7-induced proinflammatory cytokine production 
may act in priming pDC for robust type I IFN responses (Gautier et al. 2005; Lee, J et al. 
2015). This mechanism presents just one regulatory mechanism for IFN production, in 
addition to the activation of ISGs, of which regulatory proteins suppressor of cytokine 
signalling (SOCS) in particular have a role in regulating IFN production. 
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  Proinflammatory cytokines induced by TLR8 
TLR8 activation induces proinflammatory cytokines TNF, IL12, and to a lesser extent, CCL3 
(also known as MIP-1α), but less type I IFN synthesis than TLR7 (Gorden et al. 2005). The 
difference in the cytokine profile expressed between TLR7 and TLR8 is due to their 
expression in different cell populations and different cell signalling network induced as 
described above. As the name suggests, tumour necrosis factor (TNF) was originally found 
to induce cell death through activating apoptotic pathways. In an antiviral response, 
apoptosis in infected cells prevents the pathogen from replicating using the transcription 
machinery of the host cell; therefore, is a crucial component of antiviral response. Recently, 
the roles of TNF have been expanded beyond cell death and functions to support both innate 
and adaptive immune responses (Yi et al. 2018). TNF induces the secretion of some other 
cytokines such as IL1 and IL18 and in the respiratory epithelium; TNF also induces β-
defensin secretion, which is an antiviral peptide. Many viruses have developed mechanisms 
to prevent TNF mediated signalling as a defence, which demonstrates its importance to 
antiviral immunity (Waters, Pober & Bradley 2013). To support adaptive immunity, TNF co-
stimulates CD4+ and CD8+ T-cell activation and differentiation through the TNF-family 
receptor Fas (Yi et al. 2018). 
Similarly, IL12 is also induced by TLR8 agonists. Its primary function is to direct T-helper 
cell differentiation towards a Th1 response. IL12 induces the transcription factor T-bet, which 
stimulates naïve CD4+ T cells to differentiate into Th1 cells and produce IFNγ (Yu et al. 
2015). CCL3 is a proinflammatory and chemotactic factor for recruitment of IFNγ-activated 
neutrophils and CCR1-expressing eosinophils (Maurer & von Stebut 2004). IL18 and IFNγ 
are induction are mediated by TNF and IL12 secretion, and together, they activate Th1 
differentiation and enhance NK-cell cytotoxicity (Akdis et al. 2016). 
1.2.4. Innate immune response 
The antiviral innate immune response is the first non-specific response of the immune 
system against an invading pathogen before the pathogen-specific adaptive response is 
activated. The first defence involves baseline levels of antimicrobial peptides that may have 
antiviral properties also. Epithelial cells secrete antimicrobial peptides upon TLR activation, 
a mechanism that likely preserves the commensal pathogen colonies instead of activating 
the cellular responses (Uehara et al. 2007). The complement system consists of secreted 
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peptides that tag both bacteria and viruses for degradation and complement cellular immune 
responses in several ways (Hajishengallis et al. 2017). 
The next level of defence involves the recognition of pathogen degradation products, which 
triggers cellular responses. As described above for TLR7/8, PRR activation induces 
secretion of antiviral and proinflammatory cytokines and chemokines for the recruitment of 
other cell types. Although some proinflammatory cytokines support antiviral function, the 
role of IFNs is the most central in antiviral immunity as seen in those rare individuals who 
are markedly deficient in type I IFN production and highly vulnerable to lethal virus infections 
(Duncan et al. 2015; Taft & Bogunovic 2018). 
IFNs activate professional APCs such as dendritic cells and macrophages, but also other 
cells such as neutrophils and eosinophils have been shown to contribute to antigen uptake 
and presentation in viral infections (Hufford et al. 2012; Sabogal Piñeros et al. 2019; Su et 
al. 2015). They secrete chemicals to defend against the pathogen and chemokines to attract 
adaptive immune cells as a second line of defence. Neutrophils secrete extracellular traps 
and antiviral factors to attack against the pathogen (Saitoh, T et al. 2012). Eosinophils 
secrete RNA degrading ribonucleases, which partly explains their role in the ssRNA RV 
infection (Gupta et al. 2013). Other eosinophilic defence mechanisms include the secretion 
extracellular traps and reactive oxygen species species (Kovacs et al. 2014; Silveira et al. 
2019). 
Although pDC form only a fraction of immune cells, they are crucial in antiviral immunity as 
shown with pDC depletion experiments (Xi et al. 2017). Our laboratory has previously shown 
that pDCs comprise more than 90% of all IFNα producing cells, with monocytes 10% and 
other dendritic cells less than 1% (Xi et al. 2015). In support, animal models further show 
that pDC depletion diminishes type I IFN production and causes considerable viral 
pathogenicity (Swiecki, M. et al. 2010). As the primary producer of type I IFN, pDCs are 
abundant in TLR7 and TLR9 expression to respond to invading viruses. The antiviral type I 
IFN response in pDCs has been shown to be dependent on TLR7 function (Davidson et al. 
2011; Kaiko et al. 2013). The type I IFN production induces an innate immune response, 
and as a dendritic cell, pDCs are further able to activate adaptive immunity by presenting 
antigens to naïve CD4+ and CD8+ cells, playing a crucial regulative role between the innate 
and adaptive immunities (Lynch et al. 2014). 
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1.2.5. Adaptive immune response 
The activation of adaptive immunity is vital for long-lasting protection against pathogens. 
The focus of this thesis is in the innate immune responses, but to understand the complete 
antiviral immune response, adaptive immune responses are briefly discussed here. 
IFNs exhibit both direct and indirect effects of activating the T-cell immune response. Those 
mechanisms are summarised here and reviewed in full detail in Crouse, Kalinke and 
Oxenius (2015). The indirect mechanism is mediated by type I IFN-activated APCs. The 
mature APCs secrete chemokines to recruit adaptive immune cells. APCs express MHC 
molecules and co-stimulatory molecules that, together with the presented processed 
pathogen antigens, activate the adaptive immune cells to produce pathogen-specific effector 
and memory cells. APCs also secrete cytokines IL15 and IL7 that support T-cell proliferation, 
IFNγ that supports Th1-cell differentiation and IL12 that supports survival and differentiation 
of activated cells. The direct effects of type I IFN on T-cells depend on the activation 
sequence of IFNAR and T-cell receptor (TCR). If TCR activation precedes IFNAR activation, 
T-cell survival, differentiation and protection from NK-cell mediated cytotoxicity prevail, 
whereas, if IFNAR activation precedes TCR activation, T-cells activate opposite cellular 
programmes and become susceptible to NK-cell destruction. 
CD4+ T-helper cells can differentiate into Th1, Th2, Th17, Treg, Tfh, or the less well-known 
Th22, Th3, Tr1 or Th9 types. Th1 type is predominantly responsible for antiviral immune 
response and induces IL2, IFNγ and TNF cytokines. Th1 differentiation is initiated with the 
main transcription factor T-bet along with several other transcription factors, while the Th2 
transcription factor GATA-2 is suppressed (Saravia, Chapman & Chi 2019). The antiviral 
Th1 cells help activate humoral B-cell responses with IFNγ secretion, promote cytotoxic and 
memory CD8+ T-cell responses with IL2 secretion, support APC activation and also directly 
induce an antiviral state in cells and kill infected cells. After viral infection, a small population 
of Th1 cells differentiate to memory cells. (Swain, McKinstry & Strutt 2012). Evidence with 
RV and influenza infection suggests that CD4+ memory cell have a direct antiviral function, 
independent of their helper function (Muehling et al. 2016; Teijaro et al. 2010). 
Notably, CD4+ T cells have also been found to express TLR7, and TLR7 activation was 
shown to induce anergy in those cells. Deactivation of TLR7 produced better defence 
against human immunodeficiency virus (HIV), indicating that while TLR7 is critical in acute 
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infection inducing innate immunity, in chronic infections its role is more detrimental if it 
prevents proper antigen recognition by CD4+ T cells (Dominguez-Villar et al. 2015). 
Most recently, an important innate lymphoid cell (ILC) population has been identified. 
Research on ILCs has expanded rapidly and advanced the knowledge of ILC differentiation 
into type 1, 2, and 3 ILCs as well as cytotoxic NK-cells (Lim et al. 2017). The distinctive 
functions of ILC1, -2, and -3 types align with the functions of their adaptive T-helper cell 
counterparts and while it has become apparent that while they cannot exhibit specialised 
adaptive immune function, they support the Th cells in maintaining their respective cytokine 
milieu (Mjösberg & Spits 2016). An equally important function is the direct interactions ILCs 
exert on other immune and non-immune cells such as activating DCs and regulating 
epithelial function (Mjösberg & Spits 2016). 
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1.3. Asthma patients suffer from severe respiratory infections 
Asthma patients are burdened with severe respiratory infections, including those caused by 
an RV. The type 2 dominant immune response in early-onset allergic asthma and the 
‘normal’ Th1 antiviral immune response are traditionally thought to antagonise each other, 
though this is probably an oversimplification, as discussed further in sections 1.4.1 and 
1.4.2. In this section, asthma and severe respiratory infections are discussed. 
1.3.1. The definition of asthma 
Asthma is a chronic disease of the airways. Clinical symptoms, which include wheezing, 
tightness in the chest, difficulty breathing and night time coughing, can be brought on by 
various triggers. In Australia, 1 in 10 people has asthma (Australian Centre for Asthma 
Monitoring 2011), with many individuals with asthma experiencing a reduced quality of life, 
loss of productivity at work or studies, and the financial consequences of the ongoing 
healthcare costs associated with this disease. In Australia, asthma causes the death of just 
over 400 people each year (Poulos et al. 2014). 
The three cardinal features of asthma are variable airway obstruction, airway 
hyperresponsiveness and airway inflammation. The airways of people with asthma exhibit 
an exaggerated contractile response to inhaled stimuli such as allergens or smoke 
(Australia. 2015; McCarty & Ferguson 2014). Airway hyperresponsiveness facilitates 
bronchoconstriction, which is responsible for most of the physiological changes that cause 
asthma symptoms. Airway inflammation leads to more severe airway hyperresponsiveness 
(McCarty & Ferguson 2014). For example, allergen exposure stimulates the release of a 
variety of inflammatory mediators that cause airway inflammation and increase mucus 
production and bronchoconstriction by activating airway smooth muscle. Persistent asthma 
results in more permanent changes to airway structure called airway remodelling 
(Lambrecht & Hammad 2012). 
1.3.2. Different asthma phenotypes 
Different phenotypes of asthma have long been recognised, and multiple attempts have 
been made to categorise asthma based on properties such as triggers, age of onset, 
physiological features, responsiveness to treatment, and the dominant airway inflammatory 
cell type (Corren 2013; Hekking & Bel 2014). The literature recognises allergic asthma as 
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the most common asthma type, with an onset, typically in childhood. It is characterised by 
eosinophilia and allergen-specific immunoglobulin (Ig)E and is exacerbated by allergic 
triggers. Asthma symptoms are controlled with medication and asthma treatment intensity, 
responsiveness to treatment, and control of symptoms with treatment present additional 
asthma phenotype considerations. 
Asthmatic airway inflammation varies, and this has given rise to four common inflammatory 
phenotypes, namely eosinophilic asthma, neutrophilic asthma, mixed granulocytic asthma 
and paucigranulocytic asthma (Simpson et al. 2006). The most common phenotype is known 
as eosinophilic asthma and is characterised by a sputum eosinophil concentration of ≥ 
1.01% in the presence of asthma symptoms and airway hyperresponsiveness (Simpson et 
al. 2006). Eosinophilic airway inflammation in asthma occurs as a result of CD4+ T helper 
cell differentiation skewing towards a type 2 response, which is discussed in the next 
section. 
Neutrophilic asthma is characterised by an increased proportion of neutrophils in the 
airways, in the presence of asthma symptoms and airway hyperresponsiveness. Individuals 
with neutrophilic asthma tend to be non-atopic and female, with a later onset of disease 
(Green, RH et al. 2002). Neutrophilic asthma is triggered by environmental exposures such 
as ozone, bacterial endotoxins and viruses (Douwes et al. 2002). Although inflammation of 
the airways is a prominent feature of neutrophilic asthma, the cytokine response differs from 
that of eosinophilic asthma. In some asthmatics, neither an excess of neutrophils nor 
eosinophils are present in sputum despite the persistence of asthma symptoms forming the 
paucigranulocytic asthma group. The paucigranulocytic asthma type has been described as 
the most benign asthma type (Demarche et al. 2016; Ntontsi et al. 2017). In contrast, mixed 
granulocytic asthma inflammation is characterised by mixed eosinophilic and neutrophilic 
inflammation and shares features of both types (Ntontsi et al. 2017). 
With the advent of more sophisticated tools, asthma classification has moved towards the 
integration of clinical features, inflammation types and molecular properties to define more 
accurate phenotypes termed as endotypes. Classifying asthma type in more detail provides 
the prospect of identifying the endotypes most at risk of infection-related complications and 
tailoring asthma treatment to suit the patient better (Deliu et al. 2016). 
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1.3.3. Type 2 dominant inflammation in asthma 
While Th1 responses are crucial for viral defence, Th2 responses are crucial against 
parasitic pathogens. Differentiation to Th1 or Th2 is a highly polarised mechanism, as is 
evident from the crossregulation of activating cytokines and transcription factors observed 
in Th1 and Th2 responses (Saravia, Chapman & Chi 2019). Th2 responses can be 
abnormally activated by allergens in asthma, as is explained in Figure 1:2. In the lung tissue, 
the allergens detected by APCs such as DCs, macrophages and monocytes activate type 2 
immune responses. Initially, this was thought to involve only conventional T- helper cells 
(Th2), but more recent studies have highlighted the importance of ILCs, so type 2 immune 
response or type 2 inflammation are now the preferred terms (Mjösberg & Spits 2016). 
Currently, it is known that epithelial cells are also directly activated by allergens and produce 
IL33, IL25 and thymic stromal lymphopoietin (TSLP) cytokines (Angkasekwinai et al. 2007; 
Kurowska-Stolarska et al. 2008; Rochman et al. 2007). These epithelial-induced cytokines 
act on naïve T-cells and type 2 innate lymphoid cells (ILC2) to induce type 2 cytokine 
production. 
Type 2-dominant asthma inflammation is a consequence of Th2 polarisation and ILC2-
dependent processes. Type 2 cytokines IL13, IL4, IL5 and IL9, recruit eosinophils, induce 
B-cell switching to produce allergen-specific IgE and activate mast cells. Granulocyte 
infiltration in the lung causes many of the symptoms experienced by patients. In type 2 
inflammation, eosinophils, mast cells and basophils dominate and contribute to the airway 
inflammation, hyperresponsiveness, mucus secretion and epithelial cell lining damage. In 
addition to allergens, airway irritants can act via the innate ILC2 cells in asthma; these 
produce IL5 and IL13 in the absence of adaptive immunity (Hirose et al. 2017; Lambrecht & 
Hammad 2014; Scanlon & McKenzie 2012). 
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Figure 1:2 Allergic and non-allergic airway inflammation. 
In allergic airway inflammation, allergen stimulates epithelial cells to secrete IL33, TSLP, 
and IL25 and DCs to activate T-cells. Activated Th2 cells recruit eosinophils and mast cells, 
activate B-cell class switching and cause bronchial hyperreactivity. In the presence of non-
allergenic stimuli, IL33, TSLP, and IL25 are secreted by eosinophils and macrophages but 
activate ILC2 to secrete type 2 cytokines. Reprinted by permission from Springer Nature 
(Lambrecht & Hammad 2014). 
1.3.4. Severe respiratory infections and risk of exacerbations in asthma 
A comparative longitudinal study of couples where one partner was asthmatic, found that 
the asthmatic partners suffered from more severe lower respiratory infections caused by RV 
than the healthy partners, whereas upper respiratory infections occurred with similar 
frequency in both groups (Corne et al. 2002). A smaller scale study found similar results with 
experimental RV infection: asthma was associated with lower respiratory tract infection 
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rather than being limited to upper respiratory tract infection as seen in healthy people. 
Interestingly, there was a correlation between the viral load and the severity of symptoms in 
asthmatic people but not in healthy controls (Message et al. 2008). Increased RV load in 
asthma patients has not been replicated by all studies (DeMore et al. 2009; Denlinger et al. 
2011; Kennedy et al. 2014) but may be associated with co-infection with pathogenic bacteria 
(Kloepfer et al. 2014). However, influenza infections seem consistently severe in asthma 
(Kloepfer et al. 2012; Santillan Salas et al. 2013). Because many of the experimental 
infection studies include only mild asthma patients, it is possible that the increased infection 
severity might only be seen in severe asthma patients or with a large amount of virus. The 
exposure to allergens seems to also complicate the defence against a virus. Total IgE was 
shown to positively correlate with worse respiratory infection symptoms (Zambrano et al. 
2003). 
In addition to severe cold symptoms, also asthma symptoms are aggravated during 
respiratory infections. Viral infections were recognised as a major cause of asthma 
exacerbations over 20 years ago (Nicholson, Kent & Ireland 1993). RV infection was found 
to increase the risk of an asthma exacerbation almost two-fold in children (Miller et al. 2012). 
Co-exposure to allergens together with a virus may further increase the likelihood for acute 
asthma exacerbations resulting in hospitalisations, compared to just allergen or virus alone 
(Murray, CS et al. 2006). Respiratory infection is likely to cause excessive inflammation in 
the setting of the already inflamed allergic asthmatic airways. 
One explanation for the difference is altered ability to clear the viral infection. Bronchial 
epithelial cells from asthmatic people are compromised in their ability to undergo apoptosis 
(Wark et al. 2005). Because early apoptosis is important for clearing viruses, this is a 
potential mechanism by which asthmatics cannot clear viruses as efficiently as healthy 
people. Physiological properties of the asthmatic airways could contribute to infection 
susceptibility as asthmatic airways are chronically inflamed and primed for 
bronchoconstriction upon a variety of external stimuli. Since the asthmatic airways are 
already damaged from a constant state of inflammation, in theory, this could make it easier 
for pathogens to infect. The type 2 cytokine IL13 increases the numbers of mucus-producing 
goblet cells in asthma, and it was shown that RV preferentially infects goblet cells, boosting 
RV infection opportunity in asthmatic airways (Lachowicz-Scroggins et al. 2010). While 
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these mechanisms may contribute to the worse infection in asthma patients, deficiencies in 
the antiviral immune response are also likely to contribute and are discussed next. 
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1.4. Is there a deficient antiviral immune response in asthma? 
Asthma has been found to be a risk factor for several microbial infections comprehensively 
reviewed by Juhn (2014). The authors also discuss how asthma treatment plans should 
include a focus on infection prevention and argue that asthma is an immunodeficiency 
condition. In support of this idea, a recent study with over 100,000 participants revealed that 
people with asthma have a hazard ratio of 1.65 for infection-related hospitalisation (including 
non-respiratory infections) compared to people with no atopic conditions (Helby et al. 2017). 
While many questions remain, much progress has been made in previous years to 
understand how asthma patients are deficient in their antiviral immune responses. 
1.4.1. T-helper cell response imbalance 
The type 1 response is necessary for efficient antiviral immune response, whereas in 
asthma, the airway inflammation is usually characterised by a type 2 response. The bias 
towards type 2 response in asthmatics extends to antiviral response as well: while healthy 
people have a type 1 dominated response, asthmatics seem to have a more type 2 
dominated response against viral infections (Brooks et al. 2003; Message et al. 2008). The 
Th1 adaptive immune response induced by IL10 and IFNγ in experimental RV infection was 
found to be associated with milder infection in healthy controls, whereas secretion of Th2 
cytokines IL4, -5, -13 were associated with asthma and more severe infection as measured 
from sputum, blood and bronchial lavage (Message et al. 2008). We have shown that the 
type 2-skewing cytokine IL33 induces type 2-dominant RV response in asthmatics but not 
in healthy people (Jurak et al. 2018), suggesting that the allergen-induced IL33 production 
in the lung can impair sufficient Th1 polarisation for antiviral immune response. Type I IFNs 
are able to suppress type 2 immune response and upregulate type 1 response, and the 
downregulation of type 2 responses in ILC2 further reduces airway hyperreactivity, a 
mechanism which has been found to be mediated by the TLR7/8-dependent type I IFN 
production in pDC (Duerr et al. 2015; Maazi et al. 2018; Pritchard, Carroll, et al. 2012). The 
next section reviews the literature on the current understanding of IFN deficiency in asthma, 
and how this may contribute to imbalances in type 1/type 2 immune responses. 
1.4.2. How consistent is the evidence for interferon deficiency in asthma? 
Due to the central role of IFN in antiviral immune response, much of the research effort has 
focused on examining IFN production in asthma patients. IFNα production has been shown 
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to correlate with viral load, providing evidence that low IFN production can cause higher viral 
load and more severe infection (Contoli et al. 2006; Edwards, MR et al. 2013). Several 
studies to date have reported type I IFN deficiency in response to virus across various age 
groups in airway epithelial cells of asthma patients (Baraldo et al. 2012; Edwards, MR et al. 
2013; Sykes et al. 2012; Wark et al. 2009; Wark et al. 2005; Zhu et al. 2019) and in circulating 
blood leukocytes (Bufe et al. 2002; Durrani et al. 2012; Gehlhar et al. 2006; Iikura et al. 
2011; Pritchard et al. 2014). Additionally, type III IFN, the prominent IFN produced by the 
epithelium, has also been reported to be lower in asthma patients (Baraldo et al. 2012; 
Contoli et al. 2006; Edwards, MR et al. 2013). However, not all studies have confirmed IFN 
deficiency in asthma (Lopez-Souza et al. 2009; Patel et al. 2014; Sykes et al. 2012; Sykes 
et al. 2014). 
The discrepancy between the studies suggests that IFN deficiency may be associated with 
a specific asthma phenotype, and many of these studies have, therefore considered the 
heterogeneity of asthma. Some report that proper asthma symptom control may preserve 
the IFN response in asthmatics (Sykes et al. 2014) and others report that IFN deficiency is 
only observed in severe asthma (Edwards, MR et al. 2013). A limitation for considering the 
association with specific asthma phenotypes is that many of the aforementioned studies 
included only mild individuals. However, they show that inhaled steroid medications, taken 
to moderate and severe asthma symptoms, do not seem to influence IFN production (Contoli 
et al. 2006; Wark et al. 2005). The role of allergies seems important as total IgE has been 
shown to inversely correlate with IFN production (Baraldo et al. 2012; Gill et al. 2010), 
although also non-atopic asthmatic children had decreased IFN production compared to 
non-atopic non-asthmatic children (Baraldo et al. 2012). Interestingly, a study in older adults 
found that deficient IFNα production was associated with poorly controlled neutrophilic 
asthma, but was not associated with atopy or eosinophilic asthma (Simpson et al. 2016). 
The association between neutrophilic asthma and IFNα production is somewhat surprising 
considering that counterregulation between IFN production and Th2 immunity is strongly 
supported in the literature (Koltsida et al. 2011; Pritchard, White, et al. 2012). 
Together, the studies examining viral load described in section 1.3.4 and examining IFN 
production described here suggest that deficiencies in antiviral immune responses are not 
universal across all asthma patients but may only affect only a subgroup of patients or affect 
different asthma phenotypes at different degrees. A study from last year employed machine 
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learning to identify cytokine response profiles that are associated with asthma in a birth 
cohort of 300 children, studied at the age of 11 years (Custovic et al. 2018). The cluster at 
the highest risk of having asthma in the early years of life had the lowest IFN response, a 
finding which supports the notion that asthma is associated with IFN deficiency. However, 
the cluster with the highest IFN response to RV was similarly associated with asthma, but 
only when diagnosed in later childhood. The work of Custovic et al. (2018), supports the 
view that only a subgroup of asthmatics are susceptible to IFN deficiency as asthmatic 
children were present in each cytokine response cluster. Sample size is a significant 
limitation to some of these studies, for example Lopez-Souza et al. (2009) reported no 
difference in IFN synthesis between just six asthma cases and five controls. Given that the 
research field is yet to agree what asthma phenotype is most closely linked to antiviral type 
I IFN deficiency, some of these small studies are likely underpowered to show immune 
deficiency or phenotype driving the deficiency, and further investigations are needed in 
much larger studies. 
Interestedly, the number of type I IFN producing pDCs has been found increased in 
asthmatic adults, whereas their number was found reduced in preschool children who 
subsequently developed asthma (Silver et al. 2009; Spears et al. 2011; Upham et al. 2009). 
The theory of immunodeficiency in asthma, proposed by Juhn 2014, is in line with this finding 
as pDCs in asthmatics have been found deficient in producing antiviral IFNα in response to 
an influenza virus, partly mediated by IgE crosslinking of IgE receptors on the surface of 
pDC (Gill et al. 2010). Therefore, it seems plausible to propose that asthmatic adults have 
a feedback mechanism in place for increasing the number of pDC in response to viral 
infections in order to ensure sufficient type I IFN production. Such a mechanism might not 
be sufficiently developed in young children, such that a developmental delay in pDC 
maturation or attainment of maximal type I IFN synthesis might predispose to early and 
severe respiratory viral infections and subsequent asthma development. A study 
demonstrated that type I IFN production induces pDC apoptosis in the spleen, confirming a 
feedback mechanism between pDC numbers and amount of type I IFN (Swiecki, M. et al. 
2011). Furthermore, pDCs were found to downregulate type 2 cytokine response after RV 
stimulation (Pritchard, Carroll, et al. 2012). Since different types of IFN have been shown to 
be low in asthmatics upon viral stimulation, absence of negative type 2 regulation from IFN 
can further contribute towards the type 2 cytokine biased response. 
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1.4.3. Are TLR7 and TLR8 associated with asthma? 
Exogenous IFNβ is able to rescue the normal antiviral response in asthmatic bronchial 
epithelial cells; hence, the associated immune defect most likely lies upstream from type I 
IFN synthesis (Cakebread et al. 2011). Thus, the cause for low type I IFN production is likely 
to involve variations in the ability of viruses to enter cells, the ability to detect viral nucleic 
acids within cells, or the ability to induce IFN gene transcription. Deficient TLR7 function 
would explain inadequate type I IFN production and susceptibility to viral infections in 
asthma. Compromised TLR8 function could also prevent proper Th1 induction and 
contribute to Th2 bias in asthma. 
Around the same time as IFN deficiency was first identified in asthma (Bufe et al. 2002), a 
Danish research group identified the X-chromosome region that contains TLR7 and TLR8 
as a candidate region for asthma susceptibility (Haagerup et al. 2002), subsequently 
confirmed in another cohort (Brasch-Andersen et al. 2008; Haagerup et al. 2004) with the 
association restricted to TLR7 SNP rs179008 and TLR8 SNP rs2407992 (Moller-Larsen et 
al. 2008). TLR7/8 SNPs were also associated with asthma in a Chinese Han population 
(Zhang, Q et al. 2015), in Finnish children after contracting bronchiolitis as infants 
(Törmänen et al. 2017), and in Brazilian families (Genov et al. 2014). Recently, a SNP 
rs850637 in the TLR7/8 gene region was identified as an asthma risk gene in a GWAS study 
(Ferreira et al. 2019). Several associations have also been reported between allergic rhinitis 
and TLR7/8 in Swedish and Chinese populations (Nilsson et al. 2012) and a Swedish 
population (Henmyr et al. 2016). Together, these studies indicate genetic alterations in the 
TLR7/8 genes in asthma patients, with the potential to affect their function. 
Indeed, impaired TLR7 function has been reported in asthma patients. Plasmacytoid DC 
and alveolar macrophages from asthma patients were shown to express less TLR7 gene 
(Pritchard et al. 2014; Rupani et al. 2016) and protein (Rupani et al. 2016) after RV 
activation. TLR7 stimulation with a specific agonist resulted in reduced gene expression of 
several ISGs in peripheral mononuclear cells (PBMC) from asthma patients (Roponen et al. 
2010). Shikhagaie et al. (2014) showed that asthmatic patients had reduced expression of 
TLR7 in bronchial basal, ciliated and goblet epithelial cells together with leukocytes such as 
pDC, CD8+ and CD4+ T lymphocytes, EG2+ eosinophils and mast cells. The reduction in 
TLR7 expression correlated with asthma severity. Shikhagaie and colleagues (2014) also 
found overexpression in neural cells, which is intriguing. 
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Two of the studies included mild-to-moderate atopic asthmatic patients (Pritchard et al. 
2014; Roponen et al. 2010), but one study reporting changes in TLR7 expression and 
function included both atopic and non-atopic severe asthma patients (Rupani et al. 2016) 
and found that TLR7 gene expression was similar between atopic and non-atopic 
asthmatics. Roponen et al. (2010) found that the TLR7 impairment was seen only in atopic 
asthmatics and not in atopic non-asthmatics or non-atopic asthmatics, together suggesting 
that the TLR7 impairment is independent of atopy status. Instead, Rupani et al. (2016) 
showed that TLR7 gene expression correlates inversely with asthma control questionnaire 
(ACQ) score and the number of asthma exacerbations suffered in the past 12 months, 
suggesting either that poorly controlled airway inflammation might reduce TLR7 function, or 
that impaired TLR7 expression or function predisposes to repeated virus infections, poor 
asthma control and recurrent asthma exacerbations. While asthma control is similar 
between different asthma inflammatory phenotypes (Ntontsi et al. 2017), reduced TLR7 
expression was seen only in eosinophilic phenotype in another study (Hatchwell et al. 2015). 
The conflicting reports could be due to the different cell sampled, as Hatchwell et al. (2015) 
studied endobronchial biopsies. 
Even though TLR8 SNPs have been associated with asthma, research on TLR8 in asthma 
is scarce (Pritchard et al. 2014; Sykes et al. 2013). TLR7 seems to be the popular sibling 
due to its ability to induce type I IFN, whereas the role of TLR8 lies in regulating inflammatory 
responses. Animal models have studied the role of TLR8 in allergic disease; however, 
translation of those studies into human biology is difficult due to the realisation that TLR8 
function in mice differs from human TLR8. In humans, TLR8 and TLR7 are expressed in 
separate cell populations, but in mice, both are expressed together, and TLR8 is involved in 
regulating TLR7 (Paul et al. 2016; Tran, Manzin-Lorenzi & Santiago-Raber 2015). 
The indication for atopy-independent TLR7 deficiency is surprising considering the body of 
evidence suggesting a role in counterregulating type 2 responses. Gill et al. (2010) found a 
counterregulatory relationship between TLR7 and the IgE receptor, FcεRI, in pDCs. The 
finding that pDC express both TLR7 and FcεRI in abundance is intriguing as TLR7 induces 
Th1 immunity via IFNα production and FcεRI engagement inhibits IFNα production and 
induces Th2 immunity, most likely via CCL28 (Grayson et al. 2007). These findings indicate 
that pDCs have a role in regulating the balance between Th1 and Th2 responses and that 
this may be mediated via TLR7. FcεRI expression in allergic asthma patients inversely 
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correlated with IFNα response to influenza virus activated pDCs, and in addition, activation 
of FcεRI by IgE crosslinking further reduced the IFNα response and TLR7 gene expression 
(Gill et al. 2010). Conversely, TLR7 agonist or influenza virus stimulation reduced FcεRI 
receptor expression, indicating a counterregulation between the receptors (Gill et al. 2010). 
Because high blood IgE levels usually characterise allergic asthma, these results further 
support low TLR7 gene expression in allergic asthma and consequent IFN response 
impairment. On the other hand, these results suggest that TLR7 activation will downregulate 
FcεRI mediated immune response and suppress the Th2 skewed immune response that is 
characteristic of asthma and results in the symptoms. Others have supported the 
counterregulation between type I IFN production and IgE activation in pDC (Durrani et al. 
2012; Schroeder et al. 2005). 
Animal studies indicate that TLR7 agonists are capable of reducing Th2 cytokines in mice, 
though there is no consensus on whether they can induce Th1 cytokines. In several animal 
models, TLR7 agonists have been shown to reverse experimental asthma and allergies 
(Aumeunier et al. 2010; Du, Q et al. 2009; Moisan et al. 2006), as well as normalise asthma 
cytokine and remodelling (Camateros et al. 2007; Duechs et al. 2011) and associated gene 
expression (Camateros et al. 2009). It was shown that the TLR7 agonists alleviate acute 
asthma symptoms by reducing bronchoconstriction (Ekman, Adner & Cardell 2011; 
Kaufman, Fryer & Jacoby 2011). Studies have found that TLR7’s ability to diminish asthma 
symptoms is variously mediated via IL10 and IFNγ (Nencini et al. 2015), regulatory T-cells 
(Pham Van et al. 2011) or type I IFN (Matsui et al. 2012) depending on the ligand used. 
Independently of the Th2 counteracting abilities, a TLR7 agonist was also shown to directly 
reduce IgE generation in B cells, adding another means for reducing allergies (Shen, Lu & 
Wu 2008). Also, TLR8 agonist was shown to be a potent inhibitor of an allergic response in 
dogs (Royer et al. 2016). 
Animal models and ex vivo human studies (Edwards, S et al. 2013) suggest that TLR7/8 
activation has the potential to reduce the allergic and asthma inflammation and TLR7/8 
agonists are therefore highly promising for drug development purposes. The TLR7/8 
agonists in current use are conventionally used topically against external anogenital warts 
and basal cell carcinoma. Since it was first discovered that they could skew the CD4+ Th0 
cytokine response towards Th1 (Wagner et al. 1999), their usefulness in allergic disease 
has been investigated. Also, the activation of TLR7 and TLR8 has been studied as vaccine 
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adjuvants as they seem to be able to activate immunity effectively (Rajagopal et al. 2010; 
Siebeneicher et al. 2014). Some TLR7 agonists developed and trialled for reducing asthma, 
and allergic rhinitis symptoms have progressed to phase 2 (Anwar et al. 2019; Leaker et al. 
2012), and a TLR8 agonist has shown potential as an allergic rhinitis modulator due to its 
Th1 polarising cytokine repertoire (Horak 2011). 
In addition to the Th2 modulating effect, TLR7 agonists relax human airway smooth muscle 
strips in vitro (Drake et al. 2013) previously modelled only in animals (Drake et al. 2013; 
Ekman, Adner & Cardell 2011; Kaufman, Fryer & Jacoby 2011). Interestingly, the 
mechanism of bronchodilation may be independent of TLR7 signalling and instead signify 
an off-target effect of the quinoline containing TLR7 agonists (Larsson et al. 2016), further 
supporting the development of TLR7/8 agonists as asthma medications. 
1.4.4. Asthma genes associated with immune function 
The notion that asthma has a strong genetic basis is well established, with twin studies 
suggesting that genetics explain 36–77% of the asthma risk (March, Sleiman & Hakonarson 
2013). Asthma is thought to be a complex polygenic disease, so large population-level 
studies such as Genome-Wide Association Studies (GWAS) are needed to find associated 
genetic variants that may individually explain only a small amount of the risk of asthma. The 
17q12–21 locus is important in childhood-onset asthma and includes the ORM1-like protein 
3 (ORMDL3) and Gasdermin-B (GSDMB) genes, although it is notable that no association 
with allergy risk was found within this locus (Dijk et al. 2013). Instead, the IL6R gene, which 
is the receptor for IL6, is significantly associated with atopic asthma (Ferreira et al. 2011), 
and importantly, IL6 was found elevated in asthma and associated with severe asthma 
(Wood et al. 2012). In other studies, IL18R1, IL33, SMAD3, HLA-DQ and IL2RB loci have 
been associated with asthma (Zhang, Y, Moffatt & Cookson 2012). Many of these 
associated genes are related to antigen presentation, cytokine signalling and epithelial 
repair, suggesting that people with asthma have inappropriate immune responses and 
abnormal repair mechanisms, though there is little evidence in GWAS that genetic variants 
in type I IFN genes or IFNAR are associated with asthma risk. There may be a need for 
genetic studies that specifically focus on people with asthma who experience very high rates 
of respiratory viral infections. 
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A very recent GWAS study that included over 400, 000 people found an association between 
childhood asthma and the SNP rs850637 on X chromosome, in the vicinity of both TLR7 
and TLR8 genes (Ferreira et al. 2019). The SNP was further confirmed in a validation cohort 
and presents a novel finding as most asthma GWAS published to date have not analysed 
the X-chromosome. Some candidate-gene studies have reported an association between 
variants in the TLR7/TLR8 region and asthma (Genov et al. 2014; Moller-Larsen et al. 2008; 
Nilsson et al. 2012; Törmänen et al. 2017), but these were small studies with relatively weak 
associations. 
Another study searched for associations between SNPs in genes involved in antiviral 
immunity, asthma severity and respiratory infections in children (Loisel et al. 2016). The 
genes that appeared most significantly associated – STAT4 and MX1 – have been replicated 
in two other cohorts. Other key genes identified were JAK2, VDR, DDX58, and EIF2AK2. 
Many of those genes are involved in Th1 and Th2 T cell differentiation or IFN pathways. This 
study provides evidence that functional polymorphisms increase risk of asthma and 
respiratory infection severity in children. 
1.4.5. Sex-dependent immune responses 
Given that TLR7 and TLR8 are located on the X chromosome, it is relevant to review the 
epidemiological studies examining associations between sex and asthma risk. Pre-
pubescent boys are more likely to have asthma than girls (Zein & Erzurum 2015), whereas 
their asthma symptoms often diminish in adulthood. The opposite is true for girls: lower 
prevalence in childhood is balanced by higher rates of asthma in adult women. The National 
Health Survey reveals a ‘cross-over’ at the age of 20–24 when there is similar prevalence in 
both genders (Clarke, Norris & Schiller 2017). The timing of the crossover suggests a strong 
hormonal association with asthma risk, and higher testosterone levels are known to be 
protective against type 2 immunity, in men (Laffont et al. 2017). 
In relation to TLR7/8, Berghofer et al. (2006) found that TLR7 induces more IFNα in pDCs 
in females than in males. This finding is significant, considering the gender bias in asthma 
and the known associations between asthma and TLR7/8. Bias in TLR7/8 function is also 
significant for autoinflammatory diseases such as systemic lupus erythematosus SLE, in 
which there is high type I IFN production, and which is nine times more prevalent in females 
than males (Krieg 2007). Another study found there is a difference between the sex and age 
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and the adaptive immune response to RV, pre-menopausal women being the most efficient 
responders (Carroll et al. 2010). This result supports Berghofer’s findings that the TLR7 
mediated sex bias leads to more effective IFNα production women but also indicates 
hormonal influence. Laffont et al. (2014) expanded on the work of Berghofer in establishing 
sex differences in TLR7-mediated IFNα production. They used a humanised mouse model 
with human cord blood cells from men and women to show how the immune system works 
differently in female and male hormonal environment. They showed that the female 
environment and genetic factors independently influence IFNα production. 
The sexual dimorphism in the immune response appears to be common to many stimuli and 
immune conditions, as reviewed by Furman (2015). Men show a weaker response to viruses 
and are more susceptible to viral infections than women, which relates to reduced cytokine 
production. This phenomenon has been shown across viral diseases such as HIV and HPV 
as well as in weaker response to vaccines. As a consequence, there has been discussion 
whether men and women should be treated with different vaccine doses, and indeed, 
retrospective analysis of previous studies reveals that vaccine trials deemed unsuccessful 
were, in fact, successful – in women. In addition to the work of Laffont et al. (2014), several 
other studies imply that oestrogen enhances the immune response while androgen 
dampens it (Kadel & Kovats 2018). However, the enhanced immune responses may come 
with a downside, as females are at more risk of mortality from influenza infections as they 
tend to respond with a “cytokine storm” leading to worsened symptoms in cell level 
(Robinson, DP et al. 2011). These findings reiterate the importance of considering sex-
associated differences when studying antiviral and asthma immune responses. 
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1.5. Summary 
The healthy immune defence against the common cold virus RV involves TLR7/8-mediated 
type I IFN and type 1-biased cytokine production. T-helper cell polarisation towards Type 1 
response, and possibly ILC1 cells, seem to be a necessary part of the healthy antiviral 
immune response. Asthma patients have been reported to suffer from worse RV infections 
that have been associated with increased viral loads and imbalance between type 1 and 
type 2 immunity. Investigations into deficiencies have revealed deficiencies in type I and 
type III IFN production and TLR7/8 function, which may mediate this imbalance. The 
literature is controversial, and in disagreement with the asthma phenotypes that are 
associated with the antiviral immune response deficiencies, however many of the studies 
examined only small study groups. Genetic variation in TLR7/8 has been associated with 
asthma and may influence the deficient TLR7/8 reported in asthma. Strong evidence 
indicates that immune responses may vary with sex, further complicating the issue. 
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1.6. The objectives and aims of this research 
Three primary aims of this study are: 
1. To determine what clinical and immunological parameters are associated with self-
reported respiratory infection frequency, the presence of asthma, asthma severity and 
control, with a specific focus on the role of TLR7/8 gene expression and function, and the 
extent to which this differs between women and men. 
2. To examine what host and transcriptional variations predict variation in the potency of 
antiviral type I IFN responses in vitro and determine how transcriptome patterns vary 
between individuals with high and low antiviral type I IFN responses. 
3. To examine the functional impact that genetic variations in the TLR7/8 region has on 
TLR7/8 gene expression, downstream cytokine production, antiviral immunity, and immune 
cell counts in peripheral blood. 
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 CLEC4C gene expression 
can be used to quantify circulating 
plasmacytoid dendritic cells 
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Overview 
Increasing sample size for a research study decreases the chance of type I and II errors 
tremendously, however, increased sample processing time, and complexity poses a 
considerable burden for study completion. To complete the aim of 300 recruits for the current 
study, we were required to limit sample processing time to avoid considerable delays to 
proposed timelines. Plasmacytoid dendritic cells (pDC) are of considerable interest to the 
current study because they are the main producers of type I interferon, express TLR7, a 
receptor of interest for this project, and are recognised to play a role in both asthma and 
antiviral immunity. Quantifying pDC in each sample by the standard method of flow 
cytometry was not considered practical as that would have increased sample processing 
time and cost. However, because quantifying cells by flow cytometry is based on unique 
receptor detection on each cell type, we hypothesised that gene expression of these same 
unique receptors utilised in flow cytometry could be used to quantify pDC in a sample. In 
this published study, we identify two receptors (CLEC4C and LILRA4) unique to pDC, 
measure their gene expression with RT-PCR, and compare the results obtained to CLEC4C 
and LILRA4 frequency measured by flow cytometry in peripheral mononuclear cells and 
whole blood. In this published chapter, we show that the two measurements are moderately 
correlated, justifying the use of CLEC4C gene expression as a tool to estimate pDC quantity 
in circumstances where flow cytometry is not practical. These measurements were 
employed for the subsequent chapters in this thesis. We show herein that CLEC4C gene 
expression is a robust indicator of pDC quantity that is unaffected by cell activation, whereas, 
the other evaluated gene, LILRA4, was deemed unreliable as a cell marker in activated cells. 
The following published article has been edited for in-text references. 
  
2:33 
 
CLEC4C gene expression can be used to quantify circulating plasmacytoid dendritic 
cells 
Liisa Murray, M. Sc.1, Yang Xi, PhD1, John W Upham, MD, PhD1,2*, 
CLEC4C gene expression can be used to quantify circulating plasmacytoid dendritic cells, 
Journal of Immunological Methods, 
Volume 464, 
2019, 
Pages 126–130, 
ISSN 0022–1759, 
https://doi.org/10.1016/j.jim.2018.11.001. 
(http://www.sciencedirect.com/science/article/pii/S0022175918303387) 
Affiliations: 
1. The University of Queensland Diamantina Institute, The University of Queensland, 
Translational Research Institute, Brisbane, QLD 
2. Department of Respiratory Medicine, Princess Alexandra Hospital, Woolloongabba, 
QLD, Australia 
Acknowledgements: 
This work was supported by project grant APP1128010 from the National Health and 
Medical Research Council (NHMRC) of Australia. LM was supported by a Charles Mitchell 
PhD Scholarship awarded by the Asthma Foundation Queensland. The authors 
acknowledge the TRI for providing the excellent research environment and core facilities 
that enabled this research. We particularly thank the Flow Cytometry Core Facility. 
Declarations of interest: 
Authors have no conflicts of interest to disclose. 
2:34 
 
Keywords: 
pDC; CLEC4C; CD303; BDCA2; LILRA4; ILT7; CD85g; RT-PCR; FACS; gene expression; 
transcriptome; PBMC; whole blood  
2:35 
 
Abstract 
Plasmacytoid dendritic cells (pDC) are an important type I interferon producer that play an 
important role in the first line of host defence during viral infection. Abnormalities in pDC 
numbers and function have been associated with several health conditions. Quantifying pDC 
is important for understanding pDC related immune responses in viral infections and other 
diseases, however the current methods for quantifying pDC using flow cytometry have 
limited utility in large cohort studies involving multiple centres with limited access to flow 
cytometry. We reasoned that examining gene expression of the pDC marker C-type lectin 
domain family 4 member C (CLEC4C, also known as CD303 and BDCA2) in combination 
with pDC exclusive leukocyte immunoglobulin like receptor A4 (LILRA4, also known as 
CD85g and ILT7) might provide a more practical method that could be applied to multi-centre 
studies. Our results show a moderate correlation between pDC numbers measured by 
surface staining and CLEC4C gene expression in whole blood (rho=0.39, P=0.037, as well 
as a high correlation between CLEC4C gene expression in whole blood and peripheral blood 
mononuclear cells (rho=0.79, P<0.001). LILRA4 gene expression did not provide additional 
useful information. Our results indicate that measuring CLEC4C gene expression can 
provide an alternative method for quantifying pDC numbers in human samples. 
Highlights 
• CLEC4C gene expression measurement can be used to quantify relative pDC count. 
• Gene expression correlates moderately with pDC surface staining. 
• This method enables estimation of pDC counts retrospectively from transcriptome data 
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2.1. Introduction 
Plasmacytoid dendritic cells (pDC) are recognised as the predominant type I interferon 
producing cell type in the primary antiviral response. Not only do pDC constitutively express 
viral nucleic acid-sensing pattern recognition receptors such as toll-like receptors, pDC 
contribute well over 90% of the type I interferon produced during a viral infection (Xi et al. 
2015), which makes them highly relevant to host defence and pathogenesis in a variety of 
specific diseases. Alterations in numbers and function of pDC have been associated with 
delayed viral clearance (Dhamanage, Thakar & Paranjape 2016), autoimmunity, allergic 
disease and cancer (Swiecki, Melissa & Colonna 2015). 
While there are a number of methods to study pDC function in experimental animals, 
studying pDC in human diseases presents several challenges, given that they are a rare 
leukocyte population in peripheral blood, accounting for <0.4 % of peripheral blood 
mononuclear cells (PBMC). Both pDC purification and pDC depletion (Xi et al. 2017) with 
immuno-magnetic beads or fluorescence activated cell sorting (FACS) (Kassianos et al. 
2010) have been used to study pDC function. Numbers of circulating pDC can be measured 
accurately with flow cytometry, but this usually requires fresh blood samples which is not 
practical in large multi-centre cohort studies where there may not be ready access to flow 
cytometry. Recently, small volume blood samples have been used to analyse the 
transcriptome, proteome and metabolome (Urrutia et al. 2016) in various human diseases. 
With the advent of methods to collect and stabilise blood samples for subsequent gene 
expression analysis, there is now a convenient and accessible tool which can be used in 
large scale research studies, especially where there is limited capacity for sample 
processing in the field. We therefore reasoned that measuring the expression of pDC 
specific genes might provide a more convenient method for researchers to estimate pDC 
numbers in blood samples, especially in situations where flow cytometry is not readily 
available. 
CLEC4C and LILRA4 are cell surface proteins that are expressed exclusively on pDC (Cao 
& Bover 2010; Xi et al. 2017). CLEC4C is a C-type lectin domain family 4 member C (also 
known as CD303 and BDCA-2) known to regulate antigen presentation and type I interferon 
production (Dzionek et al. 2001). Leukocyte immunoglobulin like receptor A4 (LILRA4; also 
known as ILT7 and CD85g) regulates TLR-mediated type I interferon production in pDC 
(Cao & Bover 2010) providing an important negative feedback loop for type I interferon 
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production. We hypothesised that the relative gene expression of CLEC4C and LILRA4 
measured by real time PCR would correlate with pDC cell numbers 
(CLEC4C+LILRA4+CD14- cells) measured by flow cytometry. Our findings show a moderate 
correlation score of 0.39 (P=0.037) between CLEC4C gene expression and pDC cell 
numbers measured with flow cytometry, thus providing an alternative method for estimating 
the pDC numbers in circulating blood. 
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2.2. Methods 
2.2.1. Participants 
We recruited 29 participants, of which 19 were female, with a mean age of 38.6 ± 13 years. 
All participants were healthy without respiratory infections within 4 weeks prior to their study 
visit. Metro South Health Human Research Ethics Committee approved the study, and all 
participants provided written consent. 
2.2.2. Sample preparation 
10 ml of heparinised blood and a PAXgene blood tube were collected from each participant. 
An aliquot of 1ml of heparinised blood was used to evaluate the percentage of the pDC in 
the whole blood using flow cytometry (section 2.2.3). PBMC were isolated from the 
remaining blood by density gradient centrifugation using Lymphoprep (Stemcell 
technologies, Vancouver, Canada) as described previously in Roponen et al. (2010). 1 x 106 
cells were used to evaluate the percentage of pDC in PBMC (section 2.2.4) and 4 x 106 
PBMC were stored in RNAprotect (Qiagen, Hilden, Germany) for RNA extraction and 
subsequently RT-PCR (section 2.2.5). 
2.2.3. Whole blood cell preparation 
300ul of whole blood per sample was washed once with 1ml of FACs buffer (1% heat-
inactivated foetal bovine serum in phosphate-buffered saline; foetal calf serum; Bovogen 
Biologicals, Keilor East, VIC, Australia). The red blood cells were then lysed with 2ml of 1X 
BD FACS lysing solution (BD FACSTM lysing solution, BD Cat#349202, San Jose CA, USA) 
for 30mins at dark and room temperature. After centrifuging, the supernatant was removed 
and cell pellet was washed with 1ml of FACs buffer followed by surface staining (section 
2:382.2.4). 
2.2.4. Surface staining and flow cytometry analysis 
The prepared cells (section 2.2.3) and isolated PBMC (section 2.2.2) were washed with 
FACs buffer and then stained with CLEC4C-PE (CD303, Miltenyi Biotec Cat# 130–090–511, 
RRID: AB_244168), CD14-PerCP (BioLegend Cat# 301824, RRID: AB_893251) and 
LILRA4-APC (CD85g, Thermo Fisher Scientific Cat# 17–5179–41, RRID: AB_10597138) in 
FACs buffer for 30min at 4°C in dark. The cells were then washed twice with the FACs buffer 
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and fixed in 2% paraformaldehyde. A total of ~500,000 gated events were acquired using 
LSRFortessa X-20 (BD Biosciences, San Jose, CA). Data was analysed using the FlowJo 
Tree Star software (version 7.6.1; FlowJo LLC, Ashland, OR, USA). 
2.2.5. RNA extraction and quantitative RT- PCR analysis 
RNA was extracted from the PAXgene tube using Preanalytix blood RNA kit (Qiagen, 
Maryland, USA) or from the PBMC stored in RNAprotect using RNeasy mini kit (Qiagen, 
Maryland, USA) plus DNase II digestion protocol. RNA was reverse-transcribed to cDNA 
with sensiFAST cDNA synthesis kit (Bioline, London, UK). Relative quantitative RT- PCR 
was performed from the cDNA with PowerUp SYBR Green (Applied Biosystems, CA, USA) 
mastermix with Lightcycler 480 (Roche) machine. Custom primers were purchased from 
Geneworks (SA, Australia) with sequences shown in appendices. Delta Ct of CLEC4C and 
LILRA4 gene expression was obtained against the mean Ct of the two reference genes B2M 
(Beta-2-Microglobulin) and UBC (Polyubiquitin-C precursor) (primer sequences in appendix 
Table 2:1). 
2.2.6. Statistical analysis 
Nonparametric (for FACS measurements) or parametric rank correlation test were 
performed between paired samples in R version 3.4.2 (R Core Team 2018) with cor.test() 
function. To compare paired samples from the same individuals, the Wilcoxon signed rank 
test was performed using GraphPad Prism 6 for Windows (GraphPad Software, San Diego, 
CA, USA). A two-sided p-value<0.05 was considered significant.  
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2.3. Results and discussion 
To validate gene expression quantification as a measurement tool we compared relative 
quantification by RT-PCR to the current ‘gold standard’, namely surface staining with FACS. 
In theory, the pDC frequency in each of the measurements should correlate but sample 
processing and technical variability were expected to produce variations. 
LILRA4 was previously identified as being stably expressed in unstimulated pDC compared 
to other immune cell types (Cho et al. 2008). CLEC4C was recognised as a pDC specific 
cell marker in 2001 (Dzionek et al. 2001), and we previously showed that it is markedly 
reduced in pDC depleted cell populations (Xi et al. 2017), therefore we used those two 
markers to detect pDC population (Figure 2:1:A). We compared whole blood to PBMC, and 
as expected the pDC frequency was higher in PBMC than in whole blood (Figure 2:1:B). 
 
Figure 2:1 Frequency of LILRA4 and CLEC4C expressing pDC in PBMC and whole blood. 
A) Top panels shows the gating strategy. Firstly, we gated on lymphocytes and monocytes 
based on forward and side scatter properties. CD14+ cells were then excluded, and the 
percentage of CLEC4C+ LILRA4+ cells was analysed. B) The percentage of 
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CLEC4C+LILRA4+ cells was enumerated in PBMC and whole blood. Note that 
LILRA4+CLEC4C+ pDC were more frequent in PBMC than in whole blood (Mann–Whitney 
U test, p-value 1.2e-07, n = 29). 
LILRA4 and CLEC4C expression were more strongly correlated in PBMC than in whole 
blood (Figure 2:2). In fact, the correlation coefficient for LILRA4 versus CLEC4C was similar 
with both the RT-PCR method (cor=0.84) and FACS method (rho=0.89) in PBMC. However, 
in whole blood, the correlation co-efficient for LILRA4 versus CLEC4C was higher for FACS 
(rho= 0.82) than for RT-PCR (cor = 0.7). It seems likely that the lower pDC frequency in 
whole blood, and the presence of additional cell types, increases the variability between 
samples and reduces the correlation coefficient. 
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Figure 2:2. Correlations between CLEC4C and LILRA4 as measured with FACS or with RT-
PCR in PBMC or whole blood. Correlation coefficient is cor for Pearson correlation test 
performed for normally distributed PCR data and Rho for Spearman correlation test of 
nonparametric FACS data. 
Overall, correlation scores were high (Figure 2:2), so we reasoned that the combined use of 
the two markers might further increase the precision of the method. To compare the two 
methods for pDC measurement, we correlated the mean frequency of 
CLEC4C+LILRA4+CD14- cells against the mean LILRA4 and CLEC4C gene expression for 
each sample in PBMC and whole blood. Correlation analysis (Figure 2:3:A) showed that 
both samples correlated highly for FACS measurements (rho=0.76, p=1.6e-06), and 
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similarly for RT-PCR samples (cor=0.7, p=2.6e-05). We concluded that both methods are 
accurate and that is likely to be relevant for studies with large sample sizes. 
 
Figure 2:3. Correlations between PBMC or whole blood with combined or single use of gene 
expression. A) Correlation between measures of pDC numbers in whole blood and PBMC 
with FACS above and PCR below. B: Correlation of pDC measurements using CLEC4C 
gene expression alone (left) or LILRA4 gene expression alone (right) between whole blood 
PCR and FACS above or PBMC PCR below. (rho = Spearman correlation coefficient, cor = 
Pearson correlation coefficient, P = P-value, sample size n = 29) 
However, we saw no significant correlation between mean RT-PCR and FACS 
measurements in PBMC (cor=-0.019, P=0.31) or whole blood samples (rho=0.35, P=0.067) 
to compare the relative pDC count of individuals. Since the whole blood sample correlation 
reached near significance, we then examined how individual gene expressions perform in 
whole blood. CLEC4C gene expression alone in whole blood samples correlated moderately 
with the mean frequency of CLEC4C+LILRA4+CD14- cells measured by FACS (Figure 2:3:B 
upper panel, rho=0.39, P=0.037). LILRA4 gene expression was not significantly correlated 
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with pDC measured by FACS (rho=0.29, P=0.13). CLEC4C gene expression alone 
correlated strongly between PBMC and in whole blood samples (cor=0.72, P=2.8e-07, 
Figure 2:3:B lower panel)) – at similar level to that seen with FACS (rho=0.76, p=1.6e-06, 
Figure 2:3:A upper panel. These results indicate that using both pDC markers for gene 
expression analysis is not beneficial. CLEC4C appeared to be a more robust marker than 
LILRA4, as its use alone showed the best correlation between the two methods (FACS vs 
RT-PCR) and showed stronger correlation between the two samples types (whole blood vs 
PBMC). 
Because of research interest in pDC biology during viral infection, it is important that 
selected pDC markers are unaffected by the state of the pDC activation. In our results, 
CLEC4C performed consistently across the two samples types and methods but LILRA4 did 
not, especially when using RT-PCR on whole blood samples. The available evidence 
suggests that LILRA4 gene expression may be more influenced by pDC activation status 
than CLEC4C gene expression (Cho et al. 2008; Xi et al. 2017) thereby making LILRA4 
gene expression unstable as a marker for estimating pDC numbers. Therefore technical 
factors and/or biological variability (e.g. subtle changes in cell activation induced by sample 
processing) could explain why CLEC4C gene expression appears to provide a more reliable 
estimate of pDC numbers than LILRA4 gene expression. Moreover, we recognise that a low 
participant number could have limited the study. For use with larger studies, the method 
requires optimisation and measurement of a known cDNA standard measurement across 
batches as an internal control. 
In conclusion, while flow cytometry remains the ‘gold standard’ for quantifying blood pDC, 
analysis of CLEC4C gene expression does provide a valid method for assessing relative 
pDC numbers across samples. Assessing LILRA4 gene expression does not provide 
additional useful information. Here we provide evidence that FACS measurements of pDC 
and RT-PCR measurements of CLEC4C gene expression correlate to a reasonable degree, 
so we recommend the use of CLEC4C and LILRA4 surface staining or CLEC4C gene 
expression analysis for estimating pDC numbers in human blood samples. Our findings are 
relevant to researchers with an interest in measuring pDC numbers in large patient cohorts, 
especially in field studies where flow cytometry is not readily available. 
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2.4. Appendices: 
Gene Direction Primer sequence 5’ – 3’ 
LILRA4  
forward CTCGTGGTCTCAGGAGCAACT 
reverse CAGTCTTGGAATCTGACTTCTTTTGT 
CLEC4C  
forward CCTCTGTCTGACCCTGCAT 
reverse GCCAAGCCCTTAGATCCTT 
UBC  
forward GCAGTTCTTGTTTGTGGATCGCT 
reverse TGACATTCTCGATGGTGTCACTGG 
B2M  
forward AGGCTATCCAGCGTACTCCAAAGA 
reverse CGGATGGATGAAACCCAGACACAT 
Table 2:1. Relative quantity of CLEC4C and LILRA4 gene expression was determined using 
delta Ct of CLEC4C and LILRA4 gene expression against the mean Ct of two reference 
genes B2M and UBC. 
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 Clinical features and 
TLR7/8-mediated antiviral immunity 
impact respiratory infection frequency 
and asthma in a sex-dependent manner 
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3.1. Introduction 
In this chapter, we examine the clinical and immunological parameters that are associated 
with respiratory infections and asthma. 
Respiratory infections place asthma patients at an increased overall risk of experiencing 
exacerbations, especially severe exacerbations requiring hospitalisation (Busse, Lemanske 
Jr & Gern 2010; Johnston et al. 1995). In addition to increased asthma symptoms, evidence 
shows that rhinovirus (RV) infections are more severe in asthma patients, resulting in a lower 
respiratory tract infection more often than in their healthy counterparts (Corne et al. 2002). 
More severe infections in mild asthmatics were also shown with an experimental RV 
infection (Message et al. 2008). A recent study of over 100,000 participants revealed that 
asthma increased the risk of being hospitalised for infections in general (Helby et al. 2017), 
indicating increased susceptibility to infections and their consequences. Despite the current 
evidence for increased severity of respiratory infections in asthma, it is unclear whether 
asthma patients are at a greater risk of contracting respiratory infections more frequently 
than healthy people. Ramette et al. (2018) showed that asthma is associated with frequent 
and prolonged infections in children at one, four and six years of age, but for adults, the 
frequency of confirmed RV infections is similar in asthma patients compared with healthy 
partners (Corne et al. 2002). 
The severe course of respiratory infections experienced by asthma patients point to 
deficiencies in their antiviral immune responses. The aberrant immune response against 
viral infections is thought to be the result of asthma-related inflammation, but also inherited 
immune deficiencies could result in higher viral loads since many genes that have been 
associated with asthma risk are part of the immune response (Vicente, Revez & Ferreira 
2017). A growing body of literature suggests that the production of type I interferon (IFN), a 
main antiviral cytokine, is deficient in a subgroup of people with asthma (discussed in section 
1.4.2). Lower levels of type I IFN in people with asthma has been associated with specific 
features of asthma including eosinophilic airway inflammation and severe asthma symptoms 
(Baraldo et al. 2012; Sykes et al. 2014). 
Type I IFN production is triggered by pathogen pattern receptors (reviewed in section 1.2.2). 
One of those is TLR7 that is activated by single-stranded RNA (ssRNA), the most abundant 
nucleic acid amongst respiratory viruses. TLR7 and its pathway molecules are essential for 
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sufficient type I IFN production, and deficiencies have been shown in response to RV in 
asthma patients (Pritchard et al. 2014). In addition to TLR7 function, IFNα production is 
affected by several other factors: fluctuation in plasmacytoid dendritic cells (pDC), the main 
interferon alpha (IFNα) producing cell type (Xi et al. 2015), sex and age (Carroll et al. 2010), 
and TLR8, another ssRNA receptor (Wang, J et al. 2006). All these complex factors may 
contribute to variations in IFNα production. 
IFNα induced by TLR7 in pDC, as well as the proinflammatory cytokines induced by TLR8, 
are central in driving type 1-dominant antiviral immune responses. The type 2-oriented 
immunity in asthma antagonises type 1-responses, and there is evidence that TLR7 
activation helps reduce type 2 immunity in asthma (Duechs et al. 2011). However, it is 
unclear if TLR7 levels are reduced in asthma and if it is associated with asthma severity, 
control or atopic asthma. 
Deficiencies in the pDC-TLR7-IFN axis have been associated with reduced antiviral immune 
responses in asthma (Edwards et al. 2017; Lynch et al. 2014; Pritchard et al. 2014), but it is 
uncertain if this causes asthma patients to become susceptible to respiratory infections. 
Therefore, this study sought to determine what clinical and immunological parameters are 
associated with self-reported respiratory infection frequency, the presence of asthma, 
asthma severity and control, with a specific focus on the role of TLR7/8 gene expression 
and function. Further, we sought to determine to what extent these associations differ 
between women and men. 
To address these questions, we compared clinical and immunological parameters in 150 
asthma patients and 151 controls. We used multivariable linear regression model analyses 
to examine the associations between self-reported respiratory infection frequency and 
clinical and immunological parameters, including TLR7/8 gene expression at baseline, 
TLR7/8 induced cytokine production, sex, age, body mass index (BMI), and circulatory 
immune cells, including pDC. We also examined the associations of these parameters with 
asthma, asthma severity and control. 
Enhanced knowledge of deficiencies in antiviral immunity in asthma is essential to identify 
which patients are at an increased infection risk. Secondly, understanding deficiencies at 
the cellular level could eventually lead to the development of medication alleviating 
respiratory infection related asthma symptoms. 
3:49 
 
3.2. Materials and methods 
3.2.1. Participants 
 Participant selection and recruitment 
An asthma case-control study was set up to recruit 300 participants. The study received 
ethical clearance from the University of Queensland (project: 2008000037) and Metro South 
Human Research Ethics Committees (Reference: HREC/07/QPAH/146). We recruited 
participants from the Princess Alexandra (PA) Hospital campus and respiratory outpatient 
clinics, the University of Queensland campus, and through social media. All participants 
were informed about the study in layman wording and provided written informed consent 
before attendance. 
Inclusion criteria were: ≥ 18 years of age, smoke exposure < 20 pack-years of cigarettes, 
full two weeks symptom-free from respiratory infections prior to the appointment and no 
sibling already included in the study. Asthma cases were required to have a current asthma 
diagnosis, have experienced asthma-related symptoms in the past year and be treated with 
asthma medication. Participants were clear of oral corticosteroid treatment for four weeks 
and inhaled corticosteroid medication for 24 hours before sample collection. Control 
participants must never have had an asthma diagnosis. Case and control groups were 
matched for sex and age, and equal proportions of participants less than 50 years of age 
and greater than 50 years of age were included, as this is the average age for menopause 
in Australian women. The participants reported their ethnic ancestry that is further discussed 
in Chapter 5 methods. 
 Participant interview 
Each participant with asthma was assigned to a GINA (Global Initiative for Asthma) 
treatment step based on their medications, and this provided an indirect measure of asthma 
severity (https://ginasthma.org/). Participants also completed an ACQ6 (Asthma Control 
Questionnaire), which is a standardised diagnostic tool for assessing control of asthma 
symptoms within the past week (Juniper et al. 2006). An ACQ6 score of below 1.0 is 
considered well-controlled asthma. Both cases and controls answered a questionnaire 
about their demographics, history of asthma and allergic disease in their families, and annual 
respiratory infection frequency. Self-reported respiratory infection (cold) frequency per year 
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was assessed based on the following question: “How frequently have you had cold 
symptoms (at least one of these: fever, chills, sore throat, runny nose or cough for at least 
one day) per year?” 
3.2.2. Data storage 
Participant information was made anonymous by assigning a study identity number. Both 
participant and asthma questionnaires (see appendix) were generated using the Checkbox 
program (Watertown, USA) online, that participants could access to complete the 
questionnaires online before their appointment. The opted paper versions of the 
questionnaires are stored in a secure location, and the electronic copies of questionnaires 
are downloaded to a file and secured with a password in a restricted access server. Results 
from the sample measurements were recorded anonymously in a separate database. 
3.2.3. Human rhinovirus 16 
Human rhinovirus (RV)16 was grown in Ohio HeLa cells. Confluent cells were incubated 
with RV16 lysate at 37°C until 60% of the cells were lysed. The infected cells were disrupted 
with three cycles of freezing and thawing and subsequently clarified with a centrifugation 
step and Optiprep (Sigma Aldrich Pty Ltd, Germany) purification. Titration assay was then 
completed to determine the concentration of the virus. 
3.2.4. Sample processing 
We collected 41.5ml of peripheral blood that was used as follows: complete blood, 
differential leukocyte count and total IgE were measured by PA Hospital Pathology 
Department, PAXgene (PreAnalytiX, Hombrechtikon, Switzerland) tubes were collected for 
RNA extraction and incubated at room temperature for 2 hours, followed by 24 h at -200C 
and then stored at -800C, and heparinised blood samples were used for peripheral 
mononuclear cell (PBMC) isolation. 
 PBMC and PMNC isolation 
PBMC were isolated with Lymphoprep (Stemcell technologies, Tullamarine Australia) 
density gradient centrifugation and washed twice before counting with RPMI medium 1640 
(Lifetechnologies, Melbourne Australia) supplemented with 2% Foetal Calf Serum (FCS) 
and PSG (Lifetechnologies, Melbourne Australia, 100u/ml Penicillin, 100μg/ml Streptomycin 
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and 0.292mg/ml L-glutamine). The remaining granulocytes were purified with in-house red 
blood cell lysis buffer (0.144M NH4Cl, 1mM NaHCO3) and stored at -20°C. 
 PBMC treatment 
Freshly isolated PBMC were rested for one hour before culturing in RPMI medium 1640 
supplemented with 2% FCS and PSG for 24 hours with either MOI = 2.5 of RV16 or 1μM 
TLR8 specific agonist VTX-2337 (Sapphire Bioscience, Waterloo Australia), as determined 
by our dose-response optimisation and previous literature (Lu et al. 2012). The supernatant 
was stored at -200C and the PBMC cell pellets were stored in RNAprotect (Qiagen, Hilden, 
Germany) at -800C. 
 Cytokine measurement 
Enzyme-linked immunosorbent assay (ELISA) of IFNα (pan-specific, Mabtech Ab, Sweden), 
IL12 [IL12 (p70), BD OptEIA, BD Biosciences, USA] and TNF (BD Biosciences, USA) were 
used to measure cytokine levels in PBMC supernatants. Cytokine ELISAs were controlled 
for technical and biological variability with biological duplicates. 
 Gene expression quantification 
Gene expression of TLR7, TLR8, and CLEC4C from whole blood was measured as 
described in Chapter 2: section 2.2.5. The comparative Ct method (Schmittgen & Livak 
2008) was applied using B2M (Beta-2-Microglobulin) and UBC (Polyubiquitin-C precursor) 
as reference genes. Custom primer sequences are listed in Table 3:1. 
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Table 3:1 Primer sequences of the genes of interest and reference. 
Gene Direction Primer sequence 5’ – 3’ 
CLEC4C  
forward CCTCTGTCTGACCCTGCAT 
reverse GCCAAGCCCTTAGATCCTT 
TLR7 
forward ATGGTGTTTCCAATGTGGAC 
reverse GTTCGTGGGAATACCTCCAG 
TLR8 
forward TCCTTCAGTCGTCAATGCTG 
reverse CGTTTGGGGAACTTCCTGTA 
UBC  
forward GCAGTTCTTGTTTGTGGATCGCT 
reverse TGACATTCTCGATGGTGTCACTGG 
B2M  
forward AGGCTATCCAGCGTACTCCAAAGA 
reverse CGGATGGATGAAACCCAGACACAT 
3.2.5. Statistical analysis 
All statistical analyses were performed with R version 3.4.4 (R Core Team 2018). Variables 
were tested for normality and normalised using natural logarithm as required. Associations 
were tested with linear, logistic or ordinal logistic regression, as appropriate.  Multivariable 
regression model included all antiviral immune variables of interest and potential clinical 
confounders to the dependent variable. Backward stepwise regression was used to fit the 
best multivariable model reduced to 3-4 most significant variables. The independent 
variables were. The difference in sample distribution was tested with a nonparametric Mann-
Whitney U test as the distribution of all variables were skewed. Nonparametric Spearman’s 
rank correlation test was used to test the correlation between observations. p-values < 0.05 
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were considered statistically significant. Chi-square test was used to test significant 
difference in distribution between groups. 
3.3. Results 
3.3.1. Participant demographics 
We recruited 150 asthma cases and 151 control subjects. The characteristics of the two 
groups are summarised in Table 3:2. Most participants were of European descent, with 
smaller numbers of Asian descent. In comparison to controls, asthma cases comprised 
slightly more women and participants over 50 years of age, but these differences were not 
statistically significant (see Table 3:2). The asthma group reported more frequent colds (p < 
0.001) and greater exposure to children (p = 0.015) than the control group. Moreover, the 
asthma group had significantly higher body mass index (BMI) (median BMI 27.00) than the 
control group (median BMI 23.00, p < 0.001). The asthma group had significantly higher 
numbers of total blood leukocytes, neutrophils, monocytes, eosinophils, basophils and 
platelets than the healthy group, suggesting a degree of systemic inflammation. As 
expected, total IgE levels were significantly higher in the asthma group than in the healthy 
group. 
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Table 3:2 Characteristics of the study groups 
 Asthma Control p-value 
n 150 151  
Women/Men (%) 97/53 (64.7/35.3) 90/61 (59.6/40.4) 0.431 
Ancestry (%)   0.001 
      Unknown 1 (0.7) 1 (0.7)  
      Africans 0 (0.0) 1 (0.7)  
      Asians 6 (4.0) 26 (17.2)  
      Europeans 133 (88.7) 105 (69.5)  
      Mixed 10 (6.7) 18 (11.9)  
Cold frequency 3.00 [3.00, 5.00] 2.00 [1.00, 3.00] <0.001 
With children (%) 42 (28.2) 24 (15.9) 0.015 
Age at donation (years) 35.00 [26.00, 47.00] 32.00 [26.00, 44.00] 0.309 
     Over 50 (%) 35 (23.3) 31 (20.5) 0.654 
Smoked pack years  0.00 [0.00, 0.00] 0.00 [0.00, 0.00] 0.871 
BMI (kg/m2) 27.00 [23.00, 30.00] 23.00 [22.00, 26.00] <0.001 
Blood count    
     White blood cells x 109/L 6.50 [5.50, 7.70] 5.90 [4.95, 6.80] <0.001 
     Platelets x 109/L 269.00 [234.50, 301.00] 240.00 [211.50, 271.50] <0.001 
     Neutrophils x 109/L 3.68 [2.94, 4.57] 3.21 [2.75, 4.03] 0.003 
     Lymphocytes x 109/L 1.92 [1.64, 2.43] 1.87 [1.56, 2.20] 0.072 
     Monocytes x 109/L 0.53 [0.42, 0.63] 0.46 [0.37, 0.57] 0.003 
     Eosinophils x 109/L 0.25 [0.15, 0.39] 0.13 [0.08, 0.19] <0.001 
     Basophils x 109/L 0.03 [0.02, 0.04] 0.02 [0.01, 0.03] <0.001 
     IgE kU/L 143.00 [51.75, 346.75] 34.00 [13.00, 100.00] <0.001 
n = study group size, with children = household with children under 15 years of age, over 50 
= over 50 years of age, BMI = body mass index. Continuous variables are expressed as 
median [interquartile range] and categorical as frequency (percentage). p-value is shown for 
Mann-Whitney U-test between the two groups for continuous variables and Chi-square test 
for the categorical variables. Bolded p-values are statistically significant. 
3.3.2. Characteristics of the asthma group 
Most asthma participants were either in GINA step 4 (n = 55, 37%) or GINA step 1 (n = 51, 
35%) treatment groups. This likely reflects the recruitment of more severe patients from the 
clinic and mild asthma patients from the community. A relatively smaller number of 
participants were in GINA steps 2, 3 and 5 (Table 3:3). The relationships between GINA 
treatment step and asthma control, as measured by the ACQ6 score, are shown in Figure 
3:1. Predictably, higher ACQ6 scores were seen in GINA step 5 participants. The overall 
median ACQ6 score was 0.50 [interquartile range (IQR) 0.21, 1.33], indicating good overall 
asthma symptom control. 
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Measures of age, BMI, ACQ6 score, having missed work in the past 12 months, 
hospitalisation for asthma and intake of oral corticosteroid medication were significantly 
different between the GINA step groups and followed an increasing trend from GINA step 1 
through steps 3, 4 and 5 (Table 3:3), however the smallest GINA step 2 group deviated from 
those trends. Post-hoc tests with multiple testing correction indicated that the GINA step 5 
participants were significantly older, had a higher ACQ6 score and were more likely to have 
taken oral corticosteroids in the past 12 months than participants in GINA step 1. Notably, 
self-reported cold frequency did not vary across the GINA step groups. 
We also tested which variables contributed to the increase in ACQ6 score, i.e. asthma 
symptom control. Age, smoking and BMI were positively associated with ACQ6 score [ACQ6 
increased 0.01 per 1 year (p = 0.005), 0.03 per 1 smoked pack year (p = 0.031) and 0.04 
per 1 BMI unit increase (p = 0.002)]. Having been hospitalised (ever, or in the past 12 
months), having missed work or taken oral corticosteroid medication (in the past 12 months) 
were all associated with an increase in ACQ6 score [ACQ6 score increase of 0.44, 0.66, 
0.39 and 0.69 (p = 0.004, 0.11, 0.15 and p < 0.001), respectively]. Self-reported cold 
frequency was not associated with ACQ6 score. 
Although asthma severity and asthma symptom control were both influenced by common 
variables, blood eosinophil counts were similar across the GINA step groups (Table 3:3). 
However, eosinophil counts were positively associated with ACQ6 score (0.75 increase in 
ACQ6 score per 1 unit increase in eosinophilic count; p-value = 0.020). Blood neutrophil 
count and total IgE were not associated with ACQ6 score. Also, a history of having ever 
been hospitalised for asthma did not differ between asthma severity groups, whereas an 
increase in ACQ6 score was associated with both a history of asthma-related hospitalisation 
and hospitalisation in the past 12 months. 
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Figure 3:1 ACQ6 score by GINA step.  
ACQ6 score distribution by GINA step. The thick vertical line represents the median ACQ6 
score, and the thin lines represent the interquartile ranges. ¥ designates a significant Mann-
Whitney U-test with p-value < 0.0125 vs GINA step 1. 
3:57 
 
Table 3:3 Asthma participants described by GINA step group and ACQ score 
 GINA step  ACQ6 score 
 1 Mild 
2 
 
3 
 
4 
 
5 
Severe  p 
(1 Coef p (2 
n 52 7 27 55 9    
Women – n(%) 29 (55.8) 7 (100.0) 
21 
(77.8) 
38 
(69.1) 2 (22.2) 0.004 
0.04 0.823 
Age at 
donation 
(years) 
29.0 
[24.0, 
39.3] 
51.0 
[33.5, 
56.0] 
31.0 
[25.0, 
45.5] 
37.0 
[29.5, 
49.5] 
51.0 
[42.0, 
61.0] ¥ 
0.001 0.01 0.005 
Smoked pack 
years 
0.0 [0.0, 
0.0] 
0.0 [0.0, 
0.0] 
0.0 [0.0, 
0.0] 
0.0 [0.0, 
1.8] 
0.0 [0.0, 
0.0] 0.060 
0.03 0.031 
BMI (kg/m2) 
23.0 
[21.0, 
27.2] 
30.0 
[26.5, 
35.0] 
27.0 
[22.5, 
29.5] 
28.0 
[24.5, 
30.0] 
29.0 
[27.0, 
35.0] 
0.001 0.04 0.002 
Cold frequency 3.0 [3.0, 5.0] 
3.0 [3.0, 
12.0] 
3.0 [3.0, 
5.0] 
3.0 [3.0, 
5.0] 
5.5 [3.5, 
8.2] 0.658 
0.01 0.557 
ACQ6 score 0.3 [0.0, 0.7] 
0.8 [0.3, 
0.8] 
0.5 [0.3, 
1.2] 
0.8 [0.3, 
1.8] 
1.3 [1.2, 
2.3] ¥ <0.001   
IgE kU/L 
104.0 
[48.2, 
317.2] 
91.0 
[49.5, 
269.0] 
165.0 
[66.0, 
517.0] 
164.0 
[52.5, 
358.0] 
217.0 
[31.0, 
224.0] 
0.779 0.0001 0.282 
Eosinophils  
x 109/L 
0.2 [0.1, 
0.4] 
0.2 [0.2, 
0.5] 
0.3 [0.2, 
0.4] 
0.3 [0.2, 
0.4] 
0.2 [0.1, 
0.4] 0.146 
0.75 0.020 
Neutrophil  
x 109/L 
3.3 [2.7, 
4.1] 
4.4 [4.0, 
4.6] 
3.7 [3.0, 
4.7] 
4.0 [3.3, 
4.7] 
3.6 [2.6, 
6.3] 0.055 
0.08 0.133 
Asthma 
diagnosis age 
(years) 
1.0 [1.0, 
2.0] 
1.0 [1.0, 
1.0] 
1.0 [1.0, 
2.5] 
1.0 [1.0, 
2.0] 
1.0 [1.0, 
3.0] 0.668 
0.09 0.366 
In 12 months 
missed work 
for asthma 
8 (15.4) 0 (0.0) 11 (40.7) 
26 
(47.3) 
4 
(44.4) 0.002 
0.39 0.015 
Ever 
hospitalised 
for asthma 
27 
(51.9) 3 (42.9) 
12 
(44.4) 
33 
(60.0) 
8 
(88.9) 0.161 
0.44 0.004 
In 12 months 
hospitalised 
for asthma  
1 (1.9) 0 (0.0) 3 (11.1) 7 (12.7) 3 (33.3) 0.026 0.66 0.011 
In 12 months 
taken OCS 8 (15.4) 2 (28.6) 9 (33.3) 
27 
(49.1) 
9 (100.0) 
¥ <0.001 
0.69 < 0.001 
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Categorical variables are expressed as frequency (percentage), and continuous variables 
are expressed as median [interquartile range] for each GINA step group. Variables are 
tested for an association with ACQ6 score with univariate linear regression. BMI = body 
mass index, n = study group size, BMI = body mass index, ACQ = asthma control 
questionnaire, mo. = months, OCS = oral corticosteroid medication, cold frequency = 
frequency of self-reported respiratory infections. p (1 = statistical significance of the chi-
square test for categorical variables or Kruskal-Wallis test for continuous variables between 
the GINA step groups. p (2 = statistical significance of univariate test with ACQ6 score as an 
outcome variable. Coef = β-coefficient for association. ¥ = post-hoc test p < 0.05 / 4 tests = 
0.0125 vs GINA step 1. 
3.3.3. Associations between respiratory infection frequency, clinical variables, and 
antiviral immunity 
 Respiratory infection frequency correlates with baseline TLR7 gene 
expression 
We examined whether TLR7/8-related antiviral immunity is associated with self-reported 
respiratory infection frequency. We tested for a correlation between respiratory infection 
frequency and TLR7/8 gene expression in whole blood cells directly after sample collection, 
and TLR7/8 function as measured by IFNα, TNF and IL12 cytokine production in PBMC after 
TLR7/8 stimulation. We also measured CLEC4C gene expression in the whole blood 
samples, which indicates the relative quantity of pDC as described in Chapter 2. Of these 
variables, only TLR7 gene expression in whole blood was in weak inverse correlation with 
respiratory infection frequency with borderline significance (Spearman rho = -0.11, p = 0.06, 
Figure 3:2). 
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Figure 3:2 Correlation between respiratory infection (cold) frequency and antiviral immune 
response variables.  
Spearman rank correlation test was performed between cold frequency and cytokine (A) 
RV-induced IFNα, (C) TLR8 agonist-induced TNF and (E) IL12 production and gene 
A 
C 
E 
B 
D 
F 
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expression of (B) TLR7, (D) TLR8 and (F) CLEC4C in whole blood. NS = not significant, r = 
Spearman correlation score, p = p-value. 
 Determinants of respiratory infection frequency 
To mitigate the effect of potential confounders, we utilised a multivariable linear regression 
model to explain respiratory infection frequency with antiviral immune response variables. 
We included all the measured antiviral immune response variables in the linear model and 
controlled for exposure to young children, BMI, age and sex. Linear model fitting with 
stepwise reduction showed that the weak correlation between TLR7 mRNA and cold 
frequency was no longer significant, but CLEC4C expression (used as an indirect measure 
of blood pDC numbers) was associated with self-reported cold frequency when adjusted for 
TLR7 gene expression, age and BMI (Model 3:1).  
Model 3:1 Multivariable linear regression model for cold frequency 
Dependent variable: Cold frequency per year 
 
Univariate models Multivariable model 
Est. 
Coef 
CI 
2.5% 
CI 
97.5% p 
Est. 
Coef 
CI 
2.5% 
CI 
97.5% p 
CLEC4C 
mRNA 0.46 -0.058 0.98 0.081 0.63 0.09 1.16 0.02 
TLR7 
mRNA -0.36 -0.85 0.13 0.14 -0.43 -0.94 0.07 0.09 
TLR8 
mRNA -0.22 -0.73 0.30 0.41     
IFNα pg/ml 2.0E-05 -3.7E-05 7.7E-05 0.49     
TNF pg/ml 4.3E-06 -1.5E-05 2.4E-05 0.67     
IL12 pg/ml 1.5E-04 -9.8E-05 4.0E-04 0.23     
Age at 
donation -0.012 -0.018 -0.007 < 0.001 -0.01 -0.02 -0.01 < 0.001 
BMI (kg/m2) 0.017 0.003 0.031 0.021 0.03 0.01 0.04 < 0.001 
Sex -0.013 -0.16 0.13 0.86     
Have kids 0.19 0.016 0.36 0.032     
Work with 
kids 0.21 -0.022 0.45 0.076     
Multivariable model included n = 285 with 16 missing observations deleted. Adjusted R²: 0.12, 
p < 0.001. 
Cold frequency was natural log transformed. Est. coef = estimated coefficient, CI = 
confidence interval, p = p-value. 
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 Different variables explain respiratory infection frequency in men and 
women 
Next, we assessed the differences in antiviral immune variables between men and women. 
IFNα production in response to RV was higher in women than in men (median = 1007.33 
pg/ml vs median = 784.38 pg/ml; p = 0.05), and TNF and IL12 production in response to 
TLR8 activation was significantly lower in women (median TNF = 1967.44 pg/ml vs 2395.81 
pg/ml, p = 0.003; median IL12 = 131.33 pg/ml vs 205.18 pg/ml, p = 0.001). There were no 
sex related differences in baseline gene expression of TLR7, TLR8 or CLEC4C. Compared 
to younger men, older men (> 50 years) had decreased IFNα production (661.32 pg/ml vs 
969.21 pg/ml, p = 0.05) and compared to younger women, older women (> 50 years) had 
decreased baseline CLEC4C gene expression (0.08 vs 0.12, p = 0.03) and increased IL12 
production in response to TLR8 activation (193.71 pg/ml vs 123.43 pg/ml, p = 0.02) in 
women. 
Our observations that TLR7/8 immunity varies significantly with sex and age justified the 
stratification of the cold frequency Model 3:1 by sex. This stratification revealed that in 
women, younger age and higher BMI were independent predictors of cold frequency (Model 
3:2). In men, lower TLR7 and higher CLEC4C gene expression were independent predictors 
of cold frequency (Model 3:3). In women, working with children was positively associated 
with cold frequency in the univariate model, but this was no longer significant in the 
multivariable model (Model 3:2). 
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Model 3:2 Multivariable linear regression models for respiratory infection frequency in 
women 
Dependent variable: Cold frequency per year in women 
 
Univariate models Multivariable model 
Est. 
Coef 
CI 
2.5% 
CI 
97.5% p 
Est. 
Coef 
CI 
2.5% 
CI 
97.5% p 
CLEC4C 
mRNA 0.40 -0.44 1.2 0.35 0.23 -0.65 1.11 0.61 
TLR7 
mRNA -0.22 -0.81 0.36 0.45 -0.10 -0.72 0.51 0.74 
TLR8 
mRNA -0.31 -1.0 0.39 0.39     
IFNα pg/ml 2.5E-05 -4.1E-05 9.1E-05 0.46     
TNF pg/ml -3.6E-06 -3.2E-05 2.5E-05 0.81     
IL12 pg/ml -6.1E-05 -5.9E-04 4.6E-04 0.82     
Age at 
donation -0.016 -0.023 -0.009 < 0.001 -0.02 -0.03 -0.013 < 0.001 
BMI (kg/m2) 0.02 0.004 0.037 0.018 0.03 0.02 0.049 < 0.001 
Have kids 0.18 -0.042 0.39 0.11     
Work with 
kids 0.29 0.022 0.56 0.034     
Multivariable model included n = 175 with 12 missing observations deleted. Adjusted R²: 0.17, p < 
0.001. 
Cold frequency was natural log transformed. Est. coef = estimated coefficient, CI = 
confidence interval, p = p-value. 
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Model 3:3 Multivariable linear regression models for respiratory infection frequency in men 
Dependent variable: Cold frequency per year in men 
 
Univariate models Multivariable model 
Est. 
Coef 
CI 
2.5% 
CI 
97.5% p 
Est. 
Coef 
CI 
2.5% 
CI 
97.5% p 
CLEC4C 
mRNA 0.51 -0.15 1.2 0.13 0.90 0.19 1.61 0.01 
TLR7 
mRNA -0.75 -1.7 0.18 0.11 -1.13 -2.1 -0.15 0.02 
TLR8 
mRNA -0.096 -0.86 0.67 0.80     
IFNα pg/ml -3.2E-08 -1.2E-04 1.2E-04 1.0     
TNF pg/ml 1.3E-05 -1.5E-05 4.0E-05 0.36     
IL12 pg/ml 2.3E-04 -5.2E-05 5.1E-04 0.11     
Age at 
donation -0.007 -0.016 0.001 0.086 -0.01 -0.016 
6.1E-04 0.07 
BMI (kg/m2) 0.007 -0.021 0.034 0.64 0.02 -0.008 0.050 0.15 
Have kids -0.077 -0.58 0.43 0.76     
Work with 
kids 0.21 -0.076 0.49 0.15     
Multivariable model included n = 110 with 4 missing observations deleted. Adjusted R²: 0.07, p = 
0.017. 
Cold frequency was natural log transformed. Est. coef = estimated coefficient, CI = 
confidence interval, p = p-value. 
3.3.4. Asthma and antiviral immunity 
 Respiratory infection frequency is increased, and baseline TLR7 gene 
expression is decreased in asthma 
The asthma group reported significantly more frequent respiratory infections than the 
healthy control group (median 3 colds per year vs 2, p < 0.001; Table 3:2). Because of the 
crucial role of TLR7 and TLR8 in detecting respiratory virus nucleic acid, we assessed 
TLR7/8-related antiviral immune variables for association with asthma. Out of the tested 
antiviral immune response variables, only TLR7 mRNA was significantly lower in asthma 
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(median 0.26) than in control participants (median 0.28; p = 0.015; Figure 3:3). Of note, RV-
induced IFNα was similar in cases and controls. 
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Figure 3:3 Cold frequency and antiviral immune variables in asthma cases and controls. 
Median and interquartile ranges presented as boxplots for asthma and control groups for 
(A) number of colds per year; (B-D) RV-induced IFNα and TLR8 agonist-induced TNF and 
IL12 cytokine production in PBMC after 24 h stimulation; and (E-G) TLR7, TLR8 and 
CLEC4C gene expression in whole blood. p-value is shown for significant Mann-Whitney U-
test. NS = not significant. 
Because we observed that BMI was significantly associated with increased cold frequency 
(Model 3:1) and the asthma group had a significantly higher BMI than controls (Table 3:2), 
the analysis was repeated to exclude those with BMI > 27, however the difference between 
the study groups remained significant (p-value < 0.001, Figure 3:4). BMI above 27 has been 
shown to indicate higher body fat composition and obesity-associated co-morbidities 
(Fernandez-Real et al. 2001). 
 
Figure 3:4 Cold frequency between asthma cases and controls with healthy BMI.  
Median and interquartile ranges of respiratory infection frequency in asthma cases and 
controls with BMI < 27. p = p-value. 
 Association between asthma and antiviral variables 
Reported deficiencies in antiviral immunity in asthma in the literature warranted us to 
determine whether TLR7/8 related antiviral immune response variables are associated with 
asthma. We observed significantly lower baseline TLR7 gene expression in asthma cases 
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(Figure 3:3). We further examined the variables together with a multivariable logistic 
regression model that was controlled for BMI, age and sex. A logistic regression model was 
fitted with stepwise reduction. The TLR7 association with asthma remained significant in the 
model when adjusted for BMI and TNF production in response to TLR8 agonist VTX-2337 
(Model 3:4). 
Model 3:4 Multivariable logistic regression model for asthma. 
 OR = odds ratio, CI = confidence interval, p = p-value. 
 BMI and TNF production associate differently with asthma in men and 
women 
Because of the gender disparity in the prevalence of asthma and TLR7/8-related immunity, 
we examined the multivariable regression model for asthma in men and women separately 
(Model 3:5 and Model 3:6). The association between baseline TLR7 gene expression and 
asthma was not significant in the separate analysis of men and women. TLR8-induced TNF 
production was significantly associated with asthma men but not women, whereas the BMI 
association with asthma was significant in women but not men, similar to the model for cold 
frequency described above. 
Dependent variable: Asthma 
 
Univariate models Multivariable model 
OR CI 2.5% 
CI 
97.5% p OR 
CI 
2.5% 
CI 
97.5% p 
CLEC4C 
mRNA 0.44 0.076 2.3 0.34      
TLR7 
mRNA 0.12 0.023 0.62 0.013  0.12 0.020 0.69 0.020 
TLR8 
mRNA 0.26 0.047 1.3 0.11      
IFNα pg/ml 1.0 1.0 1.0 0.48      
TNF pg/ml 1.0 1.0 1.0 0.31  1.0 1.0 1.0 0.050 
IL12 pg/ml 1.0 1.0 1.0 0.18      
Sex 0.81 0.5 1.3 0.37      
Age at 
donation 1.0 0.99 1.0 0.34      
BMI (kg/m2) 1.1 1.1 1.2 < 0.001 1.1 1.1 1.2 < 0.001 
Multivariable model included n = 297 with 4 missing observations deleted. Pseudo R²: 0.13, p < 0.001. 
3:68 
 
Model 3:5 Multivariable logistic regression models for asthma in women. 
Dependent variable: Asthma in women 
 
Univariate models Multivariable model 
OR CI 2.5% 
CI 
97.5% p OR 
CI 
2.5% 
CI 
97.5% p 
CLEC4C 
mRNA 0.75 0.052 11 0.83      
TLR7 
mRNA 0.16 0.022 1.0 0.060  0.26 0.029 2.2 0.22 
TLR8 
mRNA 0.15 0.016 1.3 0.092      
IFNα pg/ml 1.0 1.0 1.0 0.29      
TNF pg/ml 1.0 1.0 1.0 0.64  1.0 1.0 1.0 0.73 
IL12 pg/ml 1.0 1.0 1.0 0.074      
Age at 
donation 1.0 0.99 1.0 0.28      
BMI (kg/m2) 1.2 1.1 1.2 < 0.001 1.2 1.1 1.2 < 0.001 
Multivariable model included n = 184 with 3 missing observations deleted. Pseudo R²: 0.17, p < 0.001. 
OR = odds ratio, CI = confidence interval, p = p-value. 
 
Model 3:6 Multivariable logistic regression models for asthma in men. 
 OR = odds ratio, CI = confidence interval, p = p-value. 
 Association between antiviral variables and different types of asthma 
Because of the wide variety of asthma symptoms in general and in our cohort (Table 3:3), 
we determined if asthma severity and asthma control are associated with clinical and 
Dependent variable: Asthma in men 
 
Univariate models Multivariable model 
OR CI 2.5% 
CI 
97.5% p OR 
CI 
2.5% 
CI 
97.5% p 
CLEC4C 
mRNA 0.33 0.027 3.0 0.35      
TLR7 
mRNA 0.067 0.0025 1.4 0.091  0.06 0.002 1.3 0.08 
TLR8 
mRNA 0.56 0.041 6.7 0.65      
IFNα pg/ml 1.0 1.0 1.0 0.78      
TNF pg/ml 1.0 1.0 1.0 0.049  1.0 1.0 1.0 0.03 
IL12 pg/ml 1.0 1.0 1.0 0.44      
Age at 
donation 1.0 0.98 1.0 0.84      
BMI (kg/m2) 1.0 0.96 1.1 0.28  1.1 0.98 1.2 0.14 
Multivariable model included n = 113 with 1 missing observation deleted. Pseudo R²: 0.12, p = 0.015. 
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antiviral immune response variables. Multivariable linear regression models were used to 
evaluate the association between asthma severity and asthma control and antiviral 
variables. Baseline TLR8 gene expression was inversely associated with ACQ6 score when 
adjusted for TLR7 gene expression, BMI, and sex (Model 3:7). Baseline TLR7 gene 
expression was not a significant predictor of asthma symptom control. 
Model 3:7 Multivariable linear regression model for asthma control. 
Dependent variable: Asthma control (ACQ6 score) 
 
Univariate models Multivariable model 
Est. 
Coef 
CI 
2.5% 
CI 
97.5% p 
Est. 
Coef 
CI 
2.5% 
CI 
97.5% p 
CLEC4C 
mRNA -0.071 -1.3 1.1 0.91      
TLR7 
mRNA -0.12 -1.3 1.0 0.83  0.88 -0.42 2.19 0.18 
TLR8 
mRNA -1.0 -2.1 0.12 0.079  -1.4 -2.7 -0.093 0.036 
IFNα pg/ml -2.4E-05 -1.7E-04 1.2E-04 0.74      
TNF pg/ml -2.1E-05 -6.0E-05 1.7E-05 0.28      
IL12 pg/ml -6.3E-05 -5.1E-04 3.9E-04 0.78      
Sex -0.036 -0.35 0.28 0.82  0.03 -0.28 0.35 0.84 
Age at 
donation 0.016 0.0048 0.027 0.005      
BMI (kg/m2) 0.040 0.015 0.066 0.002  0.04 0.01 0.07 0.004 
Multivariable model included n = 147 with 3 missing observations deleted. Adjusted R²: 0.06, p = 
0.010. 
Est. coef = estimated coefficient, CI = confidence interval, p = p-value. 
 
GINA step was treated as an ordinal variable, indicating a scale of asthma severity and 
analysed using ordinal logistic regression. GINA step group was significantly associated with 
age and BMI, but not with any antiviral immune response variables (Model 3:8). 
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Model 3:8 Multivariable ordinal logistic regression model for asthma severity. 
Dependent variable: Asthma severity (GINA step) 
 
Univariate models Multivariable model 
OR CI 2.5% 
CI 
97.5% p OR 
CI 
2.5% 
CI 
97.5% p 
CLEC4C 
mRNA 0.13 0.010 1.2 0.093     
TLR7 
mRNA 0.13 0.015 1.0 0.057 0.23 0.024 2.04 0.19 
TLR8 
mRNA 0.19 0.021 1.5 0.12     
IFNα pg/ml 1.0 1.0 1.0 0.39     
TNF pg/ml 1.0 1.0 1.0 0.73     
IL12 pg/ml 1.0 1.0 1.0 0.36     
Sex 1.0 0.53 1.9 0.98 1.4 0.70 2.7 0.36 
Age at 
donation 1.0 1 1.1 < 0.001 1.0 1.0 1.06 0.005 
BMI (kg/m2) 1.1 1.1 1.2 < 0.001 1.1 1.0 1.1 0.004 
Multivariable model included n = 150. 
OR = odds ratio, CI = confidence interval, p = p-value. 
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3.4. Discussion 
Asthma patients suffer from worse respiratory infections; however, it is unclear if they are 
infected more often and what kind of clinical and immunological factors play a role in 
infection susceptibility. This study examined clinical and immunological parameters 
associated with self-reported respiratory infection frequency, the presence of asthma, 
asthma severity and control, with special focus on the role of TLR7/8 gene expression and 
function. We wanted to further determine to what extent these associations differ between 
women and men.  
Here we show that in men, self-reported respiratory infection frequency is associated with 
reduced baseline TLR7 gene expression and increased relative pDC quantity, and in 
women, self-reported respiratory infection frequency is associated with increased BMI and 
younger age. Participants with asthma reported more frequent respiratory infections and 
had reduced TLR7 gene expression in comparison to controls. Asthma severity, as reflected 
in treatment intensity, was not associated significantly with immunological variables, but 
poor asthma symptom control was associated with reduced TLR8 gene expression and 
increased BMI. 
We assessed several TLR7/8-related antiviral immune variables for an association with 
respiratory infection frequency and detected a trend towards an inverse correlation with 
baseline TLR7 gene expression, i.e. those with the lowest TLR7 expression tended to have 
a higher frequency of self-reported respiratory infections. The weak correlation implies that 
TLR7’s role in virus recognition may be necessary for preventing respiratory infections. The 
multivariable linear regression analysis showed that the gene expression of the pDC marker 
CLEC4C, BMI and age independently predicted respiratory infection frequency. However, 
further stratification of the model by gender revealed that different variables are associated 
in men and women.  
In men, increased CLEC4C in conjunction with decreased TLR7 gene expression was 
associated with high respiratory infection frequency. This result is somewhat unexpected, 
as pDC are thought to be the primary cell type that expresses TLR7. Hence the association 
between CLEC4C expression and infection frequency was expected to be in the same 
direction as the association between TLR7 gene expression and infection frequency. Others 
have reported that TLR7 induced IFNα production is less efficient in men than in women but 
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is independent of pDC numbers (Berghofer et al. 2006). Our results suggest a similar effect 
in men, where the inverse correlation between TLR7 and respiratory infection frequency 
appears to be independent of pDC numbers. Although pDC play an essential role in antiviral 
immunity, high pDC numbers have been reported in adults with asthma (Spears et al. 2011) 
and are further elevated in response to allergen challenge (Dua et al. 2010). In contrast, 
lower numbers of blood pDC in infancy is a risk factor for more frequent respiratory tract 
infections, wheezing, and a subsequent diagnosis of asthma (Upham et al. 2009). The 
association with allergies and asthma may indicate that the functionality of pDC is different 
between asthma and controls, and the relative pDC numbers may not fully reflect pDC 
antiviral immune function. We did not see a difference in CLEC4C gene expression between 
asthma and healthy groups (Figure 3:3), yet TLR7 gene expression was lower, supporting 
an asthma-related reduction in pDC functionality. 
Another explanation for the opposite direction of effect for CLEC4C and TLR7 gene 
expression is that as the baseline gene expression was measured in whole blood, and many 
other cell types than pDC could influence TLR7 gene expression. TLR7 is expressed by 
eosinophils in asthma and appears to alter their function (Mansson & Cardell 2009). 
Furthermore, eosinophils have recently been recognised to capture viruses, a function that 
is impaired in asthma patients (Sabogal Piñeros et al.). It is, therefore, possible that a 
reduction in TLR7 gene expression across all the TLR7 expressing immune cells could 
influence cold susceptibility. 
In contrast, only young age and high BMI were significant independent predictors of higher 
cold frequency in women, with none of the immune function parameters being associated 
with cold frequency. Younger women are most likely to be in contact with small children, a 
known infection risk (Galanti et al. 2019); however, self-reported contact with children was 
not associated with cold frequency in our final fitted regression model. Protective immune 
memory associated with increased age could explain the association with age observed in 
women. Another explanation for the difference between sexes could be hormonal changes 
associated with being overweight and age, particularly in women. Substituting age 
measured as a continuous variable with a binomial variable using 50 years of age as a cut-
off in the models maintained near identical effect and significance (not shown), suggesting 
that hormonal changes associated with menopause may explain the association with age. 
The female hormone oestrogen declines with age and is higher in obese people, which here 
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would suggest that lower oestrogen levels are beneficial. Oestrogen has been shown to 
modify pDC responses through TLR7 (Seillet et al. 2012) and both TLR7/8 expression 
(Young et al. 2014). The relationship between TLR7 function and oestrogen suggests that 
female sex hormones, known to be influenced by BMI and age, might obscure any 
association between TLR7 and respiratory infection frequency. We did not collect data on 
hormonal contraceptive use, but as it is commonly used in young women, it may explain the 
age association with cold frequency (Scott, H. A. et al. 2016). In hindsight, it would have 
been interesting to have collected information from female participants on the timing of blood 
collection in relation to their individual menstrual cycles. Although obese women have higher 
oestrogen levels, there are also changes in progesterone and androgen levels that 
contribute to abnormal menstrual cycles (Escobar-Morreale et al. 2017; Lash & Armstrong 
2009) and which might modify antiviral immunity. Obesity is linked with impaired immune 
function, including altered T- and B-cell populations, altered immune responses and 
systemic inflammation (Karlsson & Beck 2010; Sheridan et al. 2011). Obese people are 
more susceptible to influenza infections (Karki et al. 2018; Louie et al. 2011), and overweight 
children are susceptible to respiratory infections (Jedrychowski et al. 1998), and our results 
indicate a similar association in adult women. 
Corne et al. (2002) followed cohabiting couples consisting of one partner with asthma and 
one without asthma for three months and those with asthma had more prolonged lower 
respiratory symptoms, though they found no difference in the frequency of RV infections. In 
contrast, our study participants with asthma reported more frequent respiratory infections 
than non-asthmatic participants. The frequency of respiratory infections was self-reported 
as an estimated number of illnesses suffered per year. A note of caution is due here since 
the study may have attracted participants who suffer from frequent respiratory infections; 
however, the median frequency of 2 colds per year in the healthy controls is in line with other 
reports (Leder et al. 2003). Additionally, recalling the number of past infections could be 
biased by factors like the severity of the experienced illnesses, gender, psychological 
factors, or motivation by the topic of the study. However, the large sample size of 301 used 
in this study is expected to mitigate some of these factors. Importantly, this study identified 
several biological variables that were independently associated with respiratory infection 
frequency, suggesting that self-reported colds has some validity as a relevant outcome. We 
suspected that obese participants might have influenced the result, however when we 
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repeated the analysis with stratification for obesity, the outcome remained the same, 
confirming that the difference is not due to BMI imbalance between the groups. 
Subsequently, we evaluated antiviral immunity in asthma. Many studies report deficient type 
I IFN production in response to viral infection in asthma (as discussed in Chapter 1, section 
1.4.2). In contrast with the previous reports of others and our own group (Edwards et al. 
2017; Pritchard et al. 2014), we did not observe lower IFNα production in response to RV in 
the asthma group in comparison to the control group. The sample size in this study was 
much larger than many previous studies, and we followed a similar protocol to others. 
However, it is possible that the long duration of two years for recruiting and performing the 
experiments could have introduced technical variables in the study. To minimise such 
variables, asthma and control participants were recruited simultaneously. Moreover, it is 
possible that IFN deficiency may be observed best at a different time point rather than the 
24 h post-stimulation time point used by this study and by others (Durrani et al. 2012; 
Gehlhar et al. 2006). It was not practical to assess IFNα production at multiple time points 
in a study of this size, nor was it feasible to study lung tissue. 
Immune responses are known to vary with season (ter Horst et al. 2016), which may affect 
IFNα responses too. Due to the higher susceptibility and worse cold infections, many of our 
asthma participants were sick during the winter months. Despite waiting at least two weeks 
after cold symptoms before sampling, the cold might have affected their immune responses. 
Another consideration is the possible effect of asthma symptoms. While most studies agree 
that IFN production is either lower or similar in asthma cases and controls, there are reports 
that IFNλ production is higher during asthma exacerbations in children (Miller et al. 2012), 
and IFNβ production in response to RV increases in IL4 and IL13 co-culture (Herbert et al. 
2017). Transcriptome studies of asthma exacerbation types reveal distinct asthma subtypes 
where IFN production during an exacerbation is either high or low (Gomez et al. 2018; Khoo 
et al. 2019). An elaborate study by Custovic et al. (2018) identified several possible clusters 
of different cytokine responses to RV in year old children and searched for associations with 
childhood asthma. Similar to the transcriptome studies (Gomez et al. 2018; Khoo et al. 
2019), they identified two clusters with the lowest and highest IFN response that were 
associated with asthma. These controversies between studies emphasise the fact that type 
I IFN deficiency probably exists in a subgroup of asthma patients, however high IFN 
production is also linked with asthma. In conjunction, the literature and our findings indicate 
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that the phenotypes associated with type I IFN response variation are not explicit and are 
most likely influenced by several variables. Our finding that IFNα was similar in those with 
asthma and healthy participants was not anticipated. However, we did observe great 
variability in IFNα response across the participants. We questioned what factors beyond 
asthma-related attributes associate with the intensity of IFNα response to RV stimulation. 
The differences between high and low IFNα responders will be examined further in Chapter 
4. 
Rather than type I IFN deficiency, we saw that the baseline TLR7 gene expression was 
lower in the asthma group, which remained significant in the fitted multivariable linear 
regression model for asthma. The association was not significant in the separate analysis 
of men and women, though this may be because the sample size was insufficient. TNF 
production and BMI were also associated with asthma; however, the effect size of TNF was 
minimal. Reduced TLR7 function in asthma is well documented: Pritchard et al. (2014) 
showed lower TLR7 gene expression in asthmatics in response to RV16 stimulation, along 
with other genes in the TLR7 signalling pathway; in an allergic mouse model, reduced TLR7 
activity was the result of Th2-immunity; and in humans lower TLR7 expression in asthma 
lungs correlated with sputum eosinophilia (Hatchwell et al. 2015). The consequence of 
impaired TLR7 function in asthma may be frequent or severe respiratory infections. These 
results suggest that altered antiviral immune responses in asthma may occur upstream of 
IFNα production. Indeed, genomic analysis of antiviral immune response pathways showed 
that apart from 5–6 core signalling factors, the pathways leading to the detection of 
pathogens and immune response are highly flexible (Troy & Bosco 2016), indicating that 
deficiencies may occur at several levels. Genetic variation in the TLR7 gene region has been 
reported to be associated with asthma, and genetic variation could explain the lower TLR7 
gene expression asthma group that we observed and lack of association with IFN 
production. The consequences of TLR7/8 gene region are studied in Chapter 5. 
Asthma is recognised as a heterogeneous disease consisting of endotypes with varied 
clinical presentation (Deliu et al. 2016). It is therefore likely that deficiencies in antiviral 
immunity are not global across all asthma patients, but specific to certain endotypes. We 
recruited participants with a spectrum of asthma severities and symptom control scores and 
used multivariable linear regression analysis to evaluate the association between several 
TLR7/8-related antiviral immune variables and asthma severity and control. Asthma control 
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was best explained by a multivariable linear regression model that included TLR7 and TLR8 
gene expression, sex and BMI. We expected to see lower TLR7 gene expression associated 
with poor asthma symptom control. In contrast, we saw reduced TLR8 gene expression. The 
central function of the cytokine repertoire induced by TLR8 is the promotion of Th1-polarised 
immune responses (Lu et al. 2012). Because type 1 immunity antagonises type 2 immunity, 
reduced TLR8 gene expression seen in asthma patients with worse asthma symptom control 
is not surprising. Although a crossregulatory relationship exists between TLR7 and TLR8 
receptors, possibly via competing for a common chaperone protein Unc93B1 (Desnues et 
al. 2014; Itoh et al. 2011), very few cells express both receptors and one of the advantages 
of using multivariable linear regression analysis is to explore confounding effects from other 
variables. The regression model included TLR7 gene expression, indicating that TLR8 gene 
expression is associated with asthma symptom control independently of the effect of TLR7 
gene expression. 
Pinpointing the asthma subgroup that is at most risk for deficiencies in antiviral immunity is 
vital for improving asthma treatment. Our study was limited to self-reported features for both 
asthma symptoms and respiratory infections. Nevertheless, the increased number of self-
reported respiratory infections in the asthma population highlights the burden of respiratory 
infections that people with asthma experience. Our results show that while TLR7 gene 
expression at baseline is reduced overall in the asthma group, this reduction is not 
associated with severe asthma or poor asthma control. In contrast, poorly controlled asthma 
patients had reduced TLR8 baseline gene expression. Our results raise the questions 
whether TLR7/8 gene expression is reduced by excessive type 2 immunity and what 
consequences reduced TLR7/8 function has on antiviral immune parameters such as 
cytokine response and infection severity and duration. A thorough analysis of different 
asthma endotypes defined by sputum markers could elucidate what asthma phenotypes 
drive the TLR7/8 deficiency or are associated with such deficiency. Our findings and the 
prospect of treating asthma with TLR7/8 agonist medications under development emphasise 
the importance of continuing research on TLR7/8 in asthma. 
Finally, the observation that the asthma group had a higher BMI than controls requires 
mention. BMI remained a significant predictor in all the linear regression models. Obesity is 
a risk factor for asthma development and is associated with more severe disease, while 
weight loss improves asthma symptoms (Scott, Hayley A. et al. 2015; Wood 2017). In 
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addition to asthma risk, obesity has been associated with an increased risk of respiratory 
infection and a decline in antiviral immunity (Karlsson & Beck 2010), raising the question as 
to whether obese asthmatics are at more risk of respiratory infections than normal-weight 
asthma patients. Obesity and asthma are associated with systemic inflammation and, in 
combination, contribute to changes in cytokine environment with a potentially detrimental 
effect on antiviral immunity. A shortcoming of our study was unmatched study groups 
regarding BMI, and we recommend considering BMI in both asthma and antiviral immunity 
studies at the study design phase. Investigating these relationships is essential, as achieving 
and maintaining a healthy weight may lead to vast improvements in both asthma symptoms 
and respiratory infection-related problems. 
In conclusion, the results presented in this chapter show a role for TLR7/8-related immunity 
in respiratory infection frequency and asthma. The predictors of frequent respiratory 
infections were different in men and women. Men are known to respond weakly to RV 
infections (Carroll et al. 2010), and our results imply that men are more sensitive to variation 
in antiviral immune response variables, whereas women are susceptible to the influence of 
BMI and age. BMI influenced all of the outcomes that we analysed, suggesting a role in both 
asthma and antiviral immunity. 
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 Transcriptional variation 
predicting a robust interferon response 
to rhinovirus challenge 
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4.1. Introduction 
Type I interferons (IFN) are vital cytokines that induce an antiviral response upon viral 
encounter. This chapter investigates the transcriptome, and how this is related to variations 
in capacity for type I IFN production in response to rhinovirus (RV). 
Type I IFNs have a dual role in activating the antiviral immune response. Initially, they induce 
an antiviral state in infected cells and activate the innate immune system, recruiting and 
stimulating antigen presenting cells (APCs) and natural killer (NK) cells. As a secondary 
antiviral response, type I IFN also directly activates adaptive immune cells such as and T- 
and B- lymphocytes to differentiate into pathogen-specific effector and memory cells 
(Crouse, Kalinke & Oxenius 2015; Levy, Marié & Durbin 2011). The subgroup of type I IFNs 
consists of several subtypes, but predominantly thirteen interferon alpha (IFNα) and one 
interferon beta (IFNβ). While almost all cells secrete IFNβ and many immune cells secrete 
IFNα, plasmacytoid dendritic cells (pDC) are the main producers of type I IFN (Xi et al. 2015). 
The shared IFN α/β receptor (IFNAR) is expressed on all nucleated cells to enable their 
response to type I IFN. Signalling through IFNAR triggers the expression of IFN stimulated 
genes (ISG) that induce an antiviral state in the cell and to produce cytokines and 
chemokines to attract immune cells. 
Type I IFN is produced constitutively in low, almost undetectable amounts (Gough et al. 
2012), and is augmented only in response to an immune stimulus, such as exposure to 
viruses. Pathogen recognition receptors (PRRs), such as toll-like receptor (TLR)7 and TLR8, 
detect viral particles that activate the antiviral immune response within which type I IFN 
production plays a crucial role. Genetic diseases that alter the type I IFN response, whether 
deficiency or abundance, result in severe pathologies, or at worst, an incompatibility with life 
(Taft & Bogunovic 2018). Sufficient type I IFN production is integral to an efficient antiviral 
immune response and correlates with viral replication in epithelial cells in vitro, and with viral 
load and disease severity in vivo (Edwards, MR et al. 2013; Hayden et al. 1998). Within the 
healthy range of type I IFN production, variation is known to arise from factors such as 
gender, age and hormones (Berghofer et al. 2006; Metcalf et al. 2015; Seillet et al. 2012). 
In Chapter 3, we observed a broad interindividual variation in IFNα response to RV 
stimulation. Previous literature highlights an optimal range of type I IFN production for 
eliciting an efficient antiviral immune response and protecting from inflammation (Taft & 
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Bogunovic 2018). Immune variation within healthy individuals influences the risk of 
immunopathologies, infections and poor vaccine response. In the era of high-throughput 
research, several researchers have taken advantage of various ‘omics technologies to study 
immune variation. This relatively new field of study provides the insight that genetics 
together with environment and host factors such as age, gender, immune cell frequency, 
microbiome and cohabitation, influence immune variation (Bakker et al. 2018; Brodin et al. 
2015; Carr et al. 2016; Kaczorowski et al. 2017; Lee, MN et al. 2014; Piasecka et al. 2018; 
Schirmer et al. 2016; ter Horst et al. 2016). Despite the extent of these studies, their ability 
to explain variations in type I IFN response to respiratory viruses is incomplete. Lee, MN et 
al. (2014) and Piasecka et al. (2018) have comprehensively studied the antiviral response 
to influenza virus A (IAV), however, the distinct host antiviral immune response to IAV may 
not translate to other respiratory viruses such as RV (Troy & Bosco 2016). 
Therefore, the experiments described in this chapter examine the extent to which 
transcriptional variations predict the antiviral type I IFN responses, comparing 
transcriptomes between individuals who exhibit very high and very low antiviral type I IFN 
responses. Knowledge about this topic is currently limited. Though Chapter 3 showed no 
clear difference in type I IFN production between asthmatic and healthy groups (Chapter 3), 
baseline gene expression levels of TLR7 were significantly lower in the asthma group than 
controls, so we also examined the extent to which transcriptomes differed between healthy 
people and those with asthma. 
Whole transcriptome analysis enables the study of total gene expression in cells and thus 
provides a tool for understanding the biological differences between conditions. To address 
our research questions, we selected participants with contrasting IFNα production in 
response to RV16 stimulation and compared their whole transcriptomes at baseline in 
unstimulated peripheral blood mononuclear cells (PBMC) and during the antiviral response 
in RV16-stimulated PBMC. Contrasting IFNα producers will help understand underlying host 
and immunological factors contributing to differences in IFNα response. 
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4.2. Materials and methods 
4.2.1. Participant selection 
 
Figure 4:1 Study design.  
Samples selected for the current study were selected from an asthma case study. 
Cytokine production in PBMC in response to stimulation with medium (control), 5μM TLR7 
specific agonist Imiquimod (Invivogen, USA) and RV16 were measured as a part of the 
experiments in Chapter 3, and the methods are described in section 3.2.4. In the recruited 
cohort of 301 people, we observed that certain individuals responded to both imiquimod and 
RV16 stimulus with highly efficient IFNα production, whereas others responded with a low 
amount of IFNα (Figure 4:2). Participants were part of the cohort described in Chapter 3 
(section 3.2.1). Clinical features were recorded, and blood cell counts were measured as 
described in Chapter 3: section 3.2. Two contrasting IFNα producing groups were selected 
from 238 samples from participants with European ancestry (Figure 4:1). Seventy-four 
samples in the highest 15% or lowest 15% of IFNα response to RV16 stimulation in PBMC 
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were selected for the current study. Thirty-six samples in the high IFNα producer group 
comprised 18 asthma and 18 healthy samples, and 38 samples in the low IFNα producer 
group comprised 19 asthma and 19 healthy samples. The high and low IFNα producer 
groups will be referred to as IFN-high and IFN-low groups from here on. 
4.2.2.  Quantification of whole blood gene expression with RT-PCR 
The methods for quantifying gene expression of TLR7, TLR8 and CLEC4C in the 
unstimulated condition in whole blood with RT-PCR are described in Chapter 2: section 2.2.5 
and Chapter 3: section 3.2.4. 
4.2.3. Sequencing of RNA extracted from PBMC 
RNA in PBMC samples was preserved in RNAprotect™ (Qiagen, Hilden, Germany) as per 
manufacturers’ instructions, and stored at -80°C. Samples were extracted for total RNA and 
sequenced at Macrogen Inc (Seoul, Rep. of Korea) with Truseq mRNA kit using the 
NovaSeq6000 platform, with a minimum of 20 million, 100bp paired-end reads per sample. 
Two PBMC RNA samples were sequenced per individual: one unstimulated (baseline) and 
one RV16-stimulated (infection) for 24 h. 
4.2.4. Alignment of sequence data 
The Genome Informatics Group at QIMR Berghofer, Queensland, Australia, aligned the 
sequence reads. Sequence reads were trimmed for adapter sequences using Cutadapt 
[version 1.11; (Martin 2011)] and aligned using STAR [version 2.5.2a; (Dobin et al. 2013)] 
to the GRCh37 assembly with the gene, transcript and exon features of Ensembl [release 
89; (Zerbino et al. 2017)] gene model. Quality control metrics were computed using RNA-
SeQC [version 1.1.8; (DeLuca et al. 2012)] and gene expression levels were quantified using 
RSEM [version 1.2.30; (Li & Dewey 2011)]. 
4.2.5. Differential gene expression analysis 
EdgeR package (Robinson, MD, McCarthy & Smyth 2010), was utilised for the discovery of 
differentially expressed genes in IFN-high group compared with IFN-low group. Library size 
was corrected using counts per million (CPM), which involves dividing each sample gene 
count by the total number of mapped reads. Genes with CPM > 2 in more than six samples 
were retained for analysis. Trimmed mean of M-values was used to normalise differences 
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in RNA composition between samples with the function calcNormFactors() from the edgeR 
package. Function glmQLFit() fits a quasi-likelihood negative binomial generalised log-linear 
model to count data. Significant genes were filtered with multiple testing corrected false 
discovery rate (FDR) < 0.05 and log fold-change > 1. RV16-stimulated and unstimulated 
samples were tested separately. 
 Biological pathway analysis 
Identification of significantly enriched biological pathways was performed using gene set 
enrichment analysis (GSEA) (Subramanian et al. 2005) focussing on genes differentially 
expressed between IFN-high and IFN-low groups at baseline and with RV16-stimulation. 
Fold change in gene expression was used for ranked list of input to GSEA, and gene 
ontology (GO) pathways with FDR < 0.25 were considered as biological pathways 
significantly related to the differentially expressed genes. 
4.2.6. Statistical analysis 
All statistical analyses were performed with R version 3.4.4 (R Core Team 2018). Variables 
were tested for normality and consequently, treated as nonparametric variables. 
CreateTableOne() function in the R package tableone was used to create the demographics 
table of the study group and perform statistical tests (Yoshida 2019). p-value < 0.05 was 
considered significant. The difference in sample distribution was tested with a nonparametric 
Mann-Whitney U test, which was considered significant with p-value < 0.05 / 6 tests = 0.008 
after multiple testing correction in section 4.3.2, and p-value < 0.05 / 4 tests = 0.013 after 
multiple testing correction in section 4.3.4. Paired nonparametric Spearman’s rank 
correlation test was used to test correlation between observations. Correlation with a p-value 
< 0.05 was considered statistically significant. In section 4.3.4 the expression of 11 IFNα 
genes that were quantified (IFNA4, IFNA7, IFNA10, IFNA16, IFNA17, IFNA13, IFNA2, 
IFNA8, IFNA1, IFNA14 and IFNA5), were summed for statistical analysis. 
 Graphs 
Boxplots and before-after plots were created with GraphPad Prism software (version 7, La 
Jolla, USA;  Figure 4:2  and Figure 4:5). Principal component analysis (PCA) was performed 
with prcomp() function and plotted using autoplot() function from ggfortify package [Figure 
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4:3 PCA analysis of unstimulated samples. and Figure 4:4; (Tang, Horikoshi & Li 2016)]. 
GSEA pathway plots were created with ggplot() function in ggplot2 package [Figure 4:7 and  
Figure 4:10 ; (Wickham 2016)], GO-pathway networks were generated in Cytoscape 
interface [San Diego, USA, (Shannon et al. 2003)], and heatmaps were created with 
Pheatmap package [Figure 4:6 and Figure 4:9; (Kolde 2019)] with base function hclust() 
clustering and dendrogram sorting with dendsort package (Sakai 2015). 
4.2.7. Access to public databases 
We searched the manually annotated records in the protein knowledgebase UniProt (The 
UniProt Consortium 2018) and PubMed (NIH, USA) for any additional literature supporting 
the understanding of the functions of the gene products. 
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4.3. Results 
4.3.1. Variation in type I interferon production 
Of the 301 participants whose cells were stimulated with TLR7 agonist and RV16 for 24 h in 
Chapter 3, we found that RV16 stimulation elicited the broadest interindividual variation in 
IFNα production in PBMC (median 969.2; IQR 529, 1633) (Figure 4:2:A). IFNα production 
in response to TLR7 agonist and RV16 were highly correlated (r = 0.66, p < 0.001), and to 
maximise the number of samples analysed within economical constraints, we chose to 
compare only unstimulated and RV16-stimulated PBMC samples. We subsequently 
selected 74 participants with the highest IFNα and lowest IFNα production in each group to 
compare differences in gene transcription associated with extreme phenotypes of IFNα 
production as visualised in Figure 4:2:B. 
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Figure 4:2 Variation in IFNα production by the stimulus.  
A) Paired IFNα produced in PBMC after 24 h of no stimulation (control), TLR7 agonist 
(imiquimod) or rhinovirus-16 (RV) stimulation. B) Relative frequency of IFNα production in 
unstimulated PBMC or in response to RV16 or TLR7 agonist. Blue RV16-stimulated samples 
with IFNα production below 414 pg/ml were chosen as IFN-low samples, and red samples 
with IFNα production above 2200 pg/ml were selected as the IFN-high samples. Dotted lines 
show the frequency distribution of each stimulation fitted to a Gaussian distribution. 
A 
B 
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4.3.2. The demographics of the study groups 
Table 4:1 compares the differences in clinical and molecular features between high and low 
IFNα producers within the asthma and healthy control groups. The primary selection criteria 
for this study was high or low IFNα production. Participants were selected separately from 
asthma and control groups to maintain equal sample size, but omitted adjustment for sex, 
age and BMI to preserve the contrast between the groups. The results show that the IFN-
low group (n = 38) had significantly higher BMI (median 23 vs 26; p = 0.001) than the IFN-
high group (n = 36), and the IFN-low group tended to be slightly older, though this was not 
statistically significant (p = 0.053). However, between asthmatic participants, low IFNα 
producers were significantly older than the high producers (p = 0.004). There were no 
significant differences in asthma control, severity, or frequency of respiratory infections 
between IFN-high and IFN-low groups. Sixty-five per cent were female; however, 
stratification by group reveals that the healthy IFN-low group has fewer females at 50%, 
however not significantly fewer in comparison to other groups (Table 4:1). 
TLR7 and TLR8 gene expression as measured in unstimulated conditions in whole blood 
were similar between the groups; however, the pDC cell marker CLEC4C gene expression 
was significantly lower in the IFN-low group (p-value < 0.001) suggesting relatively lower 
pDC cell count (as discussed in Chapter 2). TLR8-activated TNF production was also lower 
in the IFN-low group (p-value = 0.006), whereas TLR8-activated IL12 production was similar 
in both groups. Peripheral blood granulocytes and smoking status were similar in both 
groups; only eosinophils were higher in the asthma groups (p-value = 0.003). 
Table 4:1 Characteristic of the study groups classified by asthma status. 
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 IFN-high IFN-low  
 Asthma No Asthma No p 
n 18 18 19 18  
Female (%) 13 (72.2) 
13 
(72.2) 
13 
(68.4) 
9 
(50.0) 
0.438 
Age at 
donation  
27.00 
[24.00, 34.50] 
32.50 
[26.00, 43.75] 
47.00 
[35.50, 53.00] a 
36.50 
[23.25, 49.25] 
0.045 
BMI  kg/m2 23.00 
[21.25, 24.00] 
23.50 
[21.00, 26.00] 
27.00 
[25.00, 30.50] a  
24.50 
[24.00, 27.00] 
0.008  
 IFN-high: 23.00 [21.00, 25.25] IFN-low: 26.00 [24.00, 30.00] d  
GINA step (%) 7 (38.9)  6 (31.6)  0.391 
 1 (5.6)  0 (0.0)   
 1 (5.6)  3 (15.8)   
 9 (50.0)  8 (42.1)   
 0 (0.0)  2 (10.5)   
ACQ score 0.50 [0.17, 0.96] 
 0.83 
[0.25, 1.92] 
 0.271 
Cold frequency 3.00 [3.00, 5.00] 
3.00 
[1.00, 3.00] 
3.00 
[3.00, 5.00] 
 
1.50 
[1.00, 3.00] c 
0.004 
 All asthma: 3.00 [3.00, 5.00]   All Healthy: 2.00 [1.00, 3.00] e  
Gene expression in whole blood     
     TLR7 0.29 [0.24, 0.44] 
0.26 
[0.21, 0.33] 
0.25 
[0.20, 0.35] 
0.28 
[0.21, 0.36] 
0.596 
     TLR8 0.28 [0.23, 0.32] 
0.28 
[0.22, 0.39] 
0.25 
[0.20, 0.35] 
0.34 
[0.24, 0.46] 
0.198 
     CLEC4C 0.19 [0.10, 0.26] 
0.15 
[0.10, 0.22] 
0.10 
[0.06, 0.12] 
0.08 
[0.06, 0.11]  
0.006 
 IFN-high: 0.15 [0.10, 0.26] IFN-low: 0.08 [0.06, 0.11] d  
Cytokine production in PBMC     
     IFNα pg/ml 
   (RV-stim.) 
3011.11 
[2538.10, 3652.04] 
3265.26 
[2887.05, 4044.42] 
297.66 
[279.42, 346.75] a 
223.58 
[190.87, 301.19] b  
<0.001 
 IFN-high: 3068.18 [2736.95, 3866.79] IFN-low: 279.42 [196.65, 324.94] d  
     TNF pg/ml 
   (TLR8-stim.) 
3799.00 
[2347.82, 5515.34] 
2354.01 [927.12, 
4174.55] 
1654.43 [667.49, 
3439.06] 
1829.32 
[909.25, 2135.81]  
0.016 
 IFN-high: 3180.04 [1827.26, 4841.36] IFN-low: 1798.82 [754.18, 3082.33] d  
     IL12 pg/ml 
   (TLR8-stim.) 
196.74 
[113.06, 291.70] 
99.17 
[26.67, 144.82] 
202.04 
[61.75, 288.57] 
103.07 
[72.66, 184.12] 
0.102 
White blood 
cells x 109/L 
6.35 
[5.62, 7.65] 
6.60 
[5.05, 7.40] 
6.20 
[5.25, 7.65] 
5.80 
[4.90, 8.22] 
0.866 
Neutrophils x 
109/L 
3.45 
[2.87, 4.41] 
3.78 
[2.66, 4.99] 
3.48 
[2.92, 4.17] 
3.16 
[2.82, 5.37] 
0.924 
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 IFN-high IFN-low  
 Asthma No Asthma No p 
Eosinophils x 
109/L 
0.23 
[0.12, 0.38] 
0.15 
[0.08, 0.24] 
0.26 
[0.16, 0.33] 
0.11 
[0.08, 0.17] c 
0.003 
 All asthma: 0.25 [0.14, 0.36]   All healthy: 0.12 [0.08, 0.19] e  
Pack years 
smoked 
0.00 
[0.00, 0.00] 
0.00 
[0.00, 0.00] 
0.00 
[0.00, 0.00] 
0.00 
[0.00, 0.00] 
0.899 
n = study group size; TLR8-ag. stim. = TLR8 agonist VTX-2337 stimulated. Variables are 
expressed as median [interquartile range] or n observations (%). GINA step measures 
asthma severity and ACQ score asthma control score. The bold p-value indicates 
statistically significant Kruskal-Wallis ranks sum test between the four groups. Significant 
post-hoc Mann-Whitney U-test indicated as: ap < 0.008 vs IFN-high asthma group; bp < 
0.008 vs IFN-high healthy group; cp < 0.008 vs IFN-low asthma group; dp < 0.008 vs IFN-
high group; ep < 0.008 vs asthma groups. 
4.3.3. Principal component analysis of transcriptomes 
We compared the transcriptomes between the asthma and healthy IFN-high and IFN-low 
groups. Principal component analysis (PCA) of baseline and RV16-stimulated sample 
transcriptomes indicated a modest grouping of samples by IFNα producer groups across 
PC1 (unstimulated Figure 4:3, RV16-stimulated Figure 4:4). Because PCA revealed no 
apparent distinction between asthmatic and non-asthmatic samples, this warranted a pooled 
analysis of the IFN-high and IFN-low groups, regardless of asthma status, to address the 
primary objective of the study. 
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Figure 4:3 PCA analysis of unstimulated samples.  
Green indicates high and red indicates low IFNα producer samples. Round shapes indicate 
asthma and triangle shapes healthy samples. 
 
Figure 4:4 PCA analysis of RV16-stimulated samples.  
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Green indicates high and red indicates low IFNα producer samples. Round shapes indicate 
asthma and triangle shapes healthy samples. 
4.3.4. Comparison of TLR7/8-related gene expression in high and low IFNα 
producer groups 
Results in Chapter 3 indicated that baseline TLR7 and CLEC4C gene expression in whole 
blood was associated with the frequency of respiratory infections, even though there was no 
link between IFNα production and infection frequency. We compared the gene expression 
levels of TLR7 and CLEC4C as well as the related receptor TLR8 and its induced cytokines 
TNF and IL12A at baseline and under RV16 stimulation in PBMC samples. As expected, 
TLR7 and TLR8 receptor and IFNA, TNF and IL12A cytokine genes were upregulated during 
RV16 stimulation (Figure 4:5), regardless of IFNα producer group. Only CLEC4C gene 
expression levels remained the same at baseline and during RV16 stimulation, supporting 
its use as a stable pDC quantity marker, unaffected by the cell activation status. 
We then assessed whether TLR7/8-related genes at baseline predict an efficient IFNα 
response by comparing expression between the IFN-high and IFN-low groups. CLEC4C, 
TLR7 and TLR8 gene expression were significantly higher in the IFN-high group, indicating 
that baseline TLR7/8 receptor and pDC levels predict efficient IFNα response (Figure 4:5). 
IL12A baseline gene expression was also higher in the IFN-high group but not significantly 
after correction for multiple testing (p-value threshold 0.05/4 tests = 0.013). As expected, 
baseline IFNA gene expression was undetectable in both groups. 
Next, we assessed the differential expression of TLR7/8-related genes in response to the 
virus, comparing the two IFNα producer groups. During RV16 challenge, gene expression 
levels of the cytokine genes IFNA, TNF and IL12A, TLR7 receptor gene and pDC marker 
CLEC4C gene were significantly higher in the IFN-high group. However, TLR8 gene 
expression was similar in IFN-high and IFN-low groups (Figure 4:5). 
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Figure 4:5 Gene expression of TLR7/8-related immune response variables.  
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Gene expression of TLR7, TLR8, CLEC4C, the sum of IFNA genes, TNF and IL12A at 
baseline (control) and RV16-stimulated PBMC samples separated by IFNα producer group. 
p-value is shown for significant Mann-Whitney U tests. 
4.3.5. Other baseline gene expressions that differ between high and low IFNα 
producers. 
Besides TLR7/8-related immunity, we wanted to determine what other biological and 
immunological systems at baseline explain the ability to respond to viral stimulation with 
robust IFNα production. Therefore, we compared the transcriptomes of the two contrasting 
IFNα producer groups in unstimulated PBMC samples. With a cut-off of FDR q-value < 0.05 
and log fold-change > 1 of gene expression, unpaired differential gene expression analysis 
returned 39 upregulated genes (Table 4:2) and 10 downregulated genes (Table 4:3) in the 
IFN-high group. The heatmap visualisation in Figure 4:6 reveals a major subcluster of 
upregulated genes that are consistently upregulated in the IFN-high group and 
downregulated in the IFN-low group. Sample clustering with Ward hierarchical cluster 
analysis positions asthma samples randomly, which supports our results from PCA (Figure 
4:3) that differential gene expression is not influenced by asthma status. We searched the 
manually annotated records in the protein knowledgebase UniProt (The UniProt Consortium 
2018) and PubMed (NIH, USA) for any additional literature supporting the understanding of 
the functions of the gene products. Common functional groups that arose from literature are 
annotated for each gene in the tables below. 
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Figure 4:6 Baseline differential gene expression.  
Gene expression of the differentially expressed genes in unstimulated PBMC samples IFN-
high group vs IFN-low group. Log2-transformed gene expression is presented as a 
difference from the median. Samples are hierarchically clustered with Ward method and 
genes with weighted pair group method with arithmetic mean. Samples are colour-coded for 
asthma status and IFNα producer group. 
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Table 4:2 Upregulated genes at baseline  
Gene 
symbol Gene product name 
Log 
FC FDR 
O
th
er
 
Im
m
un
e 
fu
nc
tio
n 
EC
M
 
A
lle
r g
y 
Lu
ng
 
Io
n 
ch
an
ne
l 
Li
pi
d 
m
et
ab
ol
is
m
 
St
ru
ct
ur
al
 c
om
po
ne
nt
 
Tr
an
sc
rip
tio
n 
An
tiv
ira
l 
D
en
dr
iti
c 
ce
lls
 
C
he
m
ok
in
e 
An
tig
en
 p
re
se
nt
at
io
n 
NEBL Nebulette 1.76 0.0055        *      
KRT5 Keratin 5 1.05 4.32E-05     *   *      
VCAN Versican 1.17 0.0003  * * * *      *   
UBD Ubiquitin D 1.01 0.0009  *            
C1QA Complement C1q A Chain 1.23 0.0022  *            
C1QB Complement C1q B Chain 1.03 0.0041  *            
C1QC Complement C1q C Chain 1.71 0.0011  *            
MS4A6A Membrane Spanning 4-Domains A6A 1.36 0.0005  *         *   
CLEC4C C-Type Lectin Domain Family 4 Member C 1.02 0.0037 
 *         *  * 
ANOS1 Anosmin 1 1.58 0.0083        *      
ETV3L ETS Variant 3 Like 1.38 0.0321 
Vitamin 
D  
      *     
PALD1 Phosphatase Domain Containing Paladin 1 1.19 0.0003 
    *         
CXCL13 C-X-C Motif Chemokine Ligand 13 1.46 0.0282  *          *  
ASGR2 Asialoglycoprotein Receptor 2 1.15 0.0014  *            
NHS NHS Actin Remodeling Regulator 1.02 0.0001        *      
PPFIA4 PTPRF Interacting Protein Alpha 4 1.31 0.0153   *     *      
RNASE1 Ribonuclease A Family Member 1, Pancreatic 1.04 0.0180 
 *        *    
HTRA1 HtrA Serine Peptidase 1 1.43 0.0180   *           
C3 Complement C3 1.13 0.0023  *     *       
MS4A4A Membrane Spanning 4-Domains A4A 2.02 0.0044  *         *   
C6orf223 Chromosome 6 Open Reading Frame 223 1.28 0.0297 
             
FXYD6 FXYD Domain Containing Ion Transport Regulator 6 1.01 0.0180 
 *  *         * 
KCNJ15 Potassium Voltage-Gated Channel Subfamily J Member 15 1.04 0.0142 
     *        
FOXD4L3 Forkhead Box D4 Like 3 1.05 0.0178         *     
KCNJ10 Potassium Voltage-Gated Channel Subfamily J Member 10 1.08 0.0126 
     *        
LAD1 Ladinin 1 1.02 4.36E-05        *      
CHI3L1 Chitinase 3 Like 1 1.16 0.0434   *   *  *         
TNNT2 Troponin T2, Cardiac Type 1.08 0.0109 Cardiac             
IDO1 Indoleamine 2,3-Dioxygenase 1 1.16 0.0039  *         *   
CD93 CD93 Molecule 1.16 0.0003  *  *       *   
CPVL Carboxypeptidase, Vitellogenic Like 1.08 0.0007  *         *  * 
AOC1 Amine Oxidase, Copper Containing 1 1.20 0.0036  *  *          
OLFML2B Olfactomedin Like 2B 1.09 0.0143   *           
CALCRL Calcitonin Receptor Like Receptor 1.24 0.0002              
KCNMA1 Potassium Calcium-Activated Channel Subfamily M Alpha 1 1.05 0.0095 
     *        
Upregulated genes in unstimulated PBMC samples in IFN-high group in contrast with IFN-
low group and associated functional groups are annotated. FC = fold change, FDR = false 
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discovery rate. Underlined genes are differentially expressed also in RV16-stimulated 
samples. 
Table 4:3 Downregulated genes at baseline 
Gene 
symbol Gene product name 
Log 
FC FDR 
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HBA1 Hemoglobin Subunit Alpha 1 -1.92 0.0007        *  
HBA2 Hemoglobin Subunit Alpha 2 -1.89 0.0005        *  
HBB Hemoglobin Subunit Beta -1.97 0.0005        *  
PRAME Preferentially Expressed Antigen In Melanoma -1.87 0.0328 *  * * *     
HBG2 Hemoglobin Subunit Gamma 2 -1.51 0.0022       * *  
ALAS2 5'-Aminolevulinate Synthase 2 -1.65 0.0154        *  
DPYSL3 Dihydropyrimidinase Like 3 -1.75 0.0062  *        
HSPA1B Heat Shock Protein Family A (Hsp70) Member 1B 
-1.00 0.0031         * 
MET MET Proto-Oncogene, Receptor Tyrosine Kinase 
-1.07 0.0299      *    
NR4A2 Nuclear Receptor Subfamily 4 Group A Member 2 
-1.88 0.0183   *       
Downregulated genes in unstimulated PBMC samples in IFN-high group in contrast with 
IFN-low group and associated functional groups are annotated. FC = fold change, FDR = 
false discovery rate. Underlined genes are differentially expressed also in RV16-stimulated 
samples. 
The genes upregulated by the IFN-high group in comparison to the IFN-low group were most 
often related to immune function (Table 4:2), whereas the downregulated genes were most 
often related to oxygen transport (Table 4:3). The immune-related genes included those 
associated with the complement system (C1QA, C1QB, C1QC, C3, CD93), antigen 
presentation (CLEC4C, CPVL, RNASE1, ASGR2), B-cell chemokine (CXCL13), immune 
regulation (IDO1, CHI3L1, UBD, VCAN), macrophage and pDC surface markers (MS4A4A, 
MS4A6A). Three potassium channel encoding genes were upregulated (KCNJ10, KCNJ15, 
and KCNMA1). A transcription factor gene ETV3L associated with vitamin D activation was 
upregulated in the IFN-high samples. 
Pubmed searches revealed several upregulated genes that were associated with allergy 
[CD93, (Park et al. 2017); AOC1, (Anvari et al. 2015); FXYD6, (Chhiba et al. 2017)], asthma 
risk [CHI3L1, (Ober et al. 2008)] airway remodelling [VCAN, (Ayars et al. 2013); KRT5, (Ray 
et al. 2016)] and airway obstruction [PALD1, (Egana et al. 2017)]; however, the heatmap 
(Figure 4:6) shows no distinct pattern in asthma samples in relation to these genes. 
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A group of downregulated oxygen transport genes encode haemoglobin subunits (HBA1, 
HBA2, HBB, HBG2) and an enzyme involved in haem biosynthesis (ALAS2) (Table 4:3). 
The gene group forms a subcluster that is downregulated in most IFN-high samples (Figure 
4:6). Four other downregulated genes have a role in wound healing (MET, DPYSL3), stress 
response (HSPA1B) and as inflammatory markers (HSPA1B and NR4A2). 
4.3.6. Baseline biological pathway analysis of differentially expressed genes 
Gene set enrichment analysis (GSEA) was used to search for functional enrichment within 
the differentially expressed gene sets. Figure 4:7 presents the gene ontology (GO) pathways 
associated with differentially expressed genes from unstimulated samples for the IFN-high 
group compared to the IFN-low group. The upregulated pathways indicate upregulation of 
immune function, whereas the downregulated pathways are more varied in their function. A 
network representation visualises shared genes in selected pathways, (Figure 4:8), 
demonstrating considerable gene overlap within both up- and downregulated pathways. 
The list of differentially expressed genes resulted in several downregulated enriched 
pathways. The pathway for a response to oxidative stress was highly significant, with only a 
few gene members causing a strong effect. These gene members included: haemoglobin 
subunits (HBA1, HBA2, HBB) and inflammatory markers (HSPA1B and NR4A2). Together 
the downregulated gene functions and the enriched GO-pathways indicate a differential 
state of cellular stress between the IFNα producer groups, such that the cells from high IFNα 
producing individuals showed efficient downregulation of oxidative stress gene expression, 
whereas a subset low IFNα producing individuals exhibited high expression of oxidative 
stress gene expression. 
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Figure 4:7 Baseline gene ontology pathways.  
Gene ontology pathways that are enriched in the set of differentially expressed genes in 
unstimulated PBMC samples of IFN-high group in contrast with IFN-low group. FDR = false 
discovery rate, NES = normalised effect size, size = number of genes found in the pathway. 
Pathways with size > 5 are included. Pathways are sorted by significance on the horizontal 
axis and effect on the vertical axis as indicated by the dots. Size of the dot is relevant to the 
number of genes found in the pathway and colour to the effect size. 
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Figure 4:8 Baseline gene ontology pathway associations.  
Associations between selected downregulated (blue) and upregulated (red) gene ontology 
pathways in unstimulated PBMC samples. Pathways are enriched in the differentially 
expressed genes in the samples of IFN-high group in contrast IFN-low group. Pathways with 
least overlap in function were selected. Line thickness reflects the number of shared genes. 
4.3.7. RV16-stimulated gene expression and how this differs between high and 
low IFNα producers 
To understand the variation in antiviral immune response between the IFNα producer 
groups, we next assessed differential gene expression during viral challenge with RV16. 
With a cut-off of FDR q-value < 0.05 and log fold-change > 1, unpaired differential gene 
expression analysis returned 55 upregulated genes (Table 4:4), and 73 downregulated 
genes (Table 4:5) in the IFN-high group. A heatmap graphically presents the gene 
expression across the samples (Figure 4:9). Similar to the clustering analysis of the 
unstimulated samples (Figure 4:6), the RV16-stimulated samples cluster primarily by the 
IFN-producer group, rather than by the presence or absence of asthma. 
This heatmap reveals three distinct clusters of genes with similar expression patterns. The 
gene cluster in the middle contains the upregulated genes, including IFN genes. The 
expression of those genes is uniformly high in the IFN-high group and low in the IFN-low 
group. 
In contrast, the downregulated genes separate into two main clusters at the top and bottom 
of the heatmap. The downregulated gene expression is consistently low in the IFN-high 
group samples but is more varied in the IFN-low group samples. The top gene cluster 
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contains several subclusters of genes that are upregulated by distinct sample clusters. 
Whereas, the bottom cluster of genes is upregulated only by one IFN-low sample cluster 
consisting of mostly non-asthma samples. 
Some clustering with asthma and healthy samples is evident, and these sample subclusters 
upregulate specific gene subclusters. For example, a sample subcluster of asthmatic IFN-
low samples in the far right of Figure 4:9 has a high expression of two gene clusters: 
PGLYRP1, HP, TCN1, CRISP3, MMP8, CEACAM6, CEACAM8, BPI, LCN2, ALAS2 and 
HBA2, HBA1, HBB, LTF. 
We searched the manually annotated records in the protein knowledgebase UniProt, and 
any additional literature available for the function of the differentially expressed gene 
products. The most common relevant functions are annotated for each gene in Table 4:4 
and Table 4:5. 
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Figure 4:9 RV16-challenged differential gene expression.  
Gene expression of the differentially expressed genes in RV16-stimulated PBMC samples 
IFN-high group vs IFN-low group. Log2-transformed gene expression is presented as a 
difference from the median. Samples are hierarchically clustered with Ward method and 
genes with weighted pair group method with arithmetic mean. Samples are colour-coded for 
asthma status and IFNα producer group. 
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Table 4:4 Upregulated genes during RV16 challenge 
Gene 
symbol Gene product name 
Log 
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IFNA8 Interferon Alpha 8 2.67 3.32E-11  *         *     
IFNA21 Interferon Alpha 21 2.64 1.74E-10  *         *     
IFNA4 Interferon Alpha 4 2.62 1.74E-10  *         *     
IFNA1 Interferon Alpha 1 2.52 1.74E-10  *         *     
IFNA16 Interferon Alpha 16 2.42 1.79E-10  *         *     
IFNA5 Interferon Alpha 5 2.38 1.74E-10  *         *     
IFNA7 Interferon Alpha 7 2.26 6.39E-10  *         *     
IFNA17 Interferon Alpha 17 2.48 5.45E-10  *         *     
IFNW1 Interferon Omega 1 1.40 1.74E-10  *         *     
IFNA2 Interferon Alpha 2 2.37 4.01E-10  *         *     
IFNA14 Interferon Alpha 14 2.39 1.17E-09  *         *     
IFNA10 Interferon Alpha 10 2.40 2.57E-09  *         *     
IFNB1 Interferon Beta 1 2.33 1.74E-10  *         *     
IFNA13 Interferon Alpha 13 2.30 2.17E-08  *         *     
IFNA6 Interferon Alpha 6 2.21 6.33E-06  *         *     
CXCL13 C-X-C Motif Chemokine Ligand 13 1.87 2.01E-05            *    
RXFP1 Relaxin Family Peptide Receptor 1 1.53 2.17E-08     *           
LAMA3 Laminin Subunit Alpha 3 1.69 1.58E-07   *  *           
CCL19 C-C Motif Chemokine Ligand 19 1.07 4.87E-08  *          *    
AF165138.7 1.574 1.41                
PPFIA4 PTPRF Interacting Protein Alpha 4 1.74 0.0128   *             
IL18 Interleukin 18 1.07 2.17E-08  *              
CEMIP Cell Migration InducingHyaluronidase 1 
1.17 8.55E-05    *            
CCL18 C-C Motif Chemokine Ligand 18 1.20 4.36E-05  *          *    
IFNL1 Interferon Lambda 1 1.57 0.0005  *         *     
AQP9 Aquaporin 9 1.31 1.32E-07      *    *      
ELOVL7 ELOVL Fatty Acid Elongase 7  1.35 3.57E-10       *         
DEFB1 Defensin Beta 1 2.01 0.0001  *        *  *   * 
DNAAF1 Dynein Axonemal Assembly Factor1 
1.18 2.77E-06        *        
IGFBP2 Insulin Like Growth Factor BindingProtein 2  
1.24 0.0484              *  
ACOD1 Aconitate Decarboxylase 1 1.27 2.10E-06  *        * *     
SLC39A
8 Solute Carrier Family 39 Member 8
1.30 1.72E-05      *          
GPR31 G Protein-Coupled Receptor 31 1.98 0.0005 unknown               
ARNT2 Aryl Hydrocarbon Receptor NuclearTranslocator 2 
1.20 1.51E-05         *       
CCL23 C-C Motif Chemokine Ligand 23 1.46 0.0078  *          *    
CH25H Cholesterol 25-Hydroxylase 1.49 0.0006  *         *     
CD1D CD1d Molecule 1.21 0.0009  *           *   
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UBD Ubiquitin D 1.39 1.29E-05                
SDK2 Sidekick Cell Adhesion Molecule 2 1.19 0.0347 development  
             
SLC1A2 Solute Carrier Family 1 Member 2  1.18 0.0001      *    *      
CYP27B
1 
Cytochrome P450 Family 27
Subfamily B Member 1  
1.14 3.13E-05 Vitamin D  
             
UPB1 Beta-Ureidopropionase 1 1.42 1.57E-06           *     
ACHE Acetylcholinesterase (CartwrightBlood Group) 
1.28 
0.0002 
acetychol
inesteras
e 
              
IL31RA Interleukin 31 Receptor A 1.25 0.0002  *              
LAMP5 Lysosomal Associated MembraneProtein Family Member 5 
1.24 8.26E-06  *              
ABHD17
C 
Abhydrolase Domain Containing
17C 
1.04 3.84E-07       *         
CCM2L CCM2 Like Scaffold Protein 1.10 0.0077 cardiac               
CSRP2 Cysteine And Glycine Rich Protein2 
1.10 0.0002  *            *  
MAOA Monoamine Oxidase A 
1.08 
0.0018 
monoami
ne 
oxidiser 
              
GPR34 G Protein-Coupled Receptor 34 1.03 0.0020  *              
LGALS9
B Galectin 9B 
1.15 0.0485 binding protein  
             
CXCL9 C-X-C Motif Chemokine Ligand 9 1.26 0.0022  *            * * 
FLT3 Fms Related Tyrosine Kinase 3 1.54 1.11E-07  *            *  
MAP1A Microtubule Associated Protein 1A 1.22 3.02E-07        *        
FCGR1BFc Fragment Of IgG Receptor Ib 1.32 0.0016  *           *   
ADAMT
S2 
ADAM Metallopeptidase With
Thrombospondin Type 1 Motif 2 
1.09 0.0056   *             
Upregulated genes in RV16-stimulated PBMC samples in IFN-high group in contrast with 
IFN-low group and associated functional groups are annotated. FC = fold change, FDR = 
false discovery rate. Underlined genes are also differentially expressed in unstimulated 
samples. 
Table 4:5 Downregulated genes during RV16 challenge 
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FABP4 Fatty Acid Binding Protein 4 -2.65 0.0009      *           
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CXCL5 C-X-C Motif Chemokine Ligand 5 
-2.50 0.0012  *            *   
HBB Hemoglobin Subunit Beta -2.29 1.34E-05            *     
HBA1 Hemoglobin Subunit Alpha 1 -2.25 2.35E-05            *     
ALAS2 5'-Aminolevulinate Synthase 2 -2.22 0.0040            *     
NOTCH3 Notch 3 -2.20 5.37E-06             *    
CCL24 C-C Motif Chemokine Ligand 24 
-2.17 3.00E-05  *            *   
FLRT2 Fibronectin Leucine Rich Transmembrane Protein 2 
-2.12 3.07E-05       *         * 
DPYSL3 Dihydropyrimidinase Like 3 -2.07 0.0017       *         * 
HBA2 Hemoglobin Subunit Alpha 2 -2.04 4.77E-05            *     
GPC4 Glypican 4 -2.01 0.0011   *          *    
SERPINE1 Serpin Family E Member 1 -1.97 0.0004       *         * 
PID1 Phosphotyrosine Interaction Domain Containing 1 
-1.96 0.0005      *           
MMP7 Matrix Metallopeptidase 7 -1.93 0.0034   *              
MMP8 Matrix Metallopeptidase 8 -1.92 0.0060   *              
GCOM1 GRINL1A Complex Locus 1 -1.89 0.0050        *         
ITGA11 Integrin Subunit Alpha 11 -1.87 1.32E-05   *    *          
RASAL1 RAS Protein Activator Like 1 
-1.87 
2.57E-09 
Ras-cyclic 
AMP 
pathway 
               
LPL Lipoprotein Lipase -1.78 0.0012      *           
LTF Lactotransferrin -1.73 0.021         *        
TACSTD2 Tumor Associated Calcium Signal Transducer 2 
-1.70 0.0041  *               
CYP1B1 Cytochrome P450 Family 1 Subfamily B Member 1 
-1.68 1.11E-07            *     
OCSTAMP Osteoclast Stimulatory Transmembrane Protein 
-1.64 0.0039             *    
TM4SF19 Transmembrane 4 L Six Family Member 19 
-1.60 0.0006  *               
BPI Bactericidal Permeability Increasing Protein 
-1.59 0.021  *       *        
CD300LB CD300 Molecule Like Family Member B 
-1.59 4.59E-05  *    *           
CLEC5A C-Type Lectin Domain Containing 5A 
-1.59 0.0039  *               
MGAT5B 
Alpha-1,6-
Mannosylglycoprotein 6-Beta-
N-
Acetylglucosaminyltransferase 
B 
-1.55 
0.0007  *               
LCN2 Lipocalin 2 -1.54 0.033         *   *     
STAB1 Stabilin 1 -1.51 3.84E-07      *   *        
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GREM1 Gremlin 1, DAN Family BMP Antagonist 
-1.50 0.011  * * *            * 
MRC1 Mannose Receptor C-Type 1 -1.46 0.0084  *             *  
CXCL8 C-X-C Motif Chemokine Ligand 8 
-1.46 0.0042  *            *   
HBG2 Hemoglobin Subunit Gamma 2 -1.44 0.0032            *     
CD1B CD1b Molecule -1.44 0.014  *             *  
CRISP3 Cysteine Rich Secretory Protein 3 
-1.38 0.016          *       
HP Haptoglobin -1.38 0.014         *   *     
PGLYRP1 Peptidoglycan Recognition Protein 1 
-1.38 0.024         *        
CD9 CD9 Molecule -1.38 0.0003  *               
APOE Apolipoprotein E -1.38 0.0043      *           
CLEC10A C-Type Lectin Domain Containing 10A 
-1.37 0.0055  *               
COL23A1 Collagen Type XXIII Alpha 1 Chain 
-1.36 0.0035   *              
CEACAM8 
Carcinoembryonic Antigen 
Related Cell Adhesion 
Molecule 8 
-1.36 
0.049       *          
SDC2 Syndecan 2 -1.34 0.0007       *          
TKTL1 Transketolase Like 1 -1.31 0.0027             *    
SPOCD1 SPOC Domain Containing 1 -1.30 0.027        *     *    
TCN1 Transcobalamin 1 -1.29 0.039 vitamin B12 
               
CEACAM6 
Carcinoembryonic Antigen 
Related Cell Adhesion 
Molecule 6 
-1.29 
0.037       *          
OLFM1 Olfactomedin 1 -1.28 0.0034       *          
KRT72 Keratin 72 -1.27 0.0005   *              
SCG5 Secretogranin V -1.23 0.018 chaperone         *       
METTL7B Methyltransferase Like 7B -1.20 0.017 methyltransferase 
               
SPINK1 Serine Peptidase Inhibitor, Kazal Type 1 
-1.18 0.038   *              
TIMP3 TIMP Metallopeptidase Inhibitor 3 
-1.18 0.031   *              
KCNF1 
Potassium Voltage-Gated 
Channel Modifier Subfamily F 
Member 1 
-1.17 
0.046     *            
MET MET Proto-Oncogene, Receptor Tyrosine Kinase 
-1.15 0.036             *    
RASAL2 RAS Protein Activator Like 2 -1.14 6.72E-05             *    
HAMP Hepcidin Antimicrobial Peptide -1.12 0.011         *   *     
CCL1 C-C Motif Chemokine Ligand 1 -1.12 0.044  *            *   
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PODN Podocan -1.12 0.041             *   * 
KRT73 Keratin 73 -1.11 0.0008   *              
C5AR2 Complement Component 5a Receptor 2 
-1.11 3.84E-07  *            *   
SLC1A7 Solute Carrier Family 1 Member 7 
-1.11 0.037     *            
TREM2 Triggering Receptor Expressed On Myeloid Cells 2 
-1.09 0.011  *               
MMP9 Matrix Metallopeptidase 9 -1.07 0.0006   *             * 
DSC1 Desmocollin 1 -1.07 0.0011       *          
CXCL3 C-X-C Motif Chemokine Ligand 3 
-1.07 0.032  *            *   
KRT1 Keratin 1 -1.06 0.036  *               
GPAT3 Glycerol-3-Phosphate Acyltransferase 3 
-1.06 0.0017      *           
PDGFC Platelet Derived Growth Factor C 
-1.04 0.0005       *         * 
SEMA4C Semaphorin 4C -1.04 4.61E-06       *         * 
C14orf132 Chromosome 14 Open Reading Frame 132 
-1.01 0.0004 unknown                
Downregulated genes in RV16-stimulated PBMC samples in IFN-high group in contrast with 
IFN-low group and associated functional groups are annotated. FC = fold change, FDR = 
false discovery rate. Underlined genes are also differentially expressed in unstimulated 
samples. 
Table 4:4 shows gene expression of the thirteen IFNA subtypes. As expected, IFNB1, IFNL1 
and IFNW1 were increased in the IFN-high samples. Including those genes, 33 out of 56 
upregulated genes are related to immune function, and two have supporting roles in the 
antiviral immune response: breakdown of viral lipid membrane [ELOVL7, (Purdy, Shenk & 
Rabinowitz 2015)] and nucleic acid metabolism (UPB1). Interestingly, several genes that 
are downregulated have antibacterial functions, including BPI, HP, HAMP, LTF, LCN2, 
PGLYRP1, and STAB1. 
The other immune-related upregulated genes had a known cytokine (IL18, IL31RA, CXCL9, 
FLT), antibacterial [DEFB1; ACOD1; AQP9, (Perelman et al. 2016)], antiviral (DEFB1), 
chemokine (CCL18, CCL19, CCL23, CXCL13) or antigen presentation (CD1D, FCGR1B) 
function explaining their increased expression in antiviral immune response. 
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Conversely, under RV stimulation, cells from the IFN-high group showed downregulated 
gene products that were most often related to structural or extra-cellular matrix (ECM) 
function, often with opposing functions. Three matrix metalloproteinases (MMP9, MMP7, 
MMP8) were prominent: these aid in ECM breakdown; however, an opposing matrix 
metalloproteinase inactivator TIMP3, was also downregulated. SERPINE1 and COL23A1 
are also associated with ECM organisation. The gene products of COL23A1, GREM1, 
STAB1, CEACAM8, CEACAM6, DSC1, FLRT2, ITGA11, and TIMP3 have a role in cell-cell 
or cell-ECM adhesion. Similarly, SEMA4C, PDGFC, MMP9, MMP7, MMP8, CEACAM6 
upregulate cell migration, whereas PODN, CYP1B1, SERPINE1, DPYSL3 downregulate cell 
migration. The gene products of PDGFC, CEACAM6, and GREM1 upregulate cell 
proliferation, whereas PODN, CD9 downregulate cell proliferation. Also, GPC4, MET, SDC2, 
may be involved in cell proliferation. 
Three genes were upregulated, and seven were downregulated in both unstimulated and 
RV16-stimulated samples. Upregulated UBD encodes ubiquitin-like protein tagging proteins 
for degradation and regulates TNF-mediated NFKB signalling essential in innate immunity 
but it may also activate DC maturation. CXCL13 and PPFIA4 genes were upregulated, and 
they encode a B-cell chemokine and focal adhesion regulator, respectively. IFN-high 
samples downregulated the haemoglobin subunits (HBA1, HBA2, HBB, HBG2) and haem 
biosynthesis enzyme (ALAS2), cytoskeleton remodelling (DPYSL3) genes and a gene 
(MET) encoding a transmembrane receptor involved in proliferation, scattering, 
morphogenesis and survival in both conditions. 
4.3.8. RV16-stimulated biological pathway analysis of differentially expressed 
genes 
GSEA was used to search for biologically relevant functions that are enriched in the 
differentially expressed genes in the RV16-challenged samples. As expected, the 
significantly upregulated GO-pathways relate to activation of antiviral immune responses 
(Figure 4:10). The downregulated genes are involved in cell proliferation, cell-cell 
communication and cell migration, which is reflected in the enriched pathways 
(GO_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS, 
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GO_NEGATIVE_REGULATION_OF_CELL_COMMUNICATION). However, the 
downregulated pathways were statistically less significant than the upregulated pathways. 
A selection of a representative up- and downregulated pathways are presented in a network 
Figure 4:11. This network reveals high interconnectivity and several shared genes between 
the upregulated pathways and individual genes between the downregulated pathways. 
 
Figure 4:10 RV16-challenged gene ontology pathways.  
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Gene ontology pathways enriched in the differentially expressed genes in RV16-stimulated 
PBMC samples of IFN-high group compared to IFN-low group. FDR = false discovery rate, 
NES = normalised effect size, size = number of genes found in the pathway. Pathways with 
size > 15 are included. Pathways are sorted by significance on the horizontal axis and effect 
on the vertical axis as indicated by the dots. Size of the dot is relevant to the number of 
genes found in the pathway and colour to the effect size. 
 
Figure 4:11 RV16-challenged gene ontology pathway associations.  
Associations between selected downregulated (blue) and upregulated (red) gene ontology 
pathways in RV16-stimulated PBMC samples. Pathways are enriched within the 
differentially expressed genes in the samples of IFN-high group compared to IFN-low group. 
Pathways were filtered for least overlap in function. Line thickness reflects the number of 
shared genes. 
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4.4. Discussion 
Type I IFN is vital for effective antiviral immune response. Asthma has been associated with 
a deficiency in type I IFN production, and despite not showing such association in Chapter 
3, we observed a major degree of variability in the antiviral IFNα response between the study 
participants. Therefore, the first objective of this study was to identify what host and 
transcriptional factors predict variation in antiviral type I IFN response, and the second 
objective was to describe how transcriptomes vary during antiviral type I IFN response. To 
address these questions, we compared the transcriptomes of high and low IFNα producers 
at both baseline (in unstimulated PBMC) and during the antiviral response in RV16-
stimulated PBMC. In relation to demographic variables, we observed that the IFN-low group 
had a higher median BMI, and if they had asthma, they were older relative to the IFN-high 
group. The IFN-high group also had a higher CLEC4C gene expression in whole blood, 
which reflects higher circulating pDC levels, as demonstrated in Chapter 2. Transcriptome 
analysis revealed differences in immune and oxidative stress-related gene expression at 
baseline and during the antiviral immune response, differences in gene expression related 
to immune response and cell proliferation, migration and attachment-related gene 
expression. 
The current study supplements the new field of research in immune variation. At the forefront 
of this field is a Dutch research project, conducted as part of the Human Functional 
Genomics Project (HFGP), which studied immune variation in 500 healthy individuals and 
measured a comprehensive range of immune response variables. The outcomes of the 
Dutch project reported a combined effect of the environment (ter Horst et al. 2016), genetics 
(Schirmer et al. 2016) and microbiome (Schirmer et al. 2016) on immune variation, which 
was illustrated with integration of the data in a sophisticated multi-omics approach (Bakker 
et al. 2018). Unfortunately, those and other immune variation studies do not explain the 
variation in TLR7/8-mediated antiviral immune response against RV, as such, we address 
this gap in our study by including experiments with RV stimulated cells (Brodin et al. 2015; 
Lee, MN et al. 2014; Piasecka et al. 2018). 
Chapter 3 demonstrated that women are more efficient IFNα responders than men, and 
these results concur with Berghofer et al. (2006). Piasecka et al. (2018) found that IFNα 
production in response to IAV was strongest in 20–29 years old healthy people, however, 
the effect of age on gene expression was stimulus-dependent, whereas, stronger gene 
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expression in females in response to antimicrobial stimuli was often shared between 
different stimuli. In line with their results, we observed a higher median age in the asthmatic 
IFN-low group; however, both healthy groups were of similar age. The associations between 
asthma, age and sex and their impact on antiviral immunity are complicated. We currently 
understand that sex hormones influence antiviral immunity (Seillet et al. 2012; Young et al. 
2014) and asthma inflammation (Laffont et al. 2017), and that sex hormone levels decline 
with age. Consequently, in Chapter 3, we observed that age and BMI were associated with 
respiratory infection frequency in women only, implying a role for sex hormones in antiviral 
immunity. 
TLR7 mediates antiviral IFNα response to RV, and initially, we investigated how the TLR7/8-
related antiviral immune variables differ between the IFN-high and IFN-low groups at 
baseline and during the antiviral immune response. The higher baseline expression of 
CLEC4C, TLR7 and TLR8 gene expression in the IFN-high group is likely to indicate a better 
availability of the receptors and pDC hence, a higher degree of readiness to respond to viral 
stimulus. Besides the strong IFNα response to RV16, the IFN-high group responded more 
strongly to TLR8 activation with higher TNF production, indicating that the potent antiviral 
immune response is a predominant feature for the high responders. The differential gene 
expression analysis in baseline IFN-high samples, compared with IFN-low samples, further 
supports the theory of improved immune readiness level as the list of upregulated genes 
was abundant in immune-related genes and reflected in the significant immune-related GO-
pathways. In further support, we showed an inverse association between baseline TLR7 
gene expression in whole blood and cold frequency in Chapter 3, consistent with a level of 
protection from innate immune components. 
Antigen-presenting dendritic cells are essential for detecting invading pathogens and 
activating other immune cells; therefore, they play a role in both innate and adaptive immune 
response. Previous work from our research group confirmed pDC as the primary and vital 
IFNα producer cell type (Xi et al. 2015; Xi et al. 2017), and as expected, we saw that the 
pDC marker CLEC4C was more highly expressed in the IFN-high group at baseline than in 
the IFN-low group, both in whole blood and PBMC (Whole blood, Table 4:1; PBMC, Figure 
4:5). CLEC4C remained as a significant differentially expressed gene in the transcriptome 
analysis, indicating that pDC numbers at baseline are a key factor predicting the magnitude 
of the IFNα response to viral stimulation. In support of this, we discovered that another pDC 
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associated gene (MS4A6A) was highly expressed in the IFN-high group. The CLEC4C gene 
product is known to regulate both antigen presentation and type I IFN production, two 
functions of importance in the host response to viral infection. 
Other dendritic cell-associated genes (CD93, CPVL, IDO1, MS4A4A, VCAN) were also 
upregulated in the high IFNα group at baseline supporting the close relationship between 
antigen-presenting cell functions and efficient IFNα response. DC are responsible for 
sampling the environment, presenting potential antigens, and producing cytokines to 
activate an antiviral immune response. One differentially expressed gene product of ANOS1, 
is thought to regulate dendrite growth, while the endosome protein encoding ASGR2 is 
important for sampling the extracellular environment and RNASE1 encoding RNAse 
increases the availability of viral nucleic acid, which is potentially important for DC antigen 
presenting ability. These findings regarding DC function are likely to complement previous 
studies on the role T-cells play in an efficient immune response (Bakker et al. 2018; Brodin 
et al. 2015). Indeed, three potassium channel encoding genes were upregulated in the high 
IFNα group (KCNJ10, KCNJ15, and KCNMA1) and potassium ion transport channels are 
thought to be essential for activating T-cells (Feske, Skolnik & Prakriya 2012). 
In addition to the DC related genes, the number of upregulated genes in IFN-high samples 
related to the complement system was remarkable. The complement system plays a vital 
role in innate immunity clearing pathogens via the classical, lectin and alternative pathways. 
Although recently, the role of the complement system has been expanded, with a role in 
antiviral immunity being recognised (Hajishengallis et al. 2017). These genes are enriched 
in the GO-pathway for innate immune response in our study, which is consistent with the 
results of Bakker et al. (2018), who found that the genes with most interindividual variability 
in transcription were enriched in this GO-pathway (Bakker et al. 2018). 
We further compared the antiviral response of the IFN-high group to the IFN-low group 
during RV16-stimulation. The upregulated genes reflect the stronger IFNα response in the 
upregulation of IFN, Th1 and antiviral immune response genes. The significantly enriched 
GO-pathways were also related to antiviral immune response. 
Out of the 56 genes upregulated during RV16 stimulation, 10 IFN and three non-IFN genes 
were reported as significant cytokine response eQTL (expression quantitative trait loci) 
genes (Lee, MN et al. 2014). One of these genes, IL18, is a TLR8-induced cytokine which 
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activates type 1 cytokine production in natural killer (NK) cells (Gorski et al. 2006). We 
discovered increased IL18 gene expression in the IFN-high response samples. The 
association of IL18 with immune variation has previously been documented: an IL18 eQTL 
affects IFNβ cytokine response to influenza in dendritic cells (Lee, MN et al. 2014); IL18 
binding protein (IL18BP) restricts IL18 availability and inversely correlates with cytokine 
production (Bakker et al. 2018). The consistent findings regarding IL18 in these three studies 
indicate a key role for IL18 and IL18BP as immune regulators. 
The high IFNα producer group downregulated more antibacterial genes than antiviral genes. 
Only upregulated ACOD1 was indicated with a dual function in both antiviral and 
antibacterial response, whereas downregulated BPI, HAMP, LTF were clearly antibacterial 
peptides. This raises the question: Why do low IFNα producers expressed these genes 
during the antiviral response? One explanation could be an immune response that is 
unspecific to pathogen type, while high IFNα producers respond with a highly specific 
antiviral response. Another explanation may be related to co-infections. Although all subjects 
were recruited in a healthy state, and infection free for at least two weeks prior to sample 
donation, we cannot exclude the possibility that the low IFNα producers had a subtle 
underlying bacterial infection, or that these observations might be related to changes in the 
airway microbiome. Secondary bacterial infection post-viral infection is better understood 
than vice versa, but there is some evidence that asthmatic microbiomes contain pathogenic 
bacteria that may predispose individuals to a secondary viral infection. Such infection can 
lead to downregulated IFN response (Bellinghausen et al. 2016). 
One of the interesting findings was the downregulation of oxidative stress-related genes in 
the high IFNα producers and persistent expression in a subset of low IFNα producers, and 
the enrichment of the corresponding GO-pathway. Cellular oxidative stress could be the 
result of external factors such as cigarette smoke in the lung or intrinsic factors like 
production of reactive oxygen species (ROS) in the context of airway inflammation. Our 
results reflect the fact that oxidative stress could be a factor constraining appropriate IFN 
production in response to a virus. Supporting evidence comes from a study showing that the 
oxidative stress response transcription factor NRF2 downregulates antiviral type III IFN 
production in epithelial cell models (Mihaylova et al. 2018). Oxidative stress is known to be 
present in asthma and correlates with clinical severity, which could explain the weak IFNα 
response to RV16 exposure in the asthmatic IFN-low samples (Sahiner et al. 2018; Wood 
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et al. 2005). The potential benefit of addressing oxidative stress in asthma would be reduced 
virus-related asthma exacerbations by promoting a strong antiviral immune response. 
The significant difference in BMI was perhaps the most prominent differential host factor 
between the two groups. The BMI lower interquartile for the IFN-low producer groups were 
near the upper threshold of healthy BMI at 25, indicating that the majority of the IFN-low 
subjects were slightly overweight. On examination, during viral stimulation, many of the 
differentially expressed gene products engage in lipid metabolism and transport. The weight 
imbalance between the groups may explain why lipid transport (FABP4, PID1, APOE) and 
metabolism (LPL, CD300LB, STAB1, GPAT3) genes were downregulated in the healthy 
weight range, high IFNα producers, however, out of those genes at least STAB1 is important 
for bacterial membrane breakdown and may be downregulated in viral infection due to its 
antibacterial role instead. The high IFNα producer group showed high expression of genes 
(ELOVL7, ABHD17C) that are important for viral envelope lipid metabolism. In Chapter 3, 
we discovered that BMI was associated with respiratory infection frequency, and the results 
in this chapter concur: IFNα production is associated with BMI. 
The differential expression of genes related to vitamin availability requires mention. High 
IFNα producer group upregulated ETV3L, vitamin D associated transcription factor (Kariuki 
et al. 2016), in unstimulated samples; and CYP27B1, an active vitamin D form catalyser, in 
RV16-stimulated samples. TCN1, a vitamin B12 binding protein, was downregulated in 
RV16-stimulated samples. The expression of these genes indicates that the vitamin D 
availability may be necessary for a strong antiviral response. Similarly, by downregulating 
the B12 binding protein, high IFNα producers are making more B12 available (Nielsen et al. 
2012). 
The common denominator between high BMI, oxidative stress and vitamin availability is, of 
course, diet. Obesity is associated with systemic inflammation and oxidative stress and one 
explanation is poor diet (Manna & Jain 2015; Osadnik et al. 2019). Meta-analyses show that 
vitamin D supplementation, antioxidant flavonoid intake and probiotics decrease the 
incidence of respiratory infections, which supports our findings that vitamin availability and 
oxidative stress affect antiviral immunity (Martineau et al. 2017; Quick 2015; Somerville, 
Braakhuis & Hopkins 2016). A diet high in antioxidants may benefit antiviral immunity, and 
additionally, limited data show that it could alleviate asthma symptoms (Wood et al. 2008). 
Variation in gut microbiome was shown to particularly affect TNF and IFNγ production in 
4:115 
 
response to an immune stimulus (Schirmer et al. 2016). A sophisticated multi-omics analysis 
of immune variation discovered that a short-chain fatty acid metabolite produced by gut 
bacteria, and circulating high-density lipoprotein cholesterol, correlated negatively with 
influenza-induced, proinflammatory cytokine production (Bakker et al. 2018). As diet is 
known to change the microbiome, a poor diet may have an indirect effect on immunity via 
microbiome variation, and a direct effect from consumption of dietary antioxidants, fibre, fats 
and vitamins. 
The main limitation of this study was the fact that it was not possible to perform RNA-Seq 
on all 238 participants of European ancestry. For economic reasons, we elected to focus 
the transcriptomic studies on a subset of these participants, i.e. those in the highest and 
lowest quartiles of IFNα production. Unfortunately, this led to some mismatching of the 
groups with regard to BMI, age and gender. As noted in Chapter 3, these variables are 
associated with antiviral immunity, and this could have biased the findings. A further 
limitation was that we analysed equal numbers of asthma and healthy samples. Asthma-
related inflammation may have affected the gene expression, although it was not a 
significant factor in our principal component analysis and our results are in line with other 
studies, which included only healthy samples (Bakker et al. 2018; Lee, MN et al. 2014). Due 
to the restricted sample size, we chose to combine the asthma and healthy groups, an 
approach that was justified by the principal component and heat map analyses (Figures 
Figure 4:3, Figure 4:4, Figure 4:6, and Figure 4:9). The samples were selected based on 
IFNα production in response to RV16 stimulation for 24 hours; however, future studies could 
further address the transcriptomic difference between TLR7 and RV16 stimulated cells and 
examine additional time points. There has been limited research suggesting seasonal 
variation in the immune response to respiratory viruses; however, we did not account for this 
given that our samples were collected across all months between November 2014 and July 
2016 (ter Horst et al. 2016). 
Taken together, these results show that at baseline, high IFNα responders upregulated 
essential components of the innate immunity such as the complement system, pDC and DC 
genes. During the antiviral immune response, the high IFNα producers devote their 
transcriptome to the production of antiviral cytokines and effector proteins and downregulate 
the expression of genes encoding antibacterial proteins and cellular processes, such as cell 
proliferation and migration. The differential gene expression implies that people have varying 
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levels of immune system readiness that translates into a more pathogen-specific immune 
response. The difference between the high and low IFNα antiviral response may arise from 
individual host factors impacting oxidative stress, as well as vitamin D and B12 availability, 
as indicated by the differentially expressed genes. One of the most significant host factors 
associated with low IFNα production is BMI, which has been linked with oxidative stress. 
The genes associated with high and low IFNα production determined by this study may have 
implications for a better understanding of asthma, autoimmune disease and vaccine 
responses associated with aberrant type I IFN production. 
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 The impact of genetic 
variation in the TLR7/8 locus on gene 
expression, TLR7/8 function and 
immunity 
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5.1. Introduction 
Pattern recognition receptors can be regarded as the burglar alarms of innate immunity, 
sensing conserved molecular patterns present in invading pathogens. Toll-like receptor 
(TLR)7 and its paralogue TLR8 are responsible for eliciting an immune response upon 
detecting either viral or bacterial single-stranded RNA (ssRNA) (Diebold et al. 2004; Gantier 
et al. 2010; Heil et al. 2004; Mancuso et al. 2009). TLR7 and TLR8 are predominantly 
expressed on immune cells: TLR7 in pDC and B-cells and TLR8 in monocytes, 
macrophages, myeloid dendritic cells and neutrophils (Hornung et al. 2002; Makni-Maalej et 
al. 2015). However, TLR7 is also expressed in structural cells such as bronchial epithelial 
cells (Ioannidis et al. 2013; Uehara et al. 2007) and airway smooth muscle cells (Ekman, 
Adner & Cardell 2011). 
Both receptors are located in cellular endosomes wherefrom TLR7 employs a signalling 
pathway including MyD88, IRAK, and TRAF molecules to activate a transcription factor IRF7 
for cytokine induction. In contrast, TLR8 shares the use of MyD88 but uses different 
pathways and activates CREB, NF-κB and AP1 as transcription factors (described in detail 
in Chapter 1: section 1.2.3). TLR7 and TLR8 induce the production of different cytokines: 
TLR7 induces type I interferon (IFN), whereas TLR8 induces proinflammatory cytokines 
such as TNF and IL12 (Gorden et al. 2005). However, the cytokine repertoire depends on 
the receptor stimulus (Bergstrom et al. 2015; Colak et al. 2014) and intercellular endosome 
trafficking (Miyake et al. 2018), or it can be replaced by secretion of antimicrobial proteins 
such as beta-defensin 2, as shown by Uehara et al. (2007). This divergence of TLR7 and 
TLR8 function suggests that these two receptors may have complementary roles in antiviral 
immunity, and their expression may be crossregulated (Ghosh et al. 2007; Paul et al. 2016) 
possibly by a mechanism of competing for Unc93B1 chaperone (Alexopoulou, Desnues & 
Demaria 2012). 
The clearance of viruses is dependent on their efficient detection and subsequent antiviral 
immune response coordinated by cytokines. TLR7 and TLR8 detect ssRNA viruses such as 
HIV, hepatitis viruses, and most respiratory viruses and trigger type I IFN and 
proinflammatory cytokine production. In Chapter 3, we showed that baseline TLR7 gene 
expression inversely correlates with self-reported cold frequency, indicating that high levels 
of TLR7 protect from symptomatic infections. Although crucial for viral clearance, prolonged 
cytokine-induced inflammation further aggravates chronic diseases such as human 
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immunodeficiency virus (HIV) infection and hepatitis (Snell, McGaha & Brooks 2017), and 
robust TLR7/8 activation may not always be beneficial. 
Besides their role in antiviral immunity, TLR7 and TLR8 modulate other immune responses. 
TLR7-induced type I IFN and TLR8-induced TNF and IL12 promote type 1 immunity rather 
than a type 2 immune response (Pritchard, Carroll, et al. 2012; Yu et al. 2015). 
Consequently, autoimmune diseases related to type 1 immunity, such as systemic lupus 
erythematosus (SLE) are commonly associated with increased TLR7 and TLR8 function 
(Lyn-Cook et al. 2014). Autoimmune diseases are typically characterised by reactivity to 
self-antigens, as well as reactivity to self-nucleic acid recognised by TLR7 and TLR8. In 
contrast, type 2-related atopic disease such as asthma, where type 1 immunity is 
downregulated, is associated with reduced function of TLR7 and TLR8 (Roponen et al. 
2010) and mouse models show that stimulating TLR7 reverses asthma-like phenotype (Du, 
Q et al. 2009). The results in Chapter 3 concur as we detected lower baseline TLR7 gene 
expression levels in those with asthma than without. Moreover, there was evidence that the 
determinants of respiratory infection frequency varied with sex. TLR7 expression was an 
independent predictor of cold frequency in men, but not women, while rhinovirus-induced 
IFNα was higher in women than in men. Could these findings have a genetic basis? 
The genes encoding TLR7 and TLR8 are located in close proximity on the X chromosome. 
Many single nucleotide polymorphisms (SNPs) in the TLR7/TLR8 locus have been reported 
to associate with immune disease and function, providing some evidence that genetic 
variation in this region has functional consequences in several diseases. The most studied 
SNP in the region is rs179008, a functional SNP in TLR7. The rs179008: T allele was 
reported to associate compromised clearance of hepatitis C infection (Fakhir et al. 2018), 
as well as higher HIV load and accelerated disease progression (Oh et al. 2009). In contrast, 
others found that the same allele was associated with protection from viral disease, namely 
chronic hepatitis B (Buschow et al. 2018) and recurrent RV infections (Toivonen et al. 2017). 
This allele is also associated with increased asthma risk in girls (Törmänen et al. 2017) and 
increasing susceptibility to systemic lupus erythematosus (dos Santos et al. 2012). Small 
candidate-gene studies have reported weak associations between other variants in the 
TLR7/TLR8 region and asthma (Genov et al. 2014; Moller-Larsen et al. 2008; Nilsson et al. 
2012; Törmänen et al. 2017). For example, the TLR8 SNP rs2407992 was reported to 
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associate with asthma and lung function (Genov et al. 2014; Moller-Larsen et al. 2008; 
Toivonen et al. 2017). 
In summary, there is some evidence that SNPs in the TLR7/8 locus are associated with a 
viral infection and both type 1 and 2 cytokine response diseases. However, the molecular 
and cellular mechanisms underlying the reported associations are largely unknown. We 
hypothesised that such associations with immune-related diseases result from SNP effects 
on TLR7 and TLR8 expression and, consequently on the production of TLR7-induced type 
I IFN and TLR8-induced TNF and IL12 cytokines. 
Specifically, in this chapter, we examined the association between genetic variation in the 
TLR7/8 locus and the expression of TLR7 and TLR8 receptors and downstream cytokine 
production in up to 238 individuals. We also examined genetic associations with the 
frequency of self-reported respiratory infection, and immune cell counts. The primary 
analysis focused on a single variant (rs850637) reported to associate with asthma risk in a 
recent genome-wide association study (GWAS) (Ferreira et al. 2019). For completeness, 
the analysis was then expanded to all common variants within 1 Mb of TLR7/TLR8. 
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5.2. Materials and methods 
5.2.1. Participants and clinical sample collection 
A total of 238 individuals (63% female) participated in this study, including 133 (56%) with 
asthma. To limit variation arising between different ethnic populations, we included only 
participants with confirmed European ancestry. They form a subgroup of the 301 individuals 
(151 with asthma and 150 control subjects) described in Chapter 3. Self-reported ancestry 
was confirmed against genetic data collected during genotyping described in section 5.2.3. 
Peripheral blood mononuclear cells (PBMC) from these individuals were cultured with media 
(CTRL), human rhinovirus(RV)16, TLR7 agonist (imiquimod) or TLR8 agonist (VTX-2447) 
for 24 h, and cytokines (TNF, IL12 and IFNα) were measured in the supernatant, as 
described in detail in Chapter 3. Additional outcomes included TLR7 and TLR8 gene 
expression in unstimulated PBMC and whole blood and in RV16-, TLR7-, or TLR8-
stimulated PBMC, and immune cell counts. 
5.2.2. Collection of genetic information 
DNA was collected either from granulocytes isolated from whole blood or a saliva sample 
collected with an Oragene kit (DNA Genotek Inc., Canada) according to the manufacturer’s 
instructions. DNA from saliva was extracted using an extraction kit from the manufacturer, 
whereas DNA from polymorphonuclear cells was extracted with in-house buffers using the 
salt precipitation protocol. DNA samples were extracted from four participants in duplicate 
for quality control. 
5.2.3. Locus-specific and genome-wide SNP genotyping 
A total of 57 SNPs in the TLR7/8 region were genotyped at Agena Biosciences (Brisbane) 
with the MassARRAY iPLEX genotyping system. The SNPs consisted of: (1) 50 common 
SNPs (minor allele frequency (MAF) > 5%) within 100 kb of TLR7/8 that were included in 
the Affymetrix Axiom array used by the UK Biobank, which was designed to maximise the 
ability to impute unmeasured common variants; (2) three known non-synonymous variants 
in TLR7 and TLR8, all with MAF > 1%; and (3) four non-coding variants independently 
associated with TLR7 expression in lymphoblastoid cell lines (Brumpton & Ferreira 2016). 
Four DNA samples were genotyped in duplicate for quality control. Across the 57 SNPs, the 
average sample call rate (the fraction of SNPs with a non-missing genotype call) was 99.7%. 
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In parallel, DNA samples were also genotyped with the Infinium® Global Screening Array-
24 v1.0 at Human Genomics Facility in Erasmus MC, Rotterdam, The Netherlands. Six 
samples were included in duplicate for quality control. Variants within 2 Mb of TLR7 and 
TLR8 and that passed quality control filters (namely call rate > 98%, MAF > 1% and Hardy-
Weinberg equilibrium p-value < 10-6) were merged with the 57 SNPs from the custom 
genotyping project. The resulting dataset was then uploaded to the Michigan Imputation 
Server (v1.0.4) for imputation of unmeasured variants. Imputation was based on the HRC 
reference panel (r1.1, 2016), using ShapeIT (v2.r790) for phasing. For the analysis reported 
in this chapter, we analysed imputed SNPs: (1) with a MAF > 5%; (2) within 1 Mb of the 
TLR7/TLR8 region; and (3) imputed with high confidence (imputation r2 of 0.6 or greater). 
This yielded a set of 1748 SNPs. 
5.2.4. Gene expression analysis 
The expression of TLR7 and TLR8 in whole blood (collected using PAXgene tubes) was 
analysed using relative quantitative (RT)-PCR in all 238 samples. The comparative Ct 
method (Schmittgen & Livak 2008) was applied using B2M (Beta-2-Microglobulin) and UBC 
(Polyubiquitin-C precursor) as reference genes. The RNA extraction and RT-PCR methods 
are described in more detail in Chapters 2 and 3 (Sections 2.2.5 and 3.2.4). 
Additionally, transcription of TLR7, TLR8, IFNA genes, TNF, and IL12A were quantified in a 
subset of 74 control and 74 RV paired samples with RNA-sequencing performed as detailed 
in Chapter 4 methods (sections 4.2.3 and 4.2.4). The expression of 11 key IFNα genes 
(IFNA4, IFNA7, IFNA10, IFNA16, IFNA17, IFNA13, IFNA2, IFNA8, IFNA1, IFNA14 and 
IFNA5) were summed for association analyses. In secondary analyses, we also extended 
our gene expression analysis to other genes near rs850637 (+/- 1 Mb). To include all 
available genes, we removed the filter for counts per million (CPM). 
5.2.5. Access to public databases 
In addition to the gene expression dataset generated as part of this study, we also used 
publicly available databases of expression quantitative trait loci (eQTL) to identify 
associations between SNP 850637 and gene expression. We considered three tissue types 
from the Genotype-Tissue Expression (GTEx) Project, namely whole blood (n = 369), lung 
(n = 383) and spleen (n = 146). The data used for the analyses described here were obtained 
from the GTEx Portal on 26/09/2018 (GTEx Consortium 2013) 
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The second external database used was the NHLBI Framingham SNP Health Association 
Resource (SHARe), a substudy of Framingham Heart Study (FHS) Cohort (Joehanes et al. 
2017); dbGaP Study Accession: phs000342.v18.p11). We accessed this database on 
20/09/2018 to search for any significant associations between rs850637 and gene 
expression in whole blood samples (n = 5622). 
5.2.6. Statistical analysis 
All statistical analyses were performed with R version 3.4.4 (R Core Team 2018). Variables 
were tested for normality, and an inverse-normal transformation applied. Hemizygous male 
genotypes were combined with female genotypes homozygous for the same allele for 
analysis. Associations were tested with linear or logistic regression, as appropriate. Linear 
regression tests were controlled for confounding as follows: dependent variables were 
adjusted for sex and age; IFNA mRNA count for IFNα producer group; monocyte, eosinophil, 
and basophil count for asthma; and lymphocyte count for body mass index (BMI). A 
permutation approach was used to adjust for multiple testing empirically. Specifically, for 
each permutation (out of 1,000 in total), we randomly shuffled all SNPs as a block (i.e. 
preserving the correlation pattern between SNPs) between individuals and then tested the 
association between all phenotypes and all SNPs. For each permutation, we retained the 
most significant p-value observed across all SNP-phenotype combinations tested (Pmin). 
The 50th most significant Pmin across the 1,000 permutations was considered to be the 
significance threshold required to maintain a 5% type-I error rate after accounting for multiple 
testing. Power calculations were performed with minSlopeEQTL.SLR() from the powerEQTL 
package or online tool at http://osse.bii.a-star.edu.sg/. Linkage disequilibrium was tested 
with online tool at https://ldlink.nci.nih.gov (Machiela & Chanock 2015). 
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5.3. Results 
5.3.1. Does TLR7 and TLR8 gene expression differ between sexes? 
TLR7 and TLR8 function differs between the sexes, with higher IFNα production reported in 
females than in males (Berghofer et al. 2006; Torcia et al. 2012). Whether this is due to 
differences in receptor expression at baseline, or in response to activation, or whether it is 
due to alterations in intra-cellular signalling pathways, has not been clarified. Moreover, both 
TLR7 and TLR8 can escape X-chromosome inactivation (XCI) in some individuals (Chung 
et al. 2006; Souyris et al. 2018). Given these observations, we first compared gene 
expression between males and females. Females and males had similar baseline 
(unstimulated) TLR7 and TLR8 gene expression in both PBMC and whole blood samples. 
After RV16 stimulation, TLR7 gene expression was also similar between the sexes, but 
TLR8 gene expression was higher in males than in females (p = 0.003, Figure 5:1). The 
similarity in expression levels between the two groups at baseline suggests that in females, 
this locus does not escape XCI. In subsequent analyses, data from males and females were 
analysed jointly. 
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Figure 5:1 TLR7 and TLR8 gene expression in females and males.  
A B 
C D 
E F 
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Gene expression measured in whole blood (A, B) or in PBMC (C – F) at baseline (A – D) or 
after RV16 stimulation (E, F). Whole blood samples n = 238 and PBMC samples n = 74. NS 
= not significant. p-value < 0.05 shown for t-test is considered significant. 
5.3.2. Association between rs850637 and the expression of nearby genes 
A variant rs850637 (A/G) at position chrX:13005622 (GRCh38.p12) near TLR7/TLR8 was 
reported in a recent GWAS to associate with asthma risk at the genome-wide significance 
level (Ferreira et al. 2019). Specifically, the rs850637:A variant was associated with a lower 
risk of childhood asthma (odds ratio = 0.95). To investigate the mechanisms that might 
underlie this association, the association of this SNP with the expression of TLR7, TLR8 and 
23 additional genes located nearby (+/- 1 Mb) was studied (Table 5:1). 
Table 5:1 Genes near rs850637 
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Gene 
Symbol Start End 
 Strand 
Ensembl 
Gene ID Gene type Description 
RF00019 12054823 
1205
4926 - 
ENSG0000
0206792.1 Misc. RNA Y_RNA (from geneSymbol) 
FRMPD4 12138465 
1272
4523 + 
ENSG0000
0169933.12 
Protein 
coding 
Homo sapiens FERM and PDZ domain 
containing 4 (FRMPD4), mRNA. (from 
RefSeq NM_014728) 
AC002981.1 12148317 
1214
8401 - 
ENSG0000
0252111.1 miRNA AC002981.1 (from geneSymbol) 
RF00020 12149125 
1214
9238 + 
ENSG0000
0206795.1 Misc. RNA Y_RNA (from geneSymbol) 
FRMPD4-
AS1 
1237
3166 
1237
5133 - 
ENSG0000
0223487.1 antisense 
FRMPD4 antisense RNA 1 (from 
HGNC FRMPD4-AS1) 
RN7SKP290 12614002 
1261
4197 - 
ENSG0000
0271814.1 Misc. RNA 
RNA, 7SK small nuclear pseudogene 
290 (from HGNC RN7SKP290) 
PRPS2 12791369 
1282
4222 + 
ENSG0000
0101911.12 
Protein 
coding 
Homo sapiens phosphoribosyl 
pyrophosphate synthetase 2 (PRPS2), 
transcript variant 2, mRNA. (from 
RefSeq NM_002765) 
TLR7 12867082 
1289
0380 + 
ENSG0000
0196664.4 
Protein 
coding 
Homo sapiens toll like receptor 7 
(TLR7), mRNA. (from RefSeq 
NM_016562) 
TLR8-AS1 12902816 
1290
8333 - 
ENSG0000
0233338.1 antisense 
TLR8 antisense RNA 1 (from HGNC 
TLR8-AS1) 
TLR8 12906638 
1292
2202 + 
ENSG0000
0101916.11 
Protein 
coding 
Homo sapiens toll like receptor 8 
(TLR8), transcript variant 1, mRNA. 
(from RefSeq NM_016610) 
TMSB4X 12975107 
1297
7227 + 
ENSG0000
0205542.10 
Protein 
coding 
Homo sapiens thymosin beta 4, X-
linked (TMSB4X), mRNA. (from 
RefSeq NM_021109) 
FAM9C 13035632 
1304
4681 - 
ENSG0000
0187268.11 
Protein 
coding 
Homo sapiens family with sequence 
similarity 9 member C (FAM9C), 
mRNA. (from RefSeq NM_174901) 
RP11-
791M20.1/ 
AC079171.1 
1309
3659 
1309
4573 + 
ENSG0000
0261030.1 lincRNA 
Homo sapiens mRNA full length insert 
cDNA clone EUROIMAGE 712308. 
(from mRNA AL079309) 
GS1-
600G8.5 
1326
6047 
1330
3392 - 
ENSG0000
0235385.1 lincRNA GS1-600G8.5 (from geneSymbol) 
GS1-
600G8.3 
1331
0651 
1331
9933 + 
ENSG0000
0231216.1 antisense 
Homo sapiens unknown transcript 
(GS1-600G8.3), long non-coding RNA. 
(from RefSeq NR_046087) 
ATXN3L 13318235 
1331
9952 - 
ENSG0000
0123594.4 
Protein 
coding 
Homo sapiens ataxin 3 like (ATXN3L), 
mRNA. (from RefSeq NM_001135995) 
LINC01203/ 
RP11-
142G7.2 
1333
6380 
1337
3634 + 
ENSG0000
0226985.5 lincRNA 
long intergenic non-protein coding 
RNA 1203 (from HGNC LINC01203) 
RP11-1L9.1 13377187 
1340
3019 + 
ENSG0000
0226434.1 lincRNA RP11-1L9.1 (from geneSymbol) 
EGFL6 13569604 
1363
3574 + 
ENSG0000
0198759.11 
Protein 
coding 
Homo sapiens EGF like domain 
multiple 6 (EGFL6), transcript variant 
1, mRNA. (from RefSeq NM_015507) 
RN7SKP20 13596235 
1359
6548 + 
ENSG0000
0199622.1 Misc. RNA 
RNA, 7SK small nuclear pseudogene 
20 (from HGNC RN7SKP20) 
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Gene 
Symbol Start End 
 Strand 
Ensembl 
Gene ID Gene type Description 
TCEANC 13659686 
1366
3564 + 
ENSG0000
0176896.8 
Protein 
coding 
Homo sapiens transcription elongation 
factor A N-terminal and central domain 
containing (TCEANC), transcript 
variant 1, mRNA. (from RefSeq 
NM_152634) 
RAB9A 13689124 
1371
0506 + 
ENSG0000
0123595.6 
Protein 
coding 
Homo sapiens RAB9A, member RAS 
oncogene family (RAB9A), transcript 
variant 1, mRNA. (from RefSeq 
NM_004251) 
TRAPPC2 13712243 
1373
4635 - 
ENSG0000
0196459.13 
Protein 
coding 
Homo sapiens trafficking protein 
particle complex 2 (TRAPPC2), 
transcript variant 2, mRNA. (from 
RefSeq NM_014563) 
OFD1 13734744 
1376
9353 + 
ENSG0000
0046651.14 
Protein 
coding 
Homo sapiens oral-facial-digital 
syndrome 1 (OFD1), mRNA. (from 
RefSeq NM_003611) 
GPM6B 13771455 
1393
8638 - 
ENSG0000
0046653.14 
Protein 
coding 
Homo sapiens glycoprotein M6B 
(GPM6B), transcript variant 4, mRNA. 
(from RefSeq NM_001001994) 
RP1-
122K4.2 
1395
5392 
1396
3904 + 
ENSG0000
0233535.1 lincRNA RP1-122K4.2 (from geneSymbol) 
RP1-
122K4.3 
1398
0065 
1398
8820 - 
ENSG0000
0212663.2 lincRNA RP1-122K4.3 (from geneSymbol) 
GPX1P1 13378735 
1337
9340 - 
ENSG0000
0197582 
Processed 
pseudogene 
glutathione peroxidase pseudogene 1 
[Source:HGNC 
Symbol;Acc:HGNC:4560] 
GS1-
526D21.5 
1378
5519 
1378
5984 +  antisense  
PSMA6P2 12825840 
1282
6833 + 
ENSG0000
0229083.1 
Processed 
pseudogene 
proteasome subunit alpha 6 
pseudogene 2 [Source:HGNC 
Symbol;Acc:HGNC:39607] 
The official gene symbol, start and end location of the gene on the X chromosome, direction 
of transcription (strand), Ensembl gene ID, gene type, and a short description obtained from 
UCSC table browser are shown. Misc. = miscellaneous. 
 
Figure 5:2 rs850637 genomic region.  
The genomic region within 1mb of SNP rs850637as obtained from UCSC genome browser. 
The red vertical line shows the location of rs850637, between TMSB4X and FAM9C at 
chrX:13005622 (GRCh38.p12). 
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 Association between rs850637 and gene expression in PBMC 
First, we tested the association between rs850637 (MAF = 44%) and the expression of 
nearby genes in PBMC of 74 participants, cultured with or without RV16. Out of the 25 genes 
identified in the vicinity of the variant (Table 5:1, Figure 5:2), 18 genes were expressed in 
the PBMC samples and so were tested for association with rs850637 (Table 5:2). 
Table 5:2 Association between rs850637 and nearby gene expression 
The genes within 1 Mb are tested for association. Shown are the A allele association with 
the change in mRNA count, p-value of the association (p), and the number of tests 
performed (n). Unstimulated and RV16-stimulated PBMC samples were tested for an 
association. Genes underlined with a dash had low expression levels (CPM < 2). None were 
significant after multiple testing correction (p < 0.05 / 36 tests = 0.001). 
The results in Table 5:2 show that in unstimulated PBMC, the rs850637:A allele was 
associated with decreased expression of GS1-600G8.5 and TMSB4X, and increased 
expression of OFD1 and TCEANC, at a nominal significance level of p < 0.05. The 
association with TCEANC and TMSB4X was also nominally significant after RV16 
stimulation. However, GS1-600G8.5 was lowly expressed (Figure 5:3), and none of these 
associations remained significant after correcting for the number of genes tested (p < 0.05 / 
36 tests = 0.001) and so are likely to represent false-positive findings. 
Gene 
Unstimulated PBMC RV-stimulated PBMC 
Effect p n Effect p n 
AC079171.1 -0.13 0.59 35 -0.16 0.54 28 
EGFL6 0.57 0.11 9 0.05 0.83 36 
FAM9C -0.22 0.38 32 0.12 0.57 38 
GPM6B 0.03 0.82 73 -0.25 0.08 74 
GPX1P1 -0.18 0.21 73 -0.08 0.59 74 
GS1-526D21.5 -0.05 0.72 68 -0.12 0.43 71 
GS1-600G8.5 -0.60 0.02 26 -0.22 0.14 72 
OFD1 0.29 0.04 73 0.02 0.92 74 
PRPS2 0.03 0.82 73 0.17 0.25 74 
PSMA6P2 -0.07 0.71 53 -0.06 0.72 65 
RAB9A -0.11 0.47 73 -0.001 1.00 74 
RP1-122K4.3 -0.29 0.57 8 -0.03 0.96 7 
TCEANC 0.37 0.01 73 0.31 0.03 74 
TLR7 -0.001 0.99 73 0.19 0.20 74 
TLR8 -0.19 0.19 73 -0.08 0.59 74 
TLR8-AS1 0.13 0.68 14 -0.01 0.97 29 
TMSB4X -0.40 0.01 73 -0.30 0.04 74 
TRAPPC2 0.08 0.61 73 0.02 0.89 74 
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Figure 5:3 Gene expression of genes near rs850637.  
The median and interquartile range of mRNA copy number of genes near rs850637 in 
PBMC. Genes are listed in descending order of median copy number for unstimulated (left) 
and RV-stimulated PBMC samples (right). Note: TMSB4X mRNA copy number is outside 
the range visualised. 
 Association between rs850637 and gene expression measured in the 
Genotype-Tissue Expression (GTEx) project 
Next, to expand sample size and investigate the possibility that rs850637 might influence 
the expression of nearby genes in other relevant tissues, we examined the association 
between rs850637 and nearby genes using data from the GTEx project. We considered 
three tissue types relevant for asthma: whole blood (n = 369), lung (n = 383) and spleen (n 
= 146). 
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Table 5:3 Association between rs850637 and nearby gene expression in GTEx dataset 
 Lung Whole blood Spleen 
Gene NES p-value  NES p-value NES p-value 
EGFL6 0.0024 0.93   -0.95 0.34 
FAM9C     0.77 0.44 
FRMPD4 -0.015 0.77     
GPM6B -0.045 0.057 -0.029 0.38 0.18 0.85 
GPX1P1 -0.039 0.49 0.037 0.51 0.31 0.76 
GS1-600G8.5 0.027 0.58     
OFD1 -0.02 0.48 -0.023 0.38 -0.43 0.66 
PRPS2 0.024 0.43 0.03 0.21 -0.75 0.45 
RAB9A 0.0026 0.93 0.027 0.31 -1.3 0.18 
RP1-122K4.2     -0.33 0.74 
RP1-122K4.3 -0.11 0.0077   0.36 0.72 
RP11-142G7.2     2.2 0.027 
RP11-1L9.1     1.5 0.13 
RP11-791M20.1     0.44 0.66 
TCEANC -0.012 0.59 -0.025 0.44 0.7 0.49 
TLR7 0.029 0.3 0.021 0.35 -0.37 0.71 
TLR8 0.012 0.61 0.013 0.33 0.28 0.78 
TLR8-AS1 -0.19 0.00024 -0.025 0.43 -1.4 0.16 
TMSB4X -0.046 0.03 0.0036 0.87 -1.7 0.09 
TRAPPC2 -0.033 0.31 0.027 0.36 0.15 0.88 
Genes within 1mb of SNP rs850637 were tested for an association in the Genotype-Tissue 
Expression (GTEx) project dataset. The Normalised Effect Size (NES) on gene expression 
is reported for the A allele; the corresponding p-value is also shown. Whole blood (n = 369), 
lung (n = 383) and spleen (n = 146) samples were tested. Significant p-value < 0.05 / 44 
tests = 0.001 are bolded. 
The antisense gene TLR8-AS1 showed the most significant association with rs850637 (p = 
0.00024; Table 5:3), with the A allele associated with decreased TLR8-AS1 expression in 
the lung (Figure 5:4). This association remained significant after accounting for multiple 
testing (p < 0.05 / 44 tests = 0.001); there were no other associations significant at that 
threshold. 
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Figure 5:4 TLR8-AS1 gene expression by rs850637 genotype.  
Rs850637 genotype association with TLR8-AS1 normalised gene expression levels in GTEx 
dataset. Homo ref = homozygous or hemizygous for GG/G allele reference genotype, Het = 
heterozygous for GA allele, and Homo Alt = homozygous or hemizygous for AA/A allele 
alternative genotype. Graph obtained from GTEx portal. 
 Association between rs850637 and gene expression measured in whole 
blood in the large Framingham Heart Study (FHS) 
The largest eQTL study published to date, that included the X-chromosome, was performed 
with whole blood samples collected by the Framingham Heart Study (n = 5622). In this 
dataset, rs850637 was associated with the expression of TLR7, with the A allele associated 
with decreased expression (Table 5:4). 
Table 5:4 Association between rs850637 and TLR7 gene expression in FHS database 
Association 
Gene R2 Effect T p FDR 
TLR7 0.004 -0.016 -4.56 5.18e-6 1.6e-4 
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The association R2 score, A allele effect size on TLR7 gene expression, T-value, p-value 
and false discovery rate (FDR) are shown as reported in the FHS database whole blood 
samples (n = 5622). Significant FDR < 0.05 is bolded. 
 Association between rs850637 and TLR7 and TLR8-AS1 gene expression 
across three databases 
Table 5:5 compares the association between rs850637 and TLR7 and TLR8-AS1 gene 
expression across the three datasets. TLR8-AS1, that was significantly associated with 
rs850637 in the GTEx database, had low expression in our own dataset (Figure 5:3) and 
was not reported in the FHS dataset. The association between rs850637 and TLR7 gene 
expression was significant only in the FHS dataset.  
Table 5:5 Comparison of significant genes across the three studies for A allele 
The study, sample tissue type used, the effect size for rs850637 A allele on TLR8-AS1 or 
TLR7 gene expression and association p-value are shown. Significant p-values are bolded. 
5.3.3. Association between rs850637 and TLR7/TLR8 receptor function 
To assess if the SNP rs850637 affects TLR7/8 function, IFNα was used as a marker of TLR7 
function, and TNF and IL12 as a marker of TLR8 function. First, we tested the association 
between rs850637 and protein levels of these three cytokines, measured in PBMC samples 
after TLR7/8 activation with RV16 or agonists stimulation from 238 individuals. We found no 
significant associations with rs850637 (Table 5:6). 
TLR8-AS1 
 Study Tissue Effect p 
 Our samples PBMC: Unstim. 0.13 0.68 
 Our samples PBMC: RV -0.01 0.97 
 GTEx Lung -0.19 0.00024 
 GTEx Whole blood -0.025 0.43 
 GTEx Spleen -1.4 0.16 
     
TLR7 
 Study Tissue Effect p 
 Our samples PBMC: Unstim. -0.001 0.99 
 Our samples PBMC: RV 0.19 0.20 
 Our samples Whole blood 0.11 0.18 
 GTEx Lung 0.029 0.30 
 GTEx Whole blood 0.021 0.35 
 GTEx Spleen -0.37 0.71 
 FHS Whole blood -0.016 5.18E-06 
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Table 5:6 rs850637 associations with cytokines produced in PBMC. 
PBMC were stimulated to activate TLR7/8 and IFNα, TNF and IL12 measured. Results for 
rs850637 allele A association with normalised cytokine production levels and the 
corresponding p-value are shown. 
Next, we tested associations between the SNP and the expression of the genes that encode 
these cytokines, in unstimulated and RV16-stimulated PBMC samples from 74 individuals. 
We found a nominally significant association with the expression of IFNA in RV-stimulated 
samples, but this did not survive correction for multiple testing (p < 0.05 / 3 tests = 0.016). 
 Table 5:7 Associations between rs850637 and cytokine gene expression. 
The PBMC were left unstimulated or stimulated with RV16. Results for rs850637 allele A 
association mRNA count and the corresponding p-value are shown. None were statistically 
significant after multiple testing correction (p < 0.05 / 3 tests = 0.016). 
5.3.4. Association between rs850637 and clinical variables 
Next, we tested for an association between rs850637 and (1) self-reported cold frequency; 
and (2) immune cell counts. No association was seen between rs850637 and cold 
frequency. After correcting for multiple testing (p < 0.05 / 7 tests = 0.007), rs850637 was 
associated with basophil numbers in whole blood (Table 5:8), with the A allele associated 
with higher counts. A more modest association was observed between rs850637 and 
eosinophil numbers in whole blood; however, this was not significant after multiple testing 
correction. 
Cytokine Stimulus Effect p-value n 
IFNα RV16 -0.049 0.55 238 
IFNα TLR7 agonist 0.039 0.64 238 
TNF TLR8 agonist -0.046 0.58 238 
IL12 TLR8 agonist 0.011 0.89 238 
 Unstimulated PBMC RV16-stimulated PBMC 
Gene Effect p-value n Effect p-value n 
IFNA genes  0.042 0.78 72 0.24 0.021 74 
TNF -0.003 0.99 72 0.11 0.45 74 
IL12A 0.12 0.40 72 0.048 0.75 74 
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Table 5:8 rs850637 associations with cold frequency and immune cell counts. 
Results for rs850637 allele A association with the self-reported cold frequency and immune 
cell counts in whole blood and the corresponding p-value are shown. Significant p-value < 
0.05 / 7 tests = 0.007 are bolded. 
5.3.5. Association between other SNPs in/near TLR7/TLR8 and gene expression 
Next, we expanded the association analysis to other SNPs within 1 Mb of TLR7/8 genes. 
We first tested if SNPs in/near TLR7/TLR8 have an association with TLR7 and/or TLR8 
expression. Gene expression levels were measured in whole blood (n = 238) using RT-PCR, 
and in PBMC (n = 74) with RNA-seq. PBMC were cultured with or without RV16. 
We tested the association between TLR7/8 expression and a total of 1748 SNPs. The 
strongest SNP associations observed for each gene and biological sample type are shown 
in Table 5:9. None of these associations exceeded the p-value threshold required to correct 
for multiple SNP testing, specifically p = 5.2e-05 for whole blood and p = 3.6e-05 for PBMC 
samples. Using these relatively stringent thresholds, there were no significant associations 
between SNPs in/near TLR7/8 and the expression of either of these genes, though the study 
may not have had significant statistical power. 
Outcome Effect p-value n 
Cold Frequency -0.10 0.22 226 
Total White Blood Cells 0.020 0.80 236 
Platelets 0.062 0.45 235 
Neutrophils -0.070 0.39 236 
Lymphocytes 0.14 0.073 236 
Monocytes 0.15 0.073 236 
Eosinophils 0.17 0.017 236 
Basophils 0.22 0.0044 236 
5:136 
 
Table 5:9 Top association between TLR7/8 SNPs and gene expression in whole blood and 
PBMC 
Gene expression was measured at baseline in unstimulated whole blood and PBMC 
samples and RV16-stimulated PBMC samples. The top genomic marker and its effect allele, 
effect allele frequency, and position are shown. The allele association with gene expression 
and p-value are described. None were significant after multiple testing correction p < 5.2e-
05 for whole blood and p < 3.6e-05 for PBMC. 
5.3.6. Association between SNPs in/near TLR7/TLR8 and receptor function 
Next, to assess whether genetic variation in the TLR7/8 gene region could affect the function 
of those receptors, we used cytokine production in response to receptor activation as a 
proxy. We measured IFNα, which is produced in response to TLR7 activation and TNF and 
IL12 that are produced in response to TLR8 activation. We tested the association between 
SNPs and both protein and RNA levels for these three cytokines, measured in PBMC 
stimulated for 24 h with TLR7/8 receptor activators. 
Table 5:10 depicts the strongest SNP associations with cytokine protein levels. No individual 
association exceeded the p-value threshold required to correct for multiple testing, which 
was p = 2.3e-5 (correcting for the number of SNPs and cytokines). As such, within the 
constraints of study power, there was insufficient evidence for significant associations 
between the SNPs tested and protein levels of these three cytokines. 
Gene Expression Top Genomic Marker Association 
Gene Sample n SNP ID Effect Allele Allele Freq. Position Effect p 
TLR7 WB unstim. 236 rs178997 T 0.19 12900792 0.39 0.0004 
TLR7 PBMC unstim. 73 rs12382299 G 0.42 12929275 0.50 0.0020 
TLR7 PBMC RV 74 rs6640964 C 0.28 12300973 -0.58 0.0033 
TLR8 WB unstim. 236 rs5935410 T 0.16 12843546 -0.38 0.0002 
TLR8 PBMC unstim. 73 rs9780695 A 0.14 12981663 0.63 0.0003 
TLR8 PBMC RV 74 rs6640986 C 0.42 12422688 -0.44 0.0027 
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Table 5:10 Top associations between TLR7/8 SNPs and cytokine production. 
Cytokine Production Top Genomic Marker Association 
Cytokine Stimulus n SNP ID Effect Allele Allele Freq. Position Effect p 
IFNα RV16 238 rs1006239 C 0.72 12779171 0.33 0.0011 
IFNα TLR7 agonist 238 rs5935415 C 0.13 12846581 0.36 0.0037 
TNF TLR8 agonist 238 rs4830472 T 0.75 12695401 0.28 0.0003 
IL12 TLR8 agonist 238 rs5935405 C 0.26 12836807 0.36 0.0004 
IFNα, TNF and IL12 production were measured in TLR7/8 stimulated PBMC samples. The 
top genomic marker and its effect allele, effect allele frequency, and position are shown. The 
allele association with cytokine production and p-value are described. None were significant 
after multiple testing correction p < 2.3e-5. 
Results from the association analysis between SNPs and gene expression levels for the 
same three cytokines are shown in Table 5:11. Gene expression was measured in 
unstimulated and RV-stimulated PBMC (n = 74). There are 17 different gene products for 
IFNα, 11 of which were quantified in the RNA-seq data and summed for the analysis. 
Similarly, IL12 consists of two subunits transcribed by two genes: IL12A and IL12B. IL12B 
was not quantified in our data; therefore, only IL12A was analysed. There were no significant 
associations between SNPs and gene expression levels for these cytokines after accounting 
for multiple testing (p-value threshold of 1.9e-5; Table 5:11). 
Table 5:11 Top associations between TLR7/8 SNPs and cytokine gene expression. 
Cytokine Gene Expression Top Genomic Marker Association 
Gene PBMC Sample  n 
C
hr Start End SNP ID 
Effect 
Allele 
Allele 
Freq. Position Effect p 
IFNA 
genes Unstim. 25 9   rs1266352 T 0.19 12767037 1.02 0.0028 
IFNA 
genes RV16 70 9   rs2532610 A 0.25 12781526 0.61 0.0004 
TNF Unstim. 73 6 31575566 
31578
336 rs56236583 G 0.10 12592368 -0.47 0.0011 
TNF RV16 74 6 31575566 
31578
336 rs141566161 T 0.04 12683149 1.00 0.0011 
IL12 Unstim. 73 3 159988749 
15999
6012 rs6640970 A 0.23 12311026 -0.51 0.0059 
IL12 RV16 74 3 159988749 
15999
6012 rs5934027 T 0.24 12677807 -0.39 0.0048 
Gene expression was measured at baseline in unstimulated PBMC and in RV16-stimulated 
PBMC. The top genomic marker and its effect allele, effect allele frequency, and position 
are shown. The allele association with gene expression and p-value are described. None 
were significant after multiple testing correction p < 1.9e-5. 
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5.3.7. Association between SNPs in/near TLR7/TLR8 and clinical variables 
Since many respiratory viruses are ssRNA viruses that are recognised by TLR7 and TLR8, 
we hypothesised that nearby SNPs might be associated with the frequency of colds. All 
participants reported how often they suffered from upper respiratory infections (cold 
frequency). Immune cell counts are thought to influence antiviral responses, and so were 
also tested for an association with SNPs in/near TLR7/TLR8. The strongest association 
between SNPs and cold frequency is shown in Table 5:12, which was not significant after 
accounting for multiple testing (p-value threshold of 0.0001; Table 5:12). 
Table 5:12 Top association between TLR7/8 SNPs and self-reported cold frequency. 
The top genomic marker and its effect allele, allele frequency, and position are shown. The 
allele association with the self-reported cold frequency and the corresponding p-value are 
shown. None were significant after multiple testing correction p < 0.0001. 
The results from the association analysis between SNPs and immune cell counts are 
reported in Table 5:13. Immune cell counts were measured from whole blood (n = 236) using 
pathology services. There were no significant associations between SNPs and immune cell 
count after accounting for multiple testing (p-value threshold of 1.3e-05 correcting for the 
number of SNPs and cell counts; Table 5:13). 
Table 5:13 Top associations between TLR7/8 SNPs and immune cell counts. 
The top genomic marker and its effect allele, allele frequency, and position are shown. The 
allele association with immune cell counts and the corresponding p-value are shown. None 
were significant after multiple testing correction p < 1.3e-05. 
 Top genomic marker Association 
 n SNP ID Effect Allele Allele Freq. Position Effect p 
 Cold frequency 226 rs9781757 C 0.66 12988623 0.25 0.0017 
Cell Count Top Genomic Marker Association 
 n SNP ID Effect Allele 
Allele 
Freq. Position Effect p 
Total White 
Blood Cells 236 rs2699997 T 0.15 12807077 -0.27 0.0045 
Platelets 235 rs6639207 G 0.60 12607691 -0.28 0.0006 
Neutrophils 236 rs5935411 C 0.13 12843694 -0.39 0.0021 
Lymphocytes 236 rs1483191 T 0.28 12979350 0.23 0.0033 
Monocytes 236 rs5979778 G 0.24 12965184 0.23 0.0033 
Eosinophils 236 rs2074110 T 0.22 13015959 0.32 0.0001 
Basophils 236 rs955279 A 0.34 12976131 0.26 0.0009 
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5.3.8. Top SNP associations in larger datasets 
We identified the top SNPs that associated with TLR7/8 gene expression, cytokine 
production or immune variables and searched in the larger databases for an association 
between those SNPs and TLR7, TLR8, and TLR8-AS1 expression. Out of 24 top SNPs, 
seven were significant eQTLs for these genes in the larger GTEx (lung, n = 383) and 
Framingham heart study (whole blood, n = 5622) databases. Seven SNPs had been 
identified from associations with TLR7/8 baseline expression, immune cell count and cold 
frequency (Table 5:14). Asthma risk SNP rs850637 was in high linkage disequilibrium D’ > 
0.8 with the three closest SNPs (rs1483191, rs9780695, rs9781757) and in moderate 
linkage disequilibrium D’ > 0.4 with the other three SNPs (rs12382299, rs5979778, 
rs955279) (Figure 5:5). 
Table 5:14 eQTLs between top SNPs from association tests and TLR7/TLR8/TLR8-AS1 
genes. 
The association type with the top genomic marker, the genomic marker and its position, 
significant target gene, allele association with target gene expression, corresponding p-
value, the study database, and tissue sample type are shown. G = GTEx dataset F = FHS 
study, L = lung, WB = whole blood. 
Top Genomic marker Gene Association 
Association SNP ID Position Symbol Effect p Tissue Study 
Basophils 
rs955279 12994250 TLR7 0.03 8.80E-09 WB F 
rs955279 12994250 TLR8 0.01 5.85E-05 WB F 
rs955279 12994250 TLR8-AS1 0.26 9.40E-07 L G 
Cold frequency rs9781757 13006742 TLR7 0.02 4.13E-07 WB F 
Lymphocytes 
rs1483191 12997469 TLR7 0.03 9.32E-09 WB F 
rs1483191 12997469 TLR8 0.01 6.67E-05 WB F 
rs1483191 12997469 TLR8-AS1 0.23 1.30E-05 L G 
Monocytes 
rs5979778 12983303 TLR7 0.03 3.81E-12 WB F 
rs5979778 12983303 TLR8 0.02 3.06E-10 WB F 
rs5979778 12983303 TLR8-AS1 -0.33 1.80E-10 L G 
TLR7 PBMC 
unstim. rs12382299 12947394 TLR7 -0.02 1.91E-08 WB F 
TLR7 whole 
blood unstim. 
rs178997 12918911 TLR7 -0.03 6.73E-14 WB F 
rs178997 12918911 TLR8 -0.01 2.42E-08 WB F 
rs178997 12918911 TLR8-AS1 0.36 1.10E-07 L G 
TLR8 PBMC 
unstim. 
rs9780695 12999782 TLR8 -0.04 1.06E-34 WB F 
rs9780695 12999782 TLR7 -0.05 1.96E-18 WB F 
5:140 
 
 
Figure 5:5 Linkage disequilibrium D’ score matrix between the top SNPs and rs850637. 
Obtained from LDlink. 
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5.4. Discussion 
Important findings from Chapter 3 were that TLR7 gene expression on circulating leukocytes 
was lower in asthma and was associated with frequent respiratory infections in men. Those 
results align with the previous reports that TLR7 has an important role in various 
immunological conditions, including asthma (Pritchard et al. 2014; Roponen et al. 2010; 
Rupani et al. 2016). TLR7 and TLR8 are in the centre of the crossover between antiviral 
immunity and type 2 immunity related to asthma, and assessing their role is critical for 
understanding antiviral immunity in asthma. Therefore, here we evaluate the impact of 
variation in the TLR7 and TLR8 gene region on their function and other related clinical 
variables. Specifically, this study examined the association between polymorphisms in the 
TLR7/8 gene region and TLR7/8 gene expression and function, cold frequency, and immune 
cell counts. The key findings to emerge from this chapter were that SNP rs850637, located 
in the TLR7/8 locus and recently reported to be a risk factor for asthma, was associated with 
the expression of TLR7 and TLR8-AS1, and with blood basophil cell count. 
Our study included 238 people of confirmed European ancestry, with transcriptome data 
obtained from a subset of 74 unstimulated and RV16-stimulated PBMC samples. The 
investigation focused on the function of the SNP rs850637 in the available samples and 
further expanded to search associations in two publicly available databases: GTEx and 
Framingham Heart Study (FHS). 
Polymorphisms have the potential to affect nearby gene transcription by altering gene 
promoter regions or the binding of transcription factors to enhancer and silencer sequences. 
We did not detect associations between rs850637 and the expression of nearby genes in 
our samples, but in further investigations from the publicly available GTEx eQTL database, 
we found a significant negative association between rs850637:A and an antisense RNA 
gene TLR8-AS1 in the lung. TLR8-AS1 is a short non-coding gene that shares the sequence 
with TLR8 but is transcribed in the opposite direction. The specific function of TLR8-AS1 is 
unknown, but it has been identified in a study searching for lncRNAs predicting breast 
cancer survival (Fan, Ma & Liu 2018), suggesting that it has a functional role. The current 
consensus is that antisense genes have an important function regulating the gene 
expression of their corresponding sense genes (Pelechano & Steinmetz 2013), and in this 
context, it is possible that TLR8-AS1 may inhibit TLR8 expression, though this has not yet 
been proven. 
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In the FHS, the largest gene expression database that we had access to, we observed a 
negative association between the rs850637:A asthma-protective allele and TLR7 gene 
expression in whole blood. Although, the effect size of the association between rs850637 
and TLR7 expression was small, together with the negative association with TLR8-AS1 gene 
expression, these results suggest that rs850637 affects the transcription rates of nearby 
genes. If reduced TLR7 gene expression results in reduced TLR7 receptor expression in 
the cell, then the rs850637:A allele could potentially influence the IFNα-inducing function of 
TLR7. 
Contrary to what was expected from the rs850637 association with TLR7 gene expression, 
the results outlined in this chapter indicated a positive association between rs850637:A and 
IFNA gene expression in RV16-activated PBMC (Table 5:7). However, this association was 
not significant after correcting for multiple testing and was not confirmed using IFNα cytokine 
production as the outcome. There was no association between rs850637 and IFNA gene 
expression levels at baseline, which are negligible without immune stimulus (Gough et al. 
2012). We lacked data on TLR7 agonist-induced IFNA gene expression; however, the 
literature indicates that the great majority of RV-induced IFNα is mediated by TLR7 
activation, justifying the use of RV16-induced IFNA gene expression as a measurement of 
TLR7 function (Hatchwell et al. 2015; Xi et al. 2015). Even though our results indicate that 
rs850637 does not affect the TLR7 function as assessed by IFNα production, this should be 
validated in larger sample sizes, since in our study population we were not able to reproduce 
the association observed in the FHS between the SNP and TLR7 gene expression. One 
possibility is that other TLR7 functions mediate the association between rs850637 and 
asthma and this is unrelated to TLR7-induced IFNα production. TLR7 is known to also 
induce proinflammatory cytokine and antimicrobial peptide production (Saitoh, S-I et al. 
2017; Triantafilou et al. 2011; Uehara et al. 2007) and crossregulate IgE responses with the 
IgE receptor FcεRI on pDC (Gill et al. 2010; Moisan et al. 2006). Future studies should 
address how rs850637 affects TLR7 function in asthma. 
We were unable to test for a correlation between TLR7 and TLR8-AS1, due to the low mRNA 
copy numbers in our samples, but it is possible that these two genes are associated. 
Considering that the rs850637 association with TLR8-AS1 was observed only in lung tissue, 
it may also be very relevant to asthma. In GTEx, the highest expression of TLR8-AS1 is 
observed in lung, followed by spleen and whole blood. TLR8 gene expression is limited to 
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those tissues, supporting the theoretical regulatory relationship between these two genes. 
A possible mechanism of how TLR8-AS1 could indirectly regulate TLR7 activity is through 
TLR8-mediated downregulation of TLR7, which has been described in mice (Demaria et al. 
2010; Tran, Manzin-Lorenzi & Santiago-Raber 2015) and in human cells (Wang, J et al. 
2006). TLR7 and TLR8 are co-expressed only in the lung epithelial cells, monocytes and 
neutrophils restricting the TLR8-mediated regulation to only those cells. Future research 
needs to define how the rs850637 SNP affects TLR7 and TLR8-AS1 transcription and how 
TLR8-AS1, in turn, affects TLR7 and TLR8 gene expression and function. 
Interestingly, biological models show that TLR7/8 activation improves asthma phenotype 
(Drake et al. 2012), which have led to the development of TLR7 agonists as asthma 
treatment (Junt & Barchet 2015). The results in Chapter 3, showing lower TLR7 gene 
expression in asthma patients than controls, support the use of those medications, whereas, 
the observation that the rs850637:G asthma-risk allele was associated with increased TLR7 
gene expression suggests that a subgroup of asthma patients with the risk SNP may not 
benefit from treatment activating TLR7 receptor. However, the difference on TLR7 gene 
expression change was small between the alleles and the results in Chapter 3 and previous 
literature indicate an important environmental impact on TLR7 gene expression; therefore it 
is possible that the allergic type 2 cytokine milieu, sex hormones and obesity may obscure 
any genetic predisposition to high TLR7 gene expression. 
We also showed that the rs850637:A allele significantly associated with increased basophil 
counts in our study samples. One possible explanation for this observation is that the SNP 
modifies the cytokine or chemokine environment induced by TLR7 and TLR8 activation and 
this, in turn, alters the production and trafficking of basophils, and perhaps other immune 
cell populations. Basophils are a type of granulocyte that produces histamine, serotonin and 
heparin and can induce inflammation. The role of basophils in asthma has not received as 
much attention as eosinophils but is well documented (Fux & Garnier 2017). Basophils are 
known to be an effector cell that interacts with innate lymphoid cell (ILC)2 in establishing 
type 2 inflammation (Motomura et al. 2014). Importantly, basophils appear to induce type 2 
inflammation in response to RV-infection, indicating a possible role for basophils in 
balancing the antiviral and type 2 immunity in asthma (Agrawal, R et al. 2014; Leffler et al. 
2018). When establishing the connection between the SNP and asthma, the functional 
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relevance of basophils in establishing type 2 inflammation in asthma and whether it is TLR7-
mediated should be examined further. 
Among the most significant SNPs in the TLR7/8 region tested for associations, none were 
repeatedly the most significant across the tests performed but several were in high linkage 
disequilibrium with each other and may act as proxy for each other. The SNPs rs955279 
and rs1483191 were both identified for most significant association with blood leukocytes, 
rs955279 for blood leukocyte count and rs1483191 for blood basophil count. The SNPs 
rs2532610 and rs1006239 were both most associated with different IFNα measures. The 
SNPs rs5935410 and rs5935405 were identified in most significant association with TLR8 
gene expression and TLR8-induced IL-12 production, respectively. Despite not surviving the 
multiple testing adjustment, these SNP pairs in linkage disequilibrium and their similar 
associations could present candidate SNPs for further study. Additionally, the SNP rs178997 
that was most associated with increased TLR7 gene expression at baseline and is located 
in between TLR7 and TLR8 might present a prospective candidate for variant affecting TLR7 
gene expression. 
An important caveat of this study was its small sample size, which in practice provided 
adequate power to identify only relatively large SNP effects on gene expression and cytokine 
levels. To supplement the lack of power, we identified the most significant SNPs for each 
association test and searched for their eQTLs in the external GTEx and FHS databases. 
Out of those SNPs, seven were significant modifiers of TLR7, TLR8 or TLR8-AS1 gene 
expression and six in linkage disequilibrium with rs850637, suggesting that the rs850637 
haplotype may be responsible for the effect on TLR7/8/8-AS1 gene expression.  
An important consideration for the study of TLR7 and TLR8 is their reported escape from 
XCI (Chung et al. 2006; Souyris et al. 2018). Souyris et al. (2018) findings indicate that 
approximately 20% of females express both TLR7 gene copies. However, because the 
overexpression of TLR7 and TLR8 have more commonly been associated with autoimmune 
disease and their reduced function is more common in asthma, it is less likely that the XCI 
escape affects asthma patients. Additionally, because 80% of females were shown to 
silence one gene copy successfully and TLR7 or TLR8 gene expression difference was not 
significant between the sexes in our study at baseline (Figure 5:1), adjusting for XCI escape 
was regarded as unnecessary, and both sexes were combined in the analysis.  
5:145 
 
In conclusion, the data presented here links the asthma risk variant rs850637 to the 
expression of TLR7 and TLR8-AS1, as well as basophil cell count. The possibility that these 
variables are interlinked should be further investigated by assessing the potential targets of 
TLR8-AS1 and by further studying the transcriptomic profile of basophils in asthma. 
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 Conclusion and future 
directions 
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6.1. Discussion 
This thesis aimed to investigate self-reported respiratory infections and antiviral immune 
function and how these are associated with:  
• clinical and demographic parameters,  
• variations in TLR7/8 expression and function, and whether these are genetically 
regulated, and  
• the presence of asthma and asthma severity.  
The main motive for the study were previous reports of antiviral immune deficiencies, in 
asthma, specifically poor IFNα production, thought to contribute to severe respiratory 
infections and asthma exacerbation susceptibility during respiratory viral infections. To 
further study those deficiencies, in Chapter 3, we determined what clinical and 
immunological parameters are associated with self-reported respiratory infection frequency, 
the presence of asthma, asthma severity and control. Interestingly, we discovered that the 
factors associated with self-reported cold frequency vary with gender. In males, but not in 
females, cold frequency was independently associated with baseline TLR7 and CLEC4C 
gene expression, whereas in females, cold frequency was independently associated with 
age and BMI, such that even a modest increase in weight was associated with a greater 
frequency of self-reported colds.  
Asthma patients had lower baseline TLR7 gene expression than controls, and those with 
poor asthma symptom control had low TLR8 gene expression independently of TLR7 gene 
expression, sex and BMI. In women, asthma was associated with high BMI and in men with 
a modest change in the TNF response to TLR8 activation. Contrary to many previous 
reports, we did not find that asthma was associated with a systematic deficiency rhinovirus 
(RV)-stimulated IFNα production. 
To elucidate what factors are critical for an efficient antiviral IFNα response, in Chapter 4, 
we contrasted the baseline transcriptomes of high and low IFNα producer groups. We 
discovered that many innate immune variables are upregulated in the high IFNα producers. 
We also observed that low IFNα production was associated with oxidative stress at baseline 
and antibacterial peptide production during viral infection. Finally, we studied the 
consequences of genetic variation in the TLR7/8 gene region. We learnt that the asthma-
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associated rs850637 SNP is associated with TLR7 and TLR8-AS1 gene expression and 
basophil blood count but not with TLR7/8 cytokine-inducing function.  
Since the evidence emerged over 20 years ago that asthma patients are prone to respiratory 
virus-induced exacerbations (Johnston et al. 1995; Nicholson, Kent & Ireland 1993), an 
accumulating body of research has aimed to address the reasons why. Consistent with 
reports of immune deficiency in asthma, we observed a higher rate of respiratory infections 
in asthma patients than controls, which was not linked to asthma symptom severity or 
control. Contrary to expectations, we detected no consistent difference in the RV16-
stimulated IFNα response between the asthma cases and controls. A few recent studies 
have also challenged the notion that the antiviral immune response in asthma is 
characterised by type I IFN deficiency. Two transcriptomic studies show that type I IFN 
production varies between different types of respiratory infection-associated asthma 
exacerbations but is not necessarily low (Gomez et al. 2018; Khoo et al. 2019). The third 
birth-cohort study investigated the association between various cytokine responses to RV 
and childhood asthma and found that participants with the highest and lowest IFN production 
were most likely asthmatic compared to other cytokine response types. The distinction 
between those two groups was the onset of asthma (Custovic et al. 2018). Our results, 
together with the earlier reports, suggest that type I IFN deficiency is associated with only a 
subgroup of asthma patients. The previous reports and recently published data provide 
support for the hypothesis that two asthma phenotypes exist, one with low type I IFN 
response and one with high type I IFN response. The low type I IFN response is associated 
with the most severe asthma exacerbations and type 2-mediated immune responses, 
whereas a high type I IFN response is associated with less complicated asthma 
exacerbations and perhaps ILC2-mediated type 2 inflammation based on the high type 2 
immune response common to both groups in the Custovic et al. (2018) report. 
Instead, Chapter 3 showed that baseline TLR7 gene expression, rather than type I IFN, was 
significantly lower in the asthma group than the healthy group. This is interesting, given that 
TLR7 activation is thought to be the main source of IFNα in RV infection, and that we were 
unable to confirm IFNα deficiency in asthma. One possible explanation is that TLR7 exerts 
key functions that extend beyond IFNα induction. For example, during viral infection, the 
main function of TLR7 is to induce IFNα, that function is mostly driven by pDCs that are a 
minor cell population, yet TLR7 is expressed in other cell types. Other cell types are more 
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biased towards proinflammatory, and antimicrobial peptide production and even pDC 
produce proinflammatory cytokines after TLR7 stimulation before pDC clustering takes place 
(Agrawal, S & Gupta 2011; Saitoh, S-I et al. 2017; Uehara et al. 2007). Further, some 
evidence exists of the counterregulatory relationship between TLR7 and type 2 inflammation 
in mouse studies. One study shows that depletion of TLR7 in mice increases a population 
of myeloid-derived suppressor cells (MCDS) in the lungs, which contributes to Th2 cell and 
cytokine bias (Jeisy-Scott et al. 2011). Further evidence suggests that TLR7-activation in B-
cells and pDC suppresses the asthma-like phenotype and type 2 responses through the 
activation of Tregs (Khan et al. 2015; Lynch et al. 2018; Pham Van et al. 2011). Treg 
activation by pDC was further shown to be important for the prevention of asthma and 
bronchiolitis in a mouse model, suggesting a possible role in asthma pathogenesis (Lynch 
et al. 2018). In addition to Tregs, TLR7 can also suppress IL-17 secreting Th17 cells (Lukacs 
et al. 2010; Vultaggio et al. 2011; Ye et al. 2017). Th17 cytokine responses are of particular 
importance to IL17-high severe asthma type that associated with neutrophilic asthma 
inflammation providing another link between asthma and TLR7 (Chesné et al. 2014).  
In Chapter 5, we investigated if genetic variation could contribute to the reduced TLR7 gene 
expression. An association between TLR7 and asthma has recently been supported by the 
novel finding from Ferreira et al. (2019) that the single nucleotide polymorphism (SNP) 
rs850637 in the TLR7/8 gene region protects from asthma. The data presented in Chapter 
5 showed that the rs850637 SNP was associated with reduced TLR7 gene expression and 
increased basophil count in people with the asthma protective allele. Those effects were 
opposite to what we expected as basophils are often reported to contribute to asthma 
inflammation (Salter et al. 2016). Previous literature has provided evidence that TLR7 might 
be associated with asthma based on the findings of TLR7 genetic alterations in asthma 
patients (Moller-Larsen et al. 2008; Nilsson et al. 2012; Zhang, Q et al. 2015) and small 
scale studies showing low TLR7 function in the lungs of severe asthma patients (Rupani et 
al. 2016; Shikhagaie et al. 2014) and in the PBMC of allergic asthma patients (Pritchard et 
al. 2014; Roponen et al. 2010). In Chapter 3, we show with a large number of study 
participants that the baseline TLR7 gene expression reduction in asthma patients is not 
associated with asthma severity or control. What these contradictory findings may indicate, 
is that TLR7 expression is mostly under environmental (rather than genetic) influence or that 
a TLR7-high subpopulation of asthma patients exists, perhaps with similar characteristics to 
the IFN-high asthma subpopulation. 
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In contrast, we found baseline TLR8 gene expression is inversely correlated with asthma 
control, raising the possibility that TLR8 may have important regulatory properties, including 
its reported capacity to regulate TLR7 function (Desnues et al. 2014; Wang, J et al. 2006). 
TLR8 agonists have been trialled for allergy and allergic rhinitis (Horak 2011), but these 
results indicate a possible role for asthma symptom control, too. TLR8-induced cytokines 
promote Th1 polarisation, a function which may be antagonised by Th2 inflammation, which 
is abundant in poorly controlled asthma. Interestingly, the asthma SNP rs850637 that we 
investigated in Chapter 5 was also associated with decreased TLR8-AS1 gene expression. 
Antisense genes are thought to modulate their complementary genes, suggesting that 
genetic variation may also indirectly alter TLR8 gene expression via TLR8-AS1. Thus far, 
supporting evidence for TLR8’s role in asthma is scarce and hindered by the divergence of 
mouse and human TLR8 functions. Despite the shared similarity between TLR7/8, they 
appear to have distinct roles in innate immunity, and our results suggest that further work 
needs to be done to better understand TLR8 biology in asthma before considering TLR8 
agonists for reducing airway inflammation. 
Low baseline TLR7 gene expression was also associated with more frequent respiratory 
infections in men, as reported in Chapter 3. TLR8 expression was not associated with 
respiratory infection frequency; however, its proinflammatory cytokine repertoire activates 
the adaptive antiviral immune response, whereas TLR7 induces IFN-I production to activate 
the innate immune response in all cell types to impede viral reproduction. Thus, efficient 
TLR7 function is expected to have a greater role in reducing the development of 
symptomatic infection and not TLR8. In contrast to cold prevention, in Chapter 4 we found 
that the baseline gene expression of both TLR7 and TLR8 is important for robust IFNα 
response, suggesting that both receptors are necessary during the efficient antiviral immune 
response. The reduced baseline TLR7 gene expression that contributes to the frequent 
colds could be attributed to genetic variation such as the SNP rs850637 that reduces TLR7 
gene expression, although we did not see a direct association between this SNP and cold 
frequency in Chapter 5. The effect size of the SNP rs850637 A allele on TLR7 gene 
expression was small in the external database with R2 = 0.004 and our study participants 
had a good representation of all rs850637 alleles. The lack of association between the SNP 
and cold frequency suggests that the TLR7-mediated effect is most likely influenced by 
environmental factors rather than genetic factors. 
6:151 
 
In the current research project, we investigated two separate measurements of immune 
variation: in Chapter 3, we investigated self-reported respiratory infection frequency and in 
Chapter 4, antiviral IFNα production. The results presented suggest that the availability of 
the viral nucleic acid recognising receptor TLR7 is more important to prevent symptomatic 
respiratory infection than IFNα production per se, as cold frequency and IFNα production 
did not correlate. IFNα production is induced during viral infection, and an auto-feedback 
loop ensures augmented IFNα production made possible by pDC clustering (Saitoh, S-I et 
al. 2017). Therefore, it is possible that during asymptomatic infection, the small viral titre is 
not sufficient to activate the auto-feedback loop and IFNα production stays relatively 
controlled and does not reflect on the individual IFNα production capacity. Instead, variation 
in the IFNα production capacity is expected to reflect the ability to clear an infection and the 
severity and duration of a viral infection. High IFNα production may not necessarily be 
desirable, as the high IFNα production seen in auto-immune diseases such as systemic 
lupus erythematosus contributes to excessive inflammation. Moreover, here we focussed 
on TLR7 for its known major role in activating IFNα production; however variations in the 
signalling pathways and transcription factors of TLR7 and other IFNα-inducing PRRs can 
contribute to IFNα variation, and integrated signalling pathway analysis might provide a more 
comprehensive understanding on the modulators of antiviral immunity. 
Contrasting the two groups of IFNα producers indicated that the high IFNα producer group 
have a better baseline status of innate immune system readiness. They upregulate many 
more innate immunity-related genes in comparison to the low IFNα producers. In addition to 
baseline TLR7 gene expression, both TLR8 and pDC marker CLEC4C gene expression 
were higher. The greater expression of TLR7 and TLR8 is unsurprising, considering that 
TLR7 induces IFNα production and TLR8 induced cytokines support its production. Also, as 
the main IFNα producer, the increased pDC numbers are expected.  
Whereas high baseline TLR7 gene expression associated with both low frequency of 
respiratory infections and high IFNα production, high baseline pDC quantity was associated 
only with high IFNα production. Instead, in Chapter 3, we observed that in men, independent 
of baseline TLR7 gene expression, pDC quantity was higher in those with frequent 
respiratory infections. Greater pDC numbers independent of changes in TLR7 gene 
expression may be a consequence of airway inflammation as is seen in asthma (Spears et 
al. 2011) or may be due to recent subclinical virus infection. TLR7 deficiency in asthma 
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patients independent of pDC numbers has been reported by others (Pritchard et al. 2014) 
suggesting altered TLR7 function in asthma pDCs. Another consideration for the lack of 
protection of respiratory infection from pDC is the role of alveolar macrophages in the lungs 
as important type I IFN producers during viral infection (Kumagai et al. 2007), therefore pDC 
would be considered to have little effect on preventing symptomatic respiratory infection. 
Furthermore, TLR7 expression is not limited to pDC but is known to be expressed in NK 
cells, eosinophils and epithelial cells and contribute to antiviral defence in those cell types. 
CLEC4C, the pDC quantity marker, remained as one of the differentially expressed genes 
between high and low IFNα producers, further confirming its importance for IFNα production. 
Other DC related genes were also upregulated by the high IFNα producers. The complement 
system is a highly conserved and a central component of the innate immunity. Upregulation 
of the innate immune components by the high IFNα group reflected the findings of others 
that for a robust immune response the right innate immune components must be ready for 
IFNα induction (Bakker et al. 2018; Lee, MN et al. 2014). 
In addition to the immunological variants, this project found several environmental and host 
factors that are associated with variations in antiviral immune function including asthma, 
obesity, sex hormones and possibly vitamin D status. Asthma and high BMI were associated 
with frequent colds and high BMI with low IFNα production. The associations with higher 
BMI were observed with only modest changes in BMI, largely within the overweight rather 
than obese range. The asthma group had higher BMI than controls, but the frequent colds 
were not confounded by the high BMI; therefore, both asthma and BMI must increase the 
risk of respiratory infections independently. In Chapter 3, we speculated that sex hormones 
in women must have a stronger influence on respiratory infection susceptibility than antiviral 
immune variables since both BMI and age were significantly associated with cold frequency, 
whereas baseline TLR7 and pDC quantity were not. As TLR7/8 genes are located on 
chromosome X, some genetic difference in their function has been reported (Souyris et al. 
2018), however in Chapter 5 it was shown that TLR7/8 gene expression was not different 
between men and women in this project. The observed differential cytokine production 
between the genders in Chapter 3 is more likely to result from sex hormone influence or 
other environmental factors, rather than having a genetic basis. 
Perhaps the most unexpected finding was the extent that BMI influences antiviral immunity. 
Surprisingly few asthma studies examining antiviral immunity take BMI into account and 
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report it, which might confound the interpretation of their results. Considering that asthma 
and BMI are correlated, to truly dissect the immune deficiency, obesity and asthma should 
be examined as independent variables. We observed that all participants with high BMI were 
more likely to have low IFNα response and females with high BMI more likely to suffer from 
frequent respiratory infections. The reasons for these associations may be driven by poor 
diet, systemic inflammation and hormonal changes in obese individuals. 
In Chapter 4, the role of dietary status and nutrient-associated biochemical pathways were 
supported by the high BMI in the IFN-low group and the conceived link with low vitamin D 
and B12 availability and oxidative stress marker upregulation, which could be a result from 
a diet low in antioxidants. The oxidative stress response has been shown to counteract 
antiviral immune responses, which supports the association with low IFNα production 
(Mihaylova et al. 2018). In Chapter 3, high BMI was further associated with respiratory 
infection susceptibility. The significance of those associations is noteworthy, considering the 
aspect that literature has highlighted the potent ability of the gut microbiome to modify 
systemic immune responses (Schirmer et al. 2016). In a mouse model, the bacterial 
metabolite propionate was shown to protect from asthma and bronchiolitis (Lynch et al. 
2018). The benefits of healthy diet and microbiome, gained in early childhood seem 
beneficial for protection from asthma and viral infections and are likely to continue to protect 
in adulthood (Lynch et al. 2017; Wood 2017). 
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6.2. Conclusion 
The research described here improves the understanding of TLR7/8 and IFNα immune 
deficiencies in asthma, which is valuable for asthma medication development targeting 
respiratory infection induced asthma exacerbations.  
We have shown that respiratory infections are self-reported most frequently in asthma 
patients and people with high BMI, which highlights those two groups at risk of symptomatic 
respiratory infections. Host factors such as sex, age and diet and immunological modulators, 
including oxidative stress and innate immune variable expression impact variation in anti-
RV immune response, echoing previous studies. Modifiable lifestyle factors can be used to 
reduce infection-related morbidities. 
Finally, genetic variation in TLR7/8 gene region affects the expression of TLR7 gene 
expression and due to the associations with asthma may contribute towards the deficient 
TLR7 expression. 
In conclusion, the results here show a role for the IFNα-inducing TLR7 receptor in asthma 
and cold frequency. As shown in Figure 6:1, our results support that these associations are 
influenced by genetic variation and possibly TLR8 regulation of TLR7 and support a 
hypothesis of additional IFNα-independent mechanisms mediating these associations. Our 
results further show that the variation in immune responses is influenced by host factors 
such as diet, sex, age, and BMI. 
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Figure 6:1 Genetic, immunological and host factors govern asthma and antiviral immune 
responses mediated by TLR7 receptor. 
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6.3. Future directions 
The results reported here have raised important issues for future research. A detailed 
prospective study recording the respiratory infection frequency, viral titre, severity and 
duration will be able to address these features in an unbiased manner and confirm our 
findings regarding modifying immunological and host factors.  We further propose that 
considering hormonal variation resulting from the menstrual cycle, hormonal contraceptive 
and replacement use, age and BMI will provide further insight into the gender disparity that 
we observed here in regard to the determinants of respiratory infection frequency and 
cytokine production. 
Further research in the field of antiviral immunity in asthma should integrate information of 
detailed clinical parameters, inflammatory responses, and immunological factors to best 
describe the endotype of asthma patients who are at most risk of a deficient antiviral immune 
response. The work by Custovic et al. (2018), highlighted that it is still very hypothetical 
whether type 2 inflammation in asthma modifies antiviral immune responses or aberrant 
antiviral immune response predisposes to asthma, and a prospective study could best 
address that conundrum. Future research could also discover blood biomarkers as 
indicators for individuals that are a risk of hospitalisation from respiratory infection-related 
asthma exacerbations, and aid in developing treatments to relieve respiratory infection-
related asthma symptoms, which are currently limited. 
Considering the role for TLR7 in suppressing asthma inflammation, as we detected lower 
TLR7 gene expression in asthma patients compared to controls at baseline, it is possible 
that either low TLR7 gene expression is increasing type 2 inflammation in asthma, or that 
type 2 inflammation is reducing TLR7 expression levels. The cross-sectional data has limited 
capacity to address this issue, but further research can address the causal relationships 
between TLR7 function and type 2 immunity in asthma with animal models and prospective 
studies in children. The results presented in this project suggest a pDC-independent 
reduction in TLR7 gene expression in the presence of asthma that does not translate to 
reduced IFNα production capacity. Follow-up research should establish the TLR7 functions 
affected by TLR7 reduction in asthma, and if those mechanisms mediate also increased the 
frequency of respiratory infections in men.  
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Initially, we analysed only the variation in TLR7/8 genes and their functional consequences, 
however in Chapter 4 we identified which genes are important for efficient IFNα response 
and a natural progression would be to search eQTLs and genetic variation in those genes. 
Additionally, perhaps the most interesting finding emerging from Chapter 5 was the 
association between SNP and TLR8-AS1. TLR8-AS1 should be examined further to define 
its function, particularly in relation to TLR7 and TLR8 and whether it is associated with 
asthma and antiviral immune response. Previous literature suggests a TLR7-regulating role 
for TLR8, and it is possible that the regulation could take place in a genetic level and be 
mediated through TLR8-AS1. Further examination of TLR7 and TLR8 in co-expressing cell 
types can elucidate the cross-regulatory mechanisms between those receptors and the 
implications to their function. 
Finally, although BMI was not expected to emerge as one of the key outcomes in this study, 
our findings indicate that further work is needed to fully understand how an increase in BMI 
compromises antiviral immune response and the relationship between BMI, asthma and 
antiviral immune response. The associations between metabolomics, oxidative stress, 
systemic inflammation, hormonal changes and TLR7/8 immunity in relation to BMI should 
be further investigated. The research field studying modifiable lifestyle factors such as diet, 
vitamin intake, exercise, and weight-loss and their influence on the antiviral immune 
response as well as asthma is well established, and the results presented herein support 
future research in this field. 
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